18-OBE2109 -003 PROTOCOL V4.0 DATED  27 JULY  2020 Page 1 of 156 
 OBSEVA  CONFIDENTIAL  CLINIC AL STUDY PROTOCOL  
 
Protocol Number:  18-OBE2109 -[ADDRESS_926387] Number:  [ADDRESS_926388]:  Linzagolix (OBE2109)  
Study Title:  A Phase 3 multicenter, randomized, double -blind, placebo -
controlled, clinical study to assess the efficacy and safety of 
linzagolix in subjects with moderate to severe endometriosis -
associated pain.  
Short Study Title:  A phase 3 study to confirm  the efficacy and safety of 
linzagolix  to treat  endometriosis -associated pain.  
Study Name:  [CONTACT_684137]  3 
Version number : Version 4.0 
Date:  27 July20 
Replacing:  Version 3.0 – 25 June 2019  
Study Sponsor:   
ObsEva S.A. 
  
 
Clinical Trial Director:   
 
 
 
Medical Responsible :  
  
 
CRO   
 
CRO Project Director : 
  
  
 

18-OBE2109 -003 PROTOCOL V4.0 DATED  27 JULY  2020 Page 2 of 156 
 OBSEVA  CONFIDENTIAL   
 

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 3 of 156 
 OBSEVA  CONFIDENTIAL   
VERSION HISTORY  
Amendment 
Number  Amendment 
Date  General / Country -Specific/ 
Site-Specific  Amended Protocol 
version and date  
01 March 2 8, 2019  General  V2.0  – March 28, 2019 
02 June 25, 2019  General  V3.0 – June 25, 2019  
03 July 27 , 2020  General  V4.0 – July 27 , 2020  
    
    
    
    
    
    
 
  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 4 of 156 
 OBSEVA  CONFIDENTIAL   
 
CONFIDENTIAL AND PROPRIETARY  
This protocol contains confidential and proprietary information about an investigational drug and is 
provided by [CONTACT_304708] S.A., Plan -les-Ouates, Geneva, Switzerland, for the exclusive use of the 
Investigators of this clinical study and their Health Authorities/IRBs/IECs. This confidential 
information may not be disclosed to any other person without prior written consent of ObsEva S.A.  
Note: Other ObsEva  or delegate personnel  who may be contact[CONTACT_684075] a separate document, which will be updated on a regular basis when necessary.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
18-OBE2109 -[ADDRESS_926389] RESEARCH ORGANI ZATION (S) 
SIGNATORY APPROVAL PAGE  
The below si gnatories have read this trial protocol and agree with its principles. They agree to carry out 
the clinical trial in compliance with this protocol, with ICH Good Clinical Practice ( ICH GCP) and the 
applicable regulatory requirements.  
Sponsor : 
ObsEva  S.A.,  
 
Signature  [CONTACT_684138]  
 
(Clinical Trial Director ) 
 
Signature   [INVESTIGATOR_59844]  
 
(Medical Responsible ) 
 
 
Contract Research Organi zation (s): 
 
 
Signature  [CONTACT_684138]  
 
(Project Director ) 
 
 

18-OBE2109 -[ADDRESS_926390]  of the study at this site and agree to the following:  
 I understand and will conduct the study according to the protocol, any approved protocol 
amendments, ICH GCP and all applicable regulatory authority requirements and national laws.  
 I will not deviate f rom the protocol without prior written permission from the sponsor  and prior 
review and written approval from the Institutional Review Board or Independent Ethics 
Committee, except where necessary to prevent any immediate danger to the subject.  
 I have read and understand fully the Investigator Brochure (IB) for linzagolix , and I am familiar 
with the Investigational Medicinal Product (IMP) and its use according to this protocol.  
 I have sufficient time to properly conduct and complete the trial wit hin the agreed trial period, 
and I have available an adequate number of qualified staff and adequate facilities for the 
foreseen duration of the trial to conduct the trial properly and safely.  
 I will ensure that any staff at my site(s) who are involved in the study conduct are adequately 
trained regarding the IMP, the protocol and their responsibilities. In the case of delegating any 
of my study responsibilities I will provide the sponsor  with a Delegation of Activities certificate.  
 I understand that some r egulatory authorities require sponsor s of clinical studies to obtain and 
supply, when required, details about the Investigators ’ ownership interests in the sponsor  or the 
Investigational Medicinal Product and information regarding any financial ties with the sponsor . 
The sponsor  will use any such information that is collected solely for the purpose of complying 
with regulatory requirements. I therefore agree to supp ly the sponsor  with any necessary 
information regarding ownership interest and financial ties (including those of my spouse and 
dependent children), and to provide updates as necessary.  
 
 
 
   
Signature   [CONTACT_684139] [CONTACT_5627]:  
Institution:  
   
 
18-OBE2109 -[ADDRESS_926391] OF ABBREVIATION S ................................ ................................ .......................  14 
4 SYNOPSIS  ................................ ................................ ................................ ....................  19 
5 BACKGROUND INFORMATI ON ................................ ................................ ..............  32 
5.1 INTRODUCTION TO LINZ AGOLIX  ................................ ................................ ................  32 
5.2 ENDOMETRIOSIS  ................................ ................................ ................................ .............  32 
5.3 CONVENTIONAL  TREATMENT OF ENDOME TRIOSIS  ................................ ..............  32 
5.4 SUMMARY OF NON -CLINI CAL STUDIES  ................................ ................................ .... 33 
5.4.1  Non -Clinical Pharmacology  ................................ ................................ ................................ .. 33 
5.4.2  Non -Clinical Pharmacokinetics and Toxicology ................................ ................................ .... 34 
5.4.3  Non -clinical summary  ................................ ................................ ................................ ..........  35 
5.5 SUMMARY OF CLINICAL STUDIES  ................................ ................................ ..............  35 
5.5.1  Pharmacokinetics/Pharmacodynamics  ................................ ................................ ................  35 
5.5.2  Efficacy  ................................ ................................ ................................ ................................ . 37 
5.5.3  Safety  37 
5.6 RATIONALE FOR THE CU RRENT STUDY  ................................ ................................ ... 38 
5.7 SUMMARY OF OVERALL R ISKS AND BENEFITS  ................................ ......................  39 
6 OBJECTIVES  ................................ ................................ ................................ ...............  40 
6.1 EFFICACY OBJECTIVES  ................................ ................................ ................................ .. 40 
6.1.1  Prim ary ................................ ................................ ................................ ................................ . 40 
6.1.2  Secondary  ................................ ................................ ................................ ............................  40 
6.2 SAFETY OBJECTIVES  ................................ ................................ ................................ ...... 41 
6.3 EXPLORAT ORY OBJECTIVES  ................................ ................................ ........................  41 
7 ENDPOINTS  ................................ ................................ ................................ .................  41 
7.1 EFFICACY ENDPOINTS  ................................ ................................ ................................ ... 41 

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 8 of 156 
 OBSEVA  CONFIDENTIAL  7.1.1  Primary  ................................ ................................ ................................ ................................ . 41 
7.1.2  Secondary  ................................ ................................ ................................ ............................  41 
7.2 SAFETY ENDPOINTS  ................................ ................................ ................................ .......  43 
7.3 EXPLORATORY ENDPOINT S ................................ ................................ .........................  44 
8 STUDY DESIGN ................................ ................................ ................................ ...........  44 
9 STUDY POPULATION  ................................ ................................ ................................  46 
9.1 SUBJECTS  ................................ ................................ ................................ ..........................  46 
9.1.1  Description of the target population  ................................ ................................ ...................  46 
9.1.2  Number of subjects  ................................ ................................ ................................ ..............  46 
9.1.3  Study region/location  ................................ ................................ ................................ ..........  46 
9.2 ENTRY CRITERIA  ................................ ................................ ................................ .............  46 
9.2.1  Inclusion Criteria  ................................ ................................ ................................ ..................  46 
9.2.2  Exclusion Criteria ................................ ................................ ................................ ..................  47 
10 STUDY PROCEDURES AND  ASSESSMENTS  ................................ ..........................  50 
10.1 GENERAL INSTRUCTIONS  ................................ ................................ .............................  50 
10.2 OUTLINE OF STUDY PRO CEDURES AND ASSESSME NTS  ................................ .......  52 
10.2.1  Screening Period – Screening visit  ................................ ................................ .......................  52 
10.2.2  Treatment period  ................................ ................................ ................................ .................  55 
10.2.3  Follow -up period without treatment for subjects not entering the extension study  ..........  60 
10.3 EFFICACY OBSERVATION S AND MEASUREMENTS  ................................ ................  63 
10.3.1  Modified Biberoglu and Behrman questionnaire  ................................ ................................  63 
10.3.2  Daily diary  ................................ ................................ ................................ ............................  64 
10.3.3  Outcome rating scales assessed at site visits  ................................ ................................ .......  66 
10.4 SAFETY OBSERVATIONS AND MEASUREMENTS  ................................ ....................  70 
10.4.1  Adverse Events  ................................ ................................ ................................ .....................  70 
10.4.2  Physical Examination  ................................ ................................ ................................ ...........  70 
10.4.3  Vital signs  ................................ ................................ ................................ .............................  71 
10.4.4  Transvaginal ultrasound  ................................ ................................ ................................ .......  71 
10.4.5  Endometrial biopsies  ................................ ................................ ................................ ...........  71 

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 9 of 156 
 OBSEVA  CONFIDENTIAL  10.4.6  Bone mineral density and DXA  ................................ ................................ ............................  73 
10.4.7  Bone markers  ................................ ................................ ................................ .......................  73 
10.4.8  Laboratory parameters  ................................ ................................ ................................ ........  73 
10.4.9  Electrocardiogram  ................................ ................................ ................................ ................  74 
10.4.10  Columbia -Suicide Severity Rating Scale (C -SSRS)  ................................ ................................ . [ADDRESS_926392] Requirements / Independent Ethics Committee  ....................  [ADDRESS_926393] CONFIDENTIAL ITY ................................ ................................ ......................  106 
14.7 QUALITY ASSURANCE  ................................ ................................ ................................ . 106 
14.8 PROTO COL DEVIATIONS  ................................ ................................ .............................  106 
14.9 STUDY OR SITE DISCON TINUATION  ................................ ................................ .........  106 
14.10  RETENTION OF ESSENTI AL STUDY DOCUMENTS  ................................ .................  107 
14.11  PUBLICATION POLICY ................................ ................................ ................................ .. 107 

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 12 of 156 
 OBSEVA  CONFIDENTIAL  15 APPEN DICES  ................................ ................................ ................................ .............  108 
APPENDIX A.  SCHEDULE OF STUDY AS SESSMENTS – SCREENIN G AND TREATMENT PERI ODS  ............  109 
APPENDIX B.  SCHEDULE OF STUDY AS SESSMENTS – FOLLOW -UP PERIOD  ................................ .........  114 
APPENDIX C.  MODIFIED BIBEROGLU &  BEHRMAN SYMPTOM SEV ERITY SCALE*  ...............................  117 
APPENDIX D.  ENDOMETRIOSIS HEALTH  PRO FILE QUESTIONNAIRE ( EHP-30) ................................ ..... 119 
APPENDIX E.  PROMIS FATIGUE – SHO RT FORM 6A  ................................ ................................ ...........  124 
APPENDIX F.  HEALTH -RELATED PRODU CTIVITY QUESTIONNAIR E (HRPQ)  ................................ .........  125 
APPENDIX G.  HEALTH RESOURCE UTIL IZATION QUESTIONNAIR E (HRUQ)  ................................ ..........  128 
APPENDIX H.  PATIENT GLOBAL IMPRE SSION OF  CHANGE (PGIC)  ................................ .......................  [ADDRESS_926394] -TREATMENT PATIE NT GLOBAL IMPRESSION  OF CHANGE (PPGIC)  .......................  134 
APPENDIX J.  PATIENT GLOBAL IMPRE SSION OF SEVERITY (P GIS)  ................................ ......................  [ADDRESS_926395] SURGERY INTE NTION QUESTIONNAIRE (SSIQ)  ................................ ................  136 
APPENDIX L.  PHYSICIAN SURGERY IN TENTION QUESTI ONNAIRE (PSIQ)  ................................ ............  [ADDRESS_926396] OF FIGURES  
FIGURE 1 : STUDY DESIGN  ................................ ................................ ................................ ................................ ...... 45 
FIGURE 2 : SCHEDULE OF VISITS  ................................ ................................ ................................ ............................  52 
FIGURE 3 : BIOPSY PROCESS FOR MONTH 6 STUDY VISIT  ................................ ................................ ........................  71 
FIGURE 4 : BIOPSY PROCESS FOR TH E FOLLOW -UP PERIOD VISITS ................................ ................................ ...........  72 
FIGURE 5 : LINZAGOLIX /PLACEBO KIT DESIGN  ................................ ................................ ................................ .......  [ADDRESS_926397]  ASpartate amino Transferase  
AUC  Area Under the Curve  
AUC (24hr)  Area Under the plasma concentration time Curve from time [ADDRESS_926398]-
dose 
AUC 0-∞ Area Under the Curve from time [ADDRESS_926399] measurable time  
AUC τ Area Under the Curve to the end of the dosing period  
BMD  Bone Mineral Density  
BMI  Body Mass Index  
BP Blood Pressure  
Bpm Beats Per minute  
°C Degree Celsius  
CDF  Cumulative Distribution Function  
CK Creatine Kinase  
ClinRO  Clinician Reported Outcome  
Cm Centimeter(s)  
COC  Combined Oral Contraceptive  
CRA  Clinical Research Associate  
CRO  Contract Research Organi zation  
C-SSRS  Columbia -Suicide Severity Rating Scale  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 15 of 156 
 OBSEVA  CONFIDENTIAL  CTx C-terminal telopeptide  
CV Coefficient of Variation  
CYP  CYtochrome P 
DMC  Data Monitoring Committee  
dPGIS  Patient Global Impression of Severity – daily recall  
DXA  Dual -energy X -ray Absorptiometry  
DYS  Dysmenorrhea  
E2 Estradiol  
EAP  Endometriosis -Associated Pain  
ECG  Electro Cardio Gram 
eCRF  Electronic Case Report Form  
eDiary  Electronic Diary  
EHP -30 Endometriosis Health Profile – 30 
ePRO  Electronic Patient Reported Outcome  
EQ-5D-5L EuroQol 5 Dimension 5 Level questionnaire  
EU European Union  
FAS Full Analysis Set  
FDA  Food and Drug Administration  
FU Follow -Up 
FSH Follicle -Stimulating Hormone  
G Gram(s)  
GCP  Good Clinical Practice  
γGT Gamma -Glutamyl Transferase  
GGT  Gamma -Glutamyl Transpeptidase  
GMP  Good Manufacturing Practice  
hGnRH  human Gonadotropin Releasing Hormone  
HDL  High Density Lipoprotein  
18-OBE2109 -[ADDRESS_926400]  
IUD Intra -Uterine Device  
IWRS  Interactive Web Response System  
Kg Kilogram(s)  
L Liter(s)  
LDH  Lactate DeHydrogenase  
LDL  Low Density Lipoprotein  
LEEP  Loop Electrosurgical Excision Procedure  
LFT Liver Function Test  
LH Luteinizing Hormone  
LOQ  Limit Of Quantification  
mB&B  Modified Biberoglu & Behrman  
MCH  Mean Corpuscular Haemoglobin  
MCHC  Mean Corpuscular Haemoglobin Concentration  
MCV  Mean Corpuscular Volume  
Mg Milligram(s)  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 17 of 156 
 OBSEVA  CONFIDENTIAL  Min Minute(s)  
mL Milliliter(s)  
MME  Morphine Milligram Equivalent  
mPGIS  Patient Global Impression of Severity – monthly recall  
mmHg  millimeter of mercury  
msec  Millisecond  
nmol  Nanomole(s)  
NETA  NorEThisterone Acetate  
NMPP  Non-Menstrual Pelvic Pain  
NOAEL  No Observed Adverse Effect level  
NRS  Numeric Rating Scale  
NSAID  Non Steroidal Anti -Inflammatory Drug  
OAT3  Organic Anion Transporter 3  
OBE2109  (2-Hydroxyethyl)trimethylammonium -3-[2-fluoro -5-(2,3-difluoro -6-
methoxybenzyloxy) -4-methoxyphenyl] -2,4-dioxo -1,2,3,4 -
tetrahydrothieno[3,4 -d]pyrimidine -5-carboxylate  
P1NP  Proco llagen type [ADDRESS_926401]-treatment Patient Global Impression of Change  
PGIS  Patient Global Impression of Severity  
PK Pharmacokinetic  
PP Per Protocol  
PSF Pregnancy Surveillance Form  
PSIQ  Pysician Surgery Intention Question  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 18 of 156 
 OBSEVA  CONFIDENTIAL  PT Prothrombin Time 
PVC/Al  PolyVinyl Chloride/Aluminum  
QD Once daily (from the Latin Quaque Die)  
QoL Quality of Life  
QTc QT interval corrected for heart rate   
QTcF  QT interval corrected for heart rate  (QTc) using Fridericia's correction 
formula  
RBC  Red Blood Cell  
ROC  Receiver Operating Characteristic  
SAE  Serious Adverse Event  
SAP Statistical Analysis Plan  
SERM  Selective Estrogen Receptor Modulator  
SIN Subject Identification Number  
SPRM  Selective Progesterone Receptor Modulator  
SHBG  Sex Hormone -Binding Globulin  
SLE Systemic Lupus Erythematosus  
SSIQ  Subject Surgery Intention Question  
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reaction  
T1/2 Elimination half -life 
TEAE(s)  Treatment Emergent Adverse Event(s)  
TVUS  TransVaginal UltraSound  
ULN  Upper Limit of Normal  
US/[LOCATION_003]  [LOCATION_002]/[LOCATION_002] of America  
VAS  Visual Analogue Scale  
VRS  Verbal Rating Scale  
WBC  White Blood Cell  
WHO  World Health Organization  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 19 of 156 
 OBSEVA  CONFIDENTIAL  4 SYNOPSIS  
Study Title:  A Phase 3, multicenter, randomized, double -blind, placebo -controlled, clinical study to 
assess the efficacy and safety of linzagolix in subjects with moderate to severe endometriosis -
associated pain.  
Code/ Name [CONTACT_304763]:  linzagolix  (OBE2109)  Phase of Development:  3 
Objectives:  
The primary objective of this study is to demonstrate the efficacy and safety of linzagolix 
administered orally once daily for up to 3 months at a dose of 75 mg alone or of 200 mg in 
combination with add -back hormone replacement therapy ( ABT: estradiol ( E2) 1 mg  / norethisterone 
acetate  (NETA)  0.5 mg) versus placebo , while under randomi zed treatment, in the management of 
moderate to severe endometriosis -associated pain (EAP) in women with surgically confirmed 
endometriosis. The two co-primary efficacy  endpoints will be clinically meaningful reduction over 
the last 28 day s of randomized treatment up to the M onth 3 visit , along with a stable or decreased 
use of analgesics for EAP , for 1) dysmenorrhea (DYS) and for 2) non-menstrual pelvic pain (NMPP) .  
Secondary objectives include evaluation of persistence of efficacy over the last 28 day s of 
random ized treatment up to the M onth 6 visit , evaluation of pain associated with sexua l intercourse 
(dyspareunia) and def ecation (dysc hezia), difficulty of doing daily activities, analgesic use, 
assessment of subject perception of severity, change in uterine ble eding, Quality of Life (QoL) 
questionnaires, pharmacoeconomic burden of endometriosis by [CONTACT_684076], assessment of endometriosis related number of non -study health visits, number of days 
in hospi[INVESTIGATOR_684028].  
Safety and tolerability obje ctives include assessment of bone mineral density ( BMD ), endometrial 
health, cardiac  safety including QT interval prolongation, standard laboratory safety parameters, 
gynecological assessments and adverse event (AE) frequency including specific hypoestroge nic AEs. 
Exploratory objectives include assessment of bone turnover markers  and collect ion of 
pharmacokinetic (PK) and pharmacodynamic (PD) data of linzagolix for a separate modelling 
exercise.  
Endpoints : 
Efficacy endpoints   
 Primary  efficacy endpoints :  
The two co -primary , composite , efficacy endpoints are clinically meaningful reduction from 
baseline  to the last 28 days preceding the Month 3 visit (the 4 -week period preceding Month 3  
visit) or, for subjects who discontinue randomi zed treatment prior to the Month [ADDRESS_926402] 
28 days of randomi zed treatment ,  , along with a stable or decreased use of analgesics for EAP,  
in the mean daily assessment of 1) DYS and of 2) NMPP , both  measured on a Verbal Rating 
Scale (VRS) using an electronic diary ( eDiary ).. 
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 20 of 156 
 OBSEVA  CONFIDENTIAL   
 Secondary  efficacy endpoints :  
 Ranked secondary efficacy endpoints  (in the order of the endpoints to be tested) : 
 Change from baseline to Month 6 in DYS (VRS)  
 Change from baseline to Month 6 in NMPP (VRS)  
 Change from baseline to Month 6 in dyschezia (N umeric Rating Scale - NRS ) 
 Change from baseline to Month 6 in overall pelvic pain ( NRS ) 
 Change from baseline to Month 6 in the interference of pain with the ability to perform  
daily activities , measured using the pain dimension  of the Endometriosis Health 
Profile -30 (EHP -30)  
 Change from baseline to Month 6 in dyspareunia (VRS)  
 No analgesics use for EAP during the preceding 4 -week period at Month 6  
 No opia te use for EAP during the prece ding 4 -week period at Month 6  
 Additional secondary efficacy endpoints  : 
 Clinically meaningful reduction  at scheduled visits other than Month 3 for DYS and 
NMPP  
 Change from baseline to each scheduled assessment in the mean pelvic pain scores for 
DYS, NMPP and overall pelvic pain, during the previous  4-week period assessed on the 
NRS and VRS  
 Change from baseline to each scheduled assessment in the number of days with 
moderate to severe pelvic pain during the previous  4-week period assessed on the VRS  
 Change from baseline to each scheduled assessment in the mean worst pelvic pain score 
defined a s the mean of the [ADDRESS_926403] daily pain scores reported during the previous 4-
week period assessed on the NRS  
 Change from baseline to each scheduled assessment in the mean of daily dyspareunia 
scores reported during the previous 4-week period on the dyspare unia VRS  
 Change from baseline to each scheduled assessment in the mean of daily dyschezia 
scores reported during the previous 4-week period assessed on the dyschezia NRS  
 Change from baseline to each scheduled assessment in non-opi[INVESTIGATOR_2480], opio id and combined  
analgesic use  for EAP during the previous 4-week period based on pi[INVESTIGATOR_684029]  
 Change from baseline to each scheduled assessment in opi[INVESTIGATOR_684030] 4-week period based on morphine milligram 
equivalent (MME)  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 21 of 156 
 OBSEVA  CONFIDENTIAL   Change from baseline to each scheduled assessment in the number of days of analgesic 
use (including any class) for EAP during the previous 4-week period as assessed in the 
eDiary  
 Change from baseline to each scheduled assessment i n the number of days of opi[INVESTIGATOR_684031] 4-week period as assessed in the eDiary  
 Change from baseline to each scheduled assessment in the number of pelvic pain -free 
days (assessed on the VRS) during the previous 4-week period  
 Change from baseline to each scheduled assessment  in ability to perform daily activities 
during the previous 4-week period, as assessed in the eDiary  (daily function NRS ) 
 Change from baseline to each scheduled assessment in the number of days with no 
difficulty in doing daily activities due to EAP during the previous 4-week period  as 
assessed in the eDiary  (daily function NRS)  
 Change from baseline to each scheduled assessment in the number of days when 
dyspareunia was a problem during the previous 4-week period (including days when 
sexual intercourse was avoided because of anticipation of pain)  as assessed on the 
dyspareunia VRS  
 Change from baseline to each scheduled assessment in the number of days when sexual 
intercourse was avoided because of anticipation of pain during the previous 4-week 
period  as assessed on the dyspareunia VRS  
 Change from baseline to each scheduled assessm ent in the number of days with uterine 
bleeding (including spotting) during the previous 4 -week period  measured by [CONTACT_289427]  
 Change from baseline to each scheduled assessment in the number of days when school 
or work was missed due to EAP in the previous 4-week period  as reported in the eDiary  
 Change from baseline to each scheduled assessment in the number of days when the 
subject had to go to bed or lie down due to EAP in the previous  4-week period  as 
reported in the eDiary  
  
 Change from baseline to each scheduled assessment in the Pain, Control and 
powerlessness, Emotional well -being, Social s upport, Self -image dimensions and the 
Modular sexual relationship  questionnaire  of EHP -30 scores  
 Change from baseline to each scheduled assessment in the Health Related Productivity 
Questionnaire (HRPQ) scores  
 Number of non -study endometriosis related health visits, number of days in hospi[INVESTIGATOR_684032] 
(HRUQ) at each  scheduled assessment  
 Change from baseline to each scheduled assessment in the Physician/Subject Surgery 
Intention Question (PSIQ/SSIQ)  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 22 of 156 
 OBSEVA  CONFIDENTIAL   Change from baseline to each scheduled assessment in the PROMIS Fatigue – Short 
Form 6a  
 Change from baseline to each sch eduled assessment in the EuroQo L 5-Dimension 5 -
Level (EQ -5D-5L) questionnaire  
 Response at each scheduled assessment according to Patient Global Impression of 
Change (PGIC) (and Post -treatment Patient Global Impression of Change, PPGIC)  
 Change from baseline  to each scheduled assessment in the monthly PGIS (mPGIS) score  
Safety endpoints  
 Change from baseline to each scheduled assessment in BMD  measured by [CONTACT_751]-energy 
X-ray a bsorptiometry  (DXA ) of lumbar spi[INVESTIGATOR_050] (L1 -L4), femoral neck, and total hip  
 Incidence and severity of treatment emergent adverse events (TEAEs)  
 Incidence and severity of hypoestrogenic TEAEs  (hot fl ush) 
 Time to the first post -treatment menses  
 Changes in clinical laboratory assessments (hematology, biochemistry, coagulation 
parameters, hormones,  lipi[INVESTIGATOR_303648]) from baseline to each scheduled assessment  
 Any pathological changes from baseline in the endometrium as assessed by [CONTACT_684077]  
 Changes from baseline to each scheduled assessment in any other safety parameter  
including weight, vital signs, electrocardiogram ( ECG ), gynecological assessments and 
endometrial thickness  
Exploratory  endpoints  
 Change from baseline in bone turnover markers at each scheduled assessment  
 PK and PD of linzagolix  
Study Design:  This is a prospective, randomized, double -blind, placebo -controlled study to 
demonstrate the efficacy  and safety of linzagolix administered orally once daily at dose s of 75 mg 
alone and 200 mg in combination with low dose ABT  (E2 1 mg/NETA 0.5 mg) versus placebo  in the 
management of moderate to severe EAP  in women with surgically confirmed endometriosis.  
The study starts with an approximately 3 -month screening period during which subjects will receive 
no study drug. Eligibility will be confirmed based on data collected during the screening period. After 
randomization, a 6 -month Treatment Period will follow. Subjects will be randomized to one of the 
three  treatment groups : 
1. Linzagolix 75 mg   
2. Linzagolix 200 mg combined with ABT   
3. Placebo   
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 23 of 156 
 OBSEVA  CONFIDENTIAL  Randomization will be cond ucted via  an interactive web response system  (IWRS ) in a 1:1:[ADDRESS_926404] 
completed the 6 -month  treatment period may enter a separate extension study for 6 additional months 
of active treatment (no placebo control). In this extension study, subjects who previously received 
placebo  will be randomly switched to one of the two active treatments (75  mg alone or 200  mg + 
ABT) . Subjects who received active treatment  will continue with the same treatment . 
Subjects who decline to participate to or do not qualify for the extension study and who were exposed 
to at least 3 months of treatment will enter a 6 -month drug-free follow -up. At the end of the 6 -month 
follow -up period , subjects with a BMD decrease from baseline of >1.5% for lumbar spi[INVESTIGATOR_20793] >2.5% 
for total hip will have an additional DXA scan 6 months later . Subjects who discontinue treatment 
prior to Month 3 will no t enter the follow -up period.  
The main  analysis will be performed after 6 months of treatment and will  includ e all of the subjects ’ 
data up to Month 6.  
The study will last on average 15 months; 3 -month Screening  Period , 6-month Treatment Period and 
6-month Follow -up (with 1 month being defined as 28 days /4 weeks ). The duration excludes any 
washout period.  
All subjects will receive once daily either linzagolix 75 mg alone or 200 mg combined with ABT  or 
placebo for 6 months. Linzagolix or its corresponding placebo will be supplied as tablets for oral 
administration. ABT  or its corresponding placebo will be supplied as capsules for oral administration.   
Linzagolix/placebo treatments will be provided in monthly  treatment kits, packaged, label led and 
administered in the same manner to protect the blinded nature of the trial.  ABT /placebo treatments 
will be supplied as [ADDRESS_926405]’s 
randomized treatment will be provided through an IWRS.  
Study Population:  The target population will be premenopausal women aged [ADDRESS_926406] agree to use double 
non-hormonal barrier contraception from screening until 3 months after the end of treatment. From 3 
months after the end of treatment to the end of the drug -free follow -up period, contraception is still 
mandatory but hormonal cont raception is allowed.  
Four hundred and fifty  (450) randomized subjects  are planned in total ( approximately 150 subjects per 
group).  It is expected that the screen failure rate will be around 60%. Therefore, approximately 1125 
subjects will be screened in o rder to randomize 450 subjects into the study.   
The study will be conducted in a pproximately 1 00 investigational sites in the Unites States (US)  and 
Europe . Additional  sites will be identified , qualified and activated in case of recruitment issues. 
Recruitment will be competitive betwe en countries and sites.  
Eligibility Criteria:   
18-OBE2109 -[ADDRESS_926407] fulfill all of the following criteria:  
1. The subject must provide written informed consent prior to any study related procedures.  
2. The subject must be a f emale subject aged [ADDRESS_926408] recent surgical and – if available – histological diagnosis 
of pelvic endometriosis (laparoscopy, laparotomy, vaginal fornix or other biopsy) up to [ADDRESS_926409] agree to the washout intervals for prohibited therapi[INVESTIGATOR_014] (if applicable).  
5. The s ubject must  agree to switch from her usual analgesic rescue medication to only those 
permitted by [CONTACT_684078], Treatment and Follow -up Period.  
6. The subject has moderate to severe EAP  during the screening period defined as:  
a. At the screening visit,  a score of at least [ADDRESS_926410] 2 for NMPP for the 
previous month assessed with the modified Biberoglu & Behrman ( mB&B ) scale.  
b. Over two full menstrual cycles (i.e. from day [ADDRESS_926411] 
menstruation) finishing just before the baseline visit:  
i. Mean overall pelvic pain scores of at least 4 on the 0 –[ADDRESS_926412] score for each cycle separately, i.e. required  for both cycles;  
ii. At least two days with “moderate” or “severe” pain on the 0 –3 VRS for pelvic 
pain over the days with uterine bleeding for each cycle separately, i.e. required 
for both cycles;  
iii. At least two days with “moderate” or “severe” pain on the 0 –[ADDRESS_926413] 75% of days during 
the screening period.  
8. The subject has regula r menstrual cycles and the total length of the two screening menstrual 
cycles should be between [ADDRESS_926414] has a B ody Mass Index (BMI)  ≥ 18 kg/m2 at the screening visit.  
10. If of childbearing potential, the subject agrees to use one of the following birth control methods 
during the Screening  Period , the entire Treatment Period of the study and until 3 months after 
the end of treatment:  
a. Sexual abstinence, if this is the subjec t's habitual practice and/or the subject is routinely 
abstinent from heterosexual intercourse,  
b. Partner with a vasectomy with confirmed azoospermia,  
c. Double non -hormonal barrier contraception such as condom or diaphragm each 
combined with spermicide.  
18-OBE2109 -[ADDRESS_926415] is ≥ [ADDRESS_926416] not meet any of the following criteria:  
1. The subject is pregnant or breast feeding or is planning a pregnancy within the duration of the 
Treatment Period of the study.  
2. The subject is less than [ADDRESS_926417] -abortion/miscarriage at the time 
of entry into the screening period.  
3. The subject has a surgical history of:  
a. Hysterectomy,  
b. Bilateral oophorectomy,  
c. Vagotomy, bowel resection or any surgical procedure (including gastric surgery) that 
might interfere with gastrointestinal motility, pH, or absorption,  
d. Any major abdominal surgery  (including laparotomy for endometriosis) within [ADDRESS_926418] had a tubal sterilization which was performed with ESSURE™.  
5. The subject had endometrial ablation resulting in amenorrhea.  
6. The subject has at least one ovarian endometrioma with a diameter of [ADDRESS_926419] is likely to require tr eatment during the study OR received treatment within a 
specified period prior to screening with any of the medications listed below:  
a. Gonadotropin releasing hormone (GnRH) antagonists  [ADDRESS_926420] injections/3 -month depot injections  3/6 months  
c. Danazol  3 months  
d. Oral contraceptives and other sex hormones  1 month  
e. Depot contraceptives  10 months  
f. Selective Progesterone Receptor Modulators (SPRMs), Selective 
Estrogen Receptor Modulators (SERMs) and aromatase inhibitors  3 months  
g. Long acting narcotics (i.e. requiring less than once daily dosing)  1 day  
h. Systemic glucocorticoid treatments for acute diseases (not depot)  1 month  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 26 of 156 
 OBSEVA  CONFIDENTIAL  i. Medical (prescribed) marijuana  1 week  
j. In situ copper intra -uterine device (IUD)  [ADDRESS_926421] received strong CYP3A4 inducers or inhibitors that (might potentially) interact 
with ABT  within [ADDRESS_926422] has a contra -indication to ABT  including:  
a. Active deep vein thrombosis, pulmonary embolism, or history of  these conditions;  
b. Active or recent (e.g. within the past year) arterial thromboembolic disease (e.g. stroke, 
myocardial infarction);  
c. Known, suspected, or history of breast cancer;  
d. Known or suspected estrogen -dependent neoplasia;  
e. Known protein C, protein S, or antithrombin deficiency, or other known thrombophilia 
disorders, including Factor V Leiden;  
f. Migraine with aura;  
g. History of porphyria;  
h. Known hypersensitivity to the ingredients.  
12. The subject has a history of or current systemic glucocorticoid therapy f or treatment of chronic 
diseases (e.g. Systemic Lupus Erythematosus (SLE), rheumatic arthritis ). Inhaled 
glucocorticoids for e.g. asthma are not considered systemic glucocorticoids.  
13. The subject did not respond to prior treatment with GnRH agonists or GnRH antagonists for 
endometriosis.  
14. The subject has alanine aminotransferase (ALT), aspartate aminotransferase (AST), total 
bilirubin levels or gamma -glutamyl transpeptidase (GGT) level ≥ 2 times the upper limit of 
normal and indicati ve of potential  liver damag e at Screening or Day 1 (subjects with 
abnormalities at Day 1 will be withdrawn from study at reception of the results).  
15. The s ubject has clinically significant abnormal ECG, or ECG with QT interval corrected for 
heart rate (QTc) using Fridericia's correcti on formula (QTcF) > 450 msec at Screening or Day 
1 (prior to dosing).  
16. The subject has a known positive human immunodeficiency virus  (HIV) or viral Hepatitis 
serology.  
17. The subject has abnormal uterine bleeding of undiagnosed cause.  
18-OBE2109 -[ADDRESS_926423] had/has clinically significant findings from a Papanikolaou (PAP) smear test 
performed within the past 12 months or at the screening visit which will require surgical 
intervention (e.g. Loop electrosurgical excision pr ocedure (LEEP) or cervical  coniz ation).  
19. The subject has chronic pelvic pain that, in the opi[INVESTIGATOR_689], is not caused by 
[CONTACT_684079] (e.g., interstitial cystitis, presumptive adenomyosis, fibroids, non -
endometriosis -related pelvic adhesive disease, post -tubal ligation or irritable bowel syndrome).  
20. The subject has any other clinically significant gynecological condition identified during 
screening transvaginal ultrasound  (TVUS ) or endometrial biopsy which might interfere with 
the study efficacy and safety objectives  (e.g. endometritis , endometrial hyperplasia ). However, 
uterine fibroids (as long as uterus size ≤ 12 weeks, i.e. equivalen t gestational weeks) and 
adenomyosis are allowed provided they do  not interfere with the assessment of EAP  (see 
previous criterion).  
21. The subject has any known condition, including findings in the medical history or in the 
screening assessments, which in th e opi[INVESTIGATOR_684033] a risk or a 
contraindication to the participation of the subject in the trial or that could interfere with the 
trial objectives, conduct or evaluation.  
22. The subject has a history of, or known , osteoporosis , hyperparathyroidism  or other metabolic 
bone disease.  
a. Screening DXA results of the lumbar spi[INVESTIGATOR_050] (L1 –L4), femoral neck, or total hip BMD 
showing a Z -score ≤ –1.5  
b. Any condition that would interfere with obtaining adequate DXA measurements (e.g. 
weight [> 300  pounds or 136 kg], history of spi[INVESTIGATOR_61691], spi[INVESTIGATOR_530344], severe 
scoliosis)  
c. Intercurrent bone disease  
d. History of hip fracture  
e. History of pathologic or compression fractures  
f. History of bilateral hip replacement  
23. The subject has a mental condition rende ring her unable to understand the nature, scope and 
possible consequences of the study, or evidence of an uncooperative attitude.  
24. The subject has current problem with alcohol or drug abuse (including painkiller abuse).  
25. The subject has been administered wi th any experimental drug in the [ADDRESS_926424] has a history of, or active malignancy (with  or without systemic chemotherapy) 
(except treated basal carcinoma of the skin which is not an exclusion criterion).  
28. The subject has a history of attempted suicide and/or a history of, or known major psychiatric 
disorders that are not well controlled.   
18-OBE2109 -[ADDRESS_926425] (s) (IMP) : the term “Investigational Medicinal Product” (IMP) 
will refer to the ObsEva investigational drug linzagolix 75 mg tablets and 200 mg tablets , the ABT 
(E2 1 mg/NETA 0.5 mg) capsules or their matching placebos.  
Data Analysis and Statistics  
Descriptive statistics will be performed on relevant screening and baseline data (i.e. data collected 
prior to the treatment administration) and on demographic characteristics for each treatment group and 
overall. There will be  no formal comparison of baseline data, that is, no statistical hypothesis testing.  
All statistical hypothesis tests and confidence intervals will be two sided. To maintain an overall t ype 
I error rate of 0.05, as there are two linzagolix versus placebo co mparisons, Bonferoni corrected p -
values will be produced (raw p -values will be multiplied by [CONTACT_684080] 0.05), along 
with corresponding 97.5% confidence intervals.  
Each linzagolix group will need to demonstrate a statistically significant difference for both co -primary 
endpoints in order for the group to be considered more efficacious than placebo, thus  maintaining the 
overall t ype I error rate  of 0.[ADDRESS_926426] 28 days of randomized treatment . Use 
of analgesic medication for EAP  will be included in the responder definition.  A responder for the co -
primary endpoints needs to demonstrate both a reduction in pain (DYS or NMPP, depending on the 
endpoint) and a stab le or decreased use of analgesics for EAP. Anyone who does not meet both of 
these criteria will be defined as a non -responder.  
For each of the co -primary endpoints, the criterion for defining a subject as a responder over the last 
[ADDRESS_926427] eDiary; NMPP will use days with no uterine bleeding. If a subject's 
mean score for DYS is undefined numerically because her daily eDiary  reports indicate that she did 
not experience uterine bleeding on any days during the 28 calendar day time period, then the mean 
score for DYS will be set equal to zero (which reflects the absence of any DYS during that reporting 
time period). For subjects who discontinue treatment prior to Month 3, the last available observations 
prior to discontinu ation will be used, in order to estimate the treatment effect of while under treatment, 
that is the [ADDRESS_926428] dose date. The baseline mean 
overall pelvic pain scor es for DYS and NMPP will be calculated by [CONTACT_684081]  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 29 of 156 
 OBSEVA  CONFIDENTIAL  menstrual cycles during screening, which may not be exactly 28 days each. For both DYS and NMPP, 
responses of "No  pain," "Mild  pain," "Moderate  pain," and "Severe  pain" will be assig ned a score of 
0, 1, 2, and 3, respectively.  
For the assessment of a stable or decreased use of analgesics for EAP, t he analgesic use for any defined 
period will be based on the mean of the total pi[INVESTIGATOR_684034] 
(endometriosi s-associated). The total pi[INVESTIGATOR_684035], as reported in the eDiary  during the time period 
of interest. The baseline analgesic use will be calculated as the mean of daily pi[INVESTIGATOR_684036]. For purposes of determining a stable or 
decreased use of analgesics , the averaging will be done over the sa me calendar days as used for the 
pelvic pain scores. The evaluation of a stable or decreased use of analgesics will be done according to 
a pre -defined set of rules . 
The analysis of each co -primary endpoint will be conducted using a logistic regression mode l, with 
treatment group  as the main effect (three values) and including the baseline pain score as a covariate. 
Individual linzagolix versus placebo treatment group  comparisons will be made using the same logistic 
regression model.  
An additional analysis of the co -primary endpoints will be conducted to estimate the effect of treatment 
policy rather than that of while on treatment. A reference based multiple imputation approach will be 
used for subjects who discontinue the study prior  to Month 3. Further details will be provided in the 
Statistical Analysis Plan ( SAP). 
Responder T hresholds  analysis :  
For each of the co -primary endpoints, the criterion for defining a subject as a responder over the last 
28 days of randomized treatment up  to the Month 3 visit  will be a reduction of X or greater from 
baseline in pain. The threshold for response in the responder analysis (i.e., the value of X) will be 
chosen to represent a clinically meaningful reduction in pain and may not be the same for e ach 
endpoint. The threshold will be determined based on separate analyses of overall mean change using 
the mPGIS at Month 3 as an anchor. A 2 -point improvement in the mPGIS will be used to define 
responders for the primary analysis. Response categories of “very mild” and “mild” will be collapsed 
into one category prior to the analyses. Monthly questions specific to DYS, NMPP, overall pelvic pain, 
dyschezia, dyspareunia and daily function  will be  used as separate anchors,  PGIC as an anchor, 
Cumulative Distribution Function  (CDF) and Probability Density Function  (PDF) curves, and 
Receiver Operating Characteristic  (ROC) analyses will be used as supportive analyses. The thresholds 
have been estimated in an analysis of DYS and NMPP data from the Phase 2b Ed elweiss study  and 
will be re -estimated in this study, calculated based on the blinded Month 3 data. The final responder 
thresholds, taking into account the previous estimates from phase 2b, will be included in the final SAP 
prior to breaking the blind afte r Month 6. Based on the results from the Phase 2b Edelweiss study, it 
is expected that the responder thresholds will be in the range of a 0.7 to 1.25 point (40% to 50%) 
reduction in pain in the 4 -point VRS for a 2 -point improvement, and of a 0.25 to 0.75 p oint (20% to 
30%) reduction in pain in the [ADDRESS_926429], or using Koch’s method when there is also a baseline covariate. 
Full details describing the derivation and analyses of each secondary endpoint will be provided in the 
SAP.  
Safety analysis  
The safety  and tolerability profile will be assessed versus baseline conditions and differences between 
treatment groups and descriptive statistics will be produced for both values and change from baseline, 
where applicable.  
Extent of exposure and compliance will b e evaluated.  
Concomitant medications will be summarized using the World Health Organization (WHO) Drug 
Dictionary with frequencies and percentages for each treatment group. All medications administered 
between the date of the first dose and the end of the  study will be included . 
An analysis of the TEAEs will be done . AEs will be summariz ed using the Medical Dictionary for 
Regulatory Activities (MedDRA) tabulated by [CONTACT_82523]. TEAEs will be 
summarized with frequencies and percentages for each treatment group. Tabulations by [CONTACT_684082]-relatedness will also be made.  
Laboratory parameters values will be summarized for each visit for each treatment group including 
within -group changes from baseline.  
BMD values and corr esponding Z -scores will be summarized at baseline and at Month 6 for each 
treatment group, using the observed data. The within -group percent changes from baseline for BMD 
values will also be summarized, including 2 -sided 95% confidence intervals. Categoric al summaries 
of percent change from baseline will also be produced. The percent changes from baseline to Month 6 
will be compared between each of the linzagolix groups and the placebo group via analysis of co -
variance with treatment group  as the main effec t (three values) and including the baseline as a 
covariate.  
18-OBE2109 -[ADDRESS_926430] by [CONTACT_112799]. Where appropriate, changes from baseline will be presented. 
PK/PD analyses will be reported separately.  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 32 of 156 
 OBSEVA  CONFIDENTIAL  5 BACKGROUND INFORMAT ION  
5.1 INTRODUCTION  TO LINZAGOLIX  
Linzagolix  is a new , orally active, non -peptide  gonadotropin releasing hormone  (GnRH ) antagonist. It 
has been shown to significantly reduce endometriosis -associated pain (EAP) in women  with surgically 
confirmed endometriosis at once daily doses between [ADDRESS_926431] common gynecological diseases  (1). 
The condition is predominantly found in women in their reproductive years and disappears 
spontaneously after menopause. A chronic, inflammatory reaction, induced by [CONTACT_684083], results in a variety of pain symptoms including dysmenorrhea (DYS) , dyspareunia, chronic pelvic 
pain, dysuria and dyschezia  (2, 3). 
5.[ADDRESS_926432] of analgesic therapi[INVESTIGATOR_014], hormonal therapi[INVESTIGATOR_014], conservative or 
minimal invasive surgery, or a combination of these  (3). Hormonal therapi[INVESTIGATOR_684037], prevention of cyclic endome trium growth, and abolition of menstruation through 
achievement of a stable steroid hormone milieu, based on the concept that the response of the eutopic 
and ectopic endometrium is substantially similar  (4, 5). 
Combined oral contraceptives (COCs), although not approved for the treatment of EAP , are often used 
as initial therapy. Their intake results in anovulation, reduction of menstrual blood flow, decidualization 
of endometriotic lesions, down regulation of cel l proliferation and enhanced apoptosis in the 
endometrium  (6). However, over time many women on COCs no longer have adequate pain relief and 
require second -line therapy  (7).  
Progestin monotherapy can be efficacious for the reduction in EAP  as it induces anovulation and a 
hypoestrogenic state via suppression of pi[INVESTIGATOR_304678]. Progestins also have direct 
effects on the  endometrium, causing decidualiz ation of eutopic and ectopic endometrium leading to 
atrophy of the endometrio tic implants  (8). However, progestin monotherapy is often associated with 
breakthrough bleeding, alterations in mood, weight gain, and breast tenderness (9). 
Other therapi[INVESTIGATOR_684038]. For example, GnRH agonists lead through a constant stimulation of the GnRH receptor at the 
pi[INVESTIGATOR_684039] l to its desensitization and ultimately to suppression of ovulation and reduced serum 
estrogen levels; thus their use is associated with significant hypoestrogenic side -effects. Short -term 
effects include menopausal symptoms such as hot flush , vaginal dryness, loss of libido and emotional 
lability and their long -term use is limited  to 6 months  without hormonal add -back therapy  (ABT)  by 

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 33 of 156 
 OBSEVA  CONFIDENTIAL  substantial bone mineral density (BMD) reduction  (10). In addition, GnRH -agonists are administered 
as depot products which lack flexibility in case of side effects.  
For longer term use of GnRH -analogues , concurrent treatment with add -back (progestin and/or estrogen) 
hormone replacement therapy has been  shown to be effective in reducing associated BMD loss  (11). 
ABT  is generally recommended as part of initial treatment with GnRH agonists to minimize side effects .  
Randomized trial data comparing [ADDRESS_926433] on BMD  with the addition of daily 
5 mg norethisterone acetate  (NETA ) alone or in combination with estrogen  (11). ABT is considered 
mandatory for women requiring GnRH agonist retreatment / treatment expected to go beyond 6 months . 
In a prospective cohort study  comparing four different regimens of ABT, the add -back regimen 
containing 1 mg estradiol (E2) and 0.[ADDRESS_926434] efficacy in terms of quality of 
life, hypoestrogenism -associated symptoms, and BMD  (12).  
GnRH antagonists are a new potential treatment option that is hypothesized to allow dose -dependent 
control of E2 levels reducing endometriosis implants and EAP  (12). Partial or complete suppression of 
E2 is possible depending on the dose  (13). Partial suppression with elagolix [ADDRESS_926435]  on BMD and therefore allowing 
for up to 2 years administration  (14). A higher dose of elagolix 200 mg twice a day for 6 months led to 
nearly full suppression of E2, better reduction of EAP but significant reduction of BMD which limits 
treatment to 6 months  (14). 
Linzagolix is a new, orally active, non -peptide GnRH antagonist. In a Phase 2b placebo -controlled dose -
ranging study, [ADDRESS_926436] on BMD. A dose of 200 mg given once daily  for 6 months suppressed 
E2 to menopausal levels (< 20 pg/mL) , significantly decreased EAP , with better efficacy for some 
symptoms such as DYS and dy spareunia , but as expected , significantly reduced BMD at [ADDRESS_926437] been chosen to be develop ed further for the treatment of 
EAP  in order to provide dosing optionality to achieve both partial and complete E2 suppression.  
However, due to t he significant BMD loss observed with 200 mg linzagolix , this dose will be developed 
in combination with concomitant estrogen/progestogen ABT . 
The purpose of this study is to evaluate the safety, tolerability and efficacy of linzagolix in women with 
EAP . It is a Phase 3, randomized, double -blind, placebo -controlled study to demonstrate the superior 
efficacy of once daily oral 75 mg linzagolix and of once daily oral 200 mg linzagolix in combination 
with ABT on the reduction of EAP  in women with surgically  confirmed endometriosis.  
5.4 SUMMARY OF NON -CLINICAL STUDIES  
5.4.1 Non-Clinical Pharmacology  
Linzagolix  shows potent affinity for the GnRH rec eptors in different species particularly the human 
GnRH (hGnRH) receptor and acts as an antagonist in vitro  (hGnRH Ki=27.4nM). The affinity of KP017, 
the main metabolite of linzagolix , to the hGnRH receptor was shown to be 4.4 fold lower (Ki=127 nM).  
Specific effects on the endometrium were observed during in vivo studies, with linzagolix  acting through 
suppres sion of estrogen dependent endometrial proliferation in a rat autograft  endometriosis model.  

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 34 of 156 
 OBSEVA  CONFIDENTIAL  Safety pharmacology studies , including a comprehensive set of cardiovascular ion channels,  did not 
show any adverse effects on the central nervous, respi[INVESTIGATOR_684040] a clinical setting.  
5.4.2 Non-Clinical  Pharmacokinetics and Toxicology  
[IP_ADDRESS]  Pharmacokinetics  
Linzagolix  was rapi[INVESTIGATOR_304681] a 
generally dose -proportional manner. The volume s of distribution and plasma clearance were low. 
Linzagolix  is highly bound to plasma proteins (>95%) across a range of species with no concentration 
dependent changes. In human plasma, the major binding protein for linzagolix  was albumin. It does not 
exhibit blood partitioning.  
Tissue distribution of radiolabele d linzagolix  was widespread; there was no indication of unusual 
distribution or accumulation to tissues . Radioactivity was also detected in fetal tissues and milk.  
The major route of biotransformation of linzagolix  was the oxidative O -demethylation to KP0 17 
(produced via CYP2C9 metabolism) which was observed in hepatocytes of all tested species. The in 
vivo metabolic pathway of linzagolix  in mice, rats and monkeys was comparable to the in vitro data.  
Excretion of radioactivity  from radiolabeled linzagolix  was predominantly via feces  in both rats and 
monkeys . 
Pharmacokinetic  (PK)  interaction studies in vitro indicated that drugs possibly co -administered in 
clinical settings ( non steroidal anti -inflammatory drugs - NSAIDs) did not affect the plasma protein 
binding of linzagolix .  
[IP_ADDRESS]  Toxicology  
Overall, the toxicological profile of linzagolix  from repeated -dose toxicity studies was dominated by 
[CONTACT_684084] a GnRH receptor antagonist. During pi[INVESTIGATOR_304682], dose levels of 200 and 10 mg/kg/day linzagolix  were shown to be the no observed 
adverse effect level ( NOAEL ) in the main toxicology species rat (26 -week dail y oral administration) 
and monkey (39 -week daily oral administration), respectively, and resulted in therapeutic indices (based 
on total / unbound exposure) for a human dose of 200 mg/day of 6.7 / 4.6 and 0.8 / 3.6, respectively.  
Reproductive toxicity stu dies, especially fertility studies and embryo -foetal development studies in 
rabbits, were limited in dose by [CONTACT_16682] -GnRH effects of linzagolix  preventing conception or leading to 
total litter loss. The effects of linzagolix  on conception were reversible,  and rabbit embryo -foetal studies 
showed expected pharmacological activity and no adverse reprotoxic/teratogenic effect.  
No effect on pre - and postnatal development of the offspring exposed during embryo -fetal development 
and lactation was recorded.  
Linzag olix was not genotoxic nor phototoxic.  
A [ADDRESS_926438] been demonstrated in a range of 
pharmacology studies, both in vitro  and in vivo , and these also dominate the findings in the toxicology 
studies. Toxicology evalu ation in mice, rats, dogs and monkeys confirmed exaggerated pharmacological 
activity but no overt toxicity. No genotoxicity or unexpected reproduction toxicology findings in rats 
and rabbits were seen.  
In conclusion, the nonclinical package supports clini cal long-term dosing regimens up to 200 mg per 
day. 
5.5 SUMMARY OF CLINICAL STUDIES  
The efficacy, safety and PK of linzagolix  were investigated by [CONTACT_304720] (Kissei 
Pharmaceutical Co., LTD. from Japan) in two Phase 1 studies (Study KLH1101  and KLH1103 ) in 
Japanese and /or Caucasian volunteers in single and multiple doses up to 400 mg , and in three Phase 2a 
studies (Stud ies KLH1201, KLH1202 and KLH1203)  in Japanese endometriosis patients at doses up to 
200 mg daily for up to 12 weeks.  An addi tional Phase 2b study (KLH1204) has been performed  in Japan . 
Its objective was to assess the efficacy and safety of daily doses of linzagolix [ADDRESS_926439] been further investigated in six Phase 1 studies investigating the use 
of estrogen/progestin ABT , potential drug -drug interactions, bioequivalence of forumulations and the 
effect of linzagolix on the QT interval.  
The efficacy and safety of linzagolix are being investigated in US and European patients  with moderate 
to severe EAP in a dose -ranging Pha se 2b study at doses from 50 to 200 mg daily for up to 12 months 
(study 15-OBE2109 -001).  
In addition  to the endometriosis indication , two placebo -controlled Phase 3 studies (16 -OBE2109 -008 
and 16 -OBE2109 -009) assessing the efficacy and safety of linzagoli x in subjects with heavy menstrual 
bleeding associated with uterine fibroids are on going. A total of 500 subjects per study are planned to 
be enrolled in the [LOCATION_003] and Europe. Daily doses of 100 and 200 mg of linzagolix are administered with 
or without ABT (E2 1mg/ NETA 0.5mg) for up to 52 weeks.  
5.5.1 Pharmacokinetics /Pharmacodynamics  
Linzagolix  was evaluated in a Phase 1 single/repeated -dose study (Study KLH1101) in which Japanese 
and Caucasian pre - and post -menopausal women received single doses of linzagolix  from  12.5 to 700 
mg and repeated once daily doses of 100 to 400 mg once daily for 7 days under fed and fasted conditions. 
Linzagolix  was safe and well -tolerated, showed linear PK, a half -life of about 15 –[ADDRESS_926440]-menopausal women or between Japanese and Caucasian women. There 
was a dose -dependent suppression of luteinizing hormone  (LH), follicle -stimulating hormone ( FSH) 
and E2.  
Study 17 -OBE2109 -001 evaluated the tolerability and PK of a single supra -therapeutic dose of 700 mg 
linzagolix , and effects of therapeutic and supratherapeutic doses of linzagolix on the QTc i nterval  (QT 
interval corrected for heart rate ). Subjects  received a 200 mg dose of linzagolix  (therapeutic target 
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 36 of 156 
 OBSEVA  CONFIDENTIAL  exposure), a 700 mg dose of linzagolix  (supratherapeutic target exposure), a 400 mg dose of 
moxifloxacin (positive control), and placebo with an appropriate washout. Linzagolix  at [ADDRESS_926441] of linzagolix  on the heart rate corrected QT interval was identified 
with prolongations exceeding the threshold of concern by [CONTACT_684085] n 2 msec. The categorical data for QTc 
showed no values greater than 480 msec and no changes greater than 30 msec following admin istration  
of the supra therapeutic and therapeutic doses. Thus, based on the magnitude of the QTc prolongation, 
the observed effects are not considere d to be clinically significant.  
The open -label study , KLH1103 , assessed  the absorption, metabolism, and excretion of linzagolix i n 6 
women of non -childbearing potential. Linzagolix was the predominant component in plasma  and all 
plasma metabolites were present at less than 10% of the total drug related exposure. Similarly, 
unchanged linzagolix was also a major component in urine and feces. Linzagolix was eliminated in urine 
(52%) and, to a lesser extent, in feces (38%).  
Study 16 -OBE2109 -011 assessed the pharmacodynamics (PD) and safety of linzagolix  alone and 
combined with E2/  NETA add -back hormone replac ement therapy on E2 levels and vaginal bleeding. 
In this single -center, open -label, randomized, parallel -group study, 76 healthy premenopausal women 
were randomized to linzagolix  (100 mg), linzagolix / E2/ NETA (100  mg/0.5  mg/0.1  mg), linzagolix / 
E2/ NETA ( 100 mg/1  mg/0.5  mg), linzagolix  (200 mg) or linzagolix /E2/NETA (200  mg/1  mg/0.5  mg) 
once daily for [ADDRESS_926442] in 
subjects treated at 200 mg.  
A single -center, open -label, randomized, parallel -group study (study 17 -OBE2109 -008) in 32 healthy 
pre-menopausal women was performed to assess whether co -administration of ABT following 4 weeks 
of high -dose linzagolix administration alone would result in improved bleeding patterns compared to 
combined linzagolix/ABT administration. Subjects  were randomized to once daily linzagolix 
(200 mg)/ABT for 10 weeks or linzagolix (200  mg) for 4 weeks followed by [CONTACT_684086] 
(200 mg)/ABT for 6 weeks. Starti ng the administration of linzagolix and hormonal ABT together 
provided better bleeding control than delaying the A BT treatment start for 4 weeks.  
In a drug -drug interaction study  with women of child bearing potential (Study 16 -OBE2109 -005), 
linzagolix did not induce CYP3A4 and there was no clinically significant food effect . In another drug -
drug interaction study (Study 17 -OBE2109 -006) the OATP1B1/1B3 inhibitor rifampi[INVESTIGATOR_2513] (600  mg single 
dose) had no clinically relevant effects on t he PK of linzagolix . Additional drug -drug interaction studies 
(Studies 18 -OBE2109 -006 and 18 -OBE2109 -007) showed linzagolix to have no effect on OAT3 
substrate benzylpenicillin and to increase the exposure to CYP2C8 substrate repaglinide. Linzagolix is 
considered to be a weak  inhibitor of the CYP2C8 enzyme.  
A single -center, open -label, randomized, two -period cross -over study in 20 healthy pre -menopausal 
women (Study 17 -OBE2109 -004) aimed to demonstrate the bioequivalence of linzagolix formulation A 
(reference  formulation ), use d in Phase 2b Edelweiss  study 15 -OBE2109 -001, and formulation B ( test 
formulation ) planned to be used in the current  Phase [ADDRESS_926443] formulation was fo und to be bioequivalent to the reference f ormulat ion for Cmax 
and area under the curves  (AUCs ) of linzagolix and KP017 (metabolite). A single administration of 
linzagolix formulations A and B to healthy female participants was safe and well tolerated.  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 37 of 156 
 OBSEVA  CONFIDENTIAL  5.5.2 Efficacy  
The clinical efficacy of linzagolix  has been  investi gated in  five Phase 2 studies . 
In a Phase 2 clinical study  conducted in Japan  in patients with endometriosis (Study KLH1201), 50 or 
200 mg linzagolix  was orally administered once daily for 8 weeks. Linzagolix  improved endometriosis 
symptoms and con tinuously suppressed E2 in a dose -dependent manner.  
In a Phase 2 clinical study  conducted in Japan  in patients with endometriosis (Study KLH1202), 50, 
100, or 200 mg linzagolix  or placebo was orally administered once daily for 12 weeks. Linzagolix  
signific antly reduced endometriosis pain symptoms compared with placebo.  
In a Phase 2 clinical study  conducted in Japan  in patients with endometriosis (Study KLH1203), 75 or 
150 mg linzagolix  was orally administered once daily for 8 weeks. Linzagolix  improved endometriosis 
symptoms and continuously suppressed E2 in a dose -dependent manner.  
A Phase 2b study (KLH1204) conducted in Japan assessed the efficacy and safety of once daily doses 
of linzagolix 25 mg, 50 mg, 75 mg and 100 mg for up to 24 weeks i n subjects with EAP . There was a 
dose dependent improvement of EAP , with significant improvement compared to placebo at the 75 and 
100 mg doses.  
In an ongoing  Phase 2b study conducted in US and Europe  in patients with endometriosis  (Study 15 -
OBE2109 -001, also known as Edelweiss ), doses of 50, 75, 100, 200 mg linzagolix  or placebo were 
administered orally, once daily for up to 52 weeks.  Linzagolix significantly  decreased  EAP  after 12 
weeks at doses of 75, 100 and 200 mg  and the effects were maintained  or increased  at 24 weeks.  
5.5.3 Safety  
More than 1,500 subjects were exposed to different doses (25, 50, 75, 100, 200, 400 mg) of linzagolix 
from [ADDRESS_926444] on total plasma linzagolix exposure. In women with severe 
hepatic impairment (Child -Pugh C), [ADDRESS_926445] on total plasma linzagolix exposure. In women with severe 
renal impairment (eGFR <30 mL/min/1.73 m2) or end -stage renal disease, approximately 2 -fold 
unbound mean exposure s were recorded. In renal impaired subjects , a single dose of 200 mg was  well 
tolerated.  
The expected side effects of l inzagolix are disturbances of the menstrual cycle and hypoestrogenic 
adverse events ( AEs) (metrorrhagia and hot fl ush). 
In the Phase 2b Edelweiss  trial, changes from baseline to week 24 in BMD w ere measured by [CONTACT_751]-
energy X -ray absorptiometry  (DXA ) scan, using central reading. Partial E2  suppression achieved with 
linzagolix 75  mg was associated with a mean percent change from baseline in s pi[INVESTIGATOR_9210] (the site of 
18-OBE2109 -[ADDRESS_926446] bone loss) of ‐0.8% (95% CI ‐1.57, ‐0.03) after 6 months of treatment, while achieving 
improvement of the conditions in the majority of patients. As expected, full E2 suppression with 
linzagolix 200  mg lowers BMD by [CONTACT_726]  2.5%, which indicate s the need for a low dose ABT for 
use beyond 6 months . 
In multiple -dose studies, a dose -dependent occurrence of hot flush  was observed (14.63%, 27.27%, 
27.8%, 30% and 40.7% at [ADDRESS_926447] ively ). In the 
Phase 2b Edelweiss  trial, a moderate proportion of patients reported a dose -dependent increase in hot 
flush  (at week 12 , placebo: 10.9% reporting at least one hot flush ; 75mg: 18.4%; 200  mg: 42.1%  - at 
week 24 , 75 mg: 19.0%; 200  mg: 45.6%).  
Anticipated adverse events (AE) are events that were not necessarily observed with linzagolix but can 
be anticipated based on the drug’s pharmacological action and/or class effects, such as: i ncrease in liver 
function test parameters, headache, dizziness, nausea, hyperhidrosis, blood cholesterol increased, low 
density lipoprotein increased  and BMD loss . 
In few subjects, an increase in transaminase values exceeding 3>ULN (Upper Limit of Normal) was 
observed under treatment, most often the increase in transaminase values was reversible and decreased 
spontaneously under treatment up to normal. These increased transaminase values were not associated 
with increased bilirubin values.  
A borderline effe ct of linzagolix on the heart  rate corrected QT interval was identified with 
prolongations exceeding the threshold of concern by [CONTACT_684087] [ADDRESS_926448] majority of related AEs were reported as being of “mild” or “moderate” intensity ; only very 
few related events were reported as being of “severe” intensity.  
5.6 RATIONALE FOR THE CURRENT STUDY  
Linzagolix  has been shown to suppress LH and E2  dose dependently  and to significantly reduce EAP  in 
women  with moderate  to severe EAP  with a good safety and tolerability profile.   
In the dose -ranging study ( 15-OBE2109 -001), daily doses of 75, [ADDRESS_926449] s of daily doses of 75, 100 and 200 mg 
were  maintained  or increased at 24 weeks. For overall pelvic pain , 49%, 62%, 56% and 56%  of subjects 
responded (30% reduction in pelvic pain) to the dose s of 50, 75, 100 and 200 mg linz agolix  compared 
to 35% in placebo . For DYS , 43%, 68%, 69%, 79%  of subjects responded to the dose of 50 mg, 75 mg,  
100 mg and 200 mg , respectively,  compared to 29% in placebo.  For NMPP , 37%, 46%, 59%, 62% and 
48% of subjects responded to  the doses of 50, 75, 100 and 200 mg linzagolix , respectively,  compared 
to 37% in placebo.  Suppression of E2 was dose dependent  with partial suppression achieved with once 
daily 75  mg dose and complete suppression with once daily 200  mg dose . Mean percent (95% CI , P 
value) BMD changes for lumbar spi[INVESTIGATOR_684041] 24 in the 50, 75, 100 and 200 mg dose 
groups were 0.137% ( -0.83, -1.11, P=.777), 0.798% ( -1.57, -0.03, P=.042), -1.365% ( -2.14, -0.59, 
P<.001), -2.602% ( -3.56, -1.65, P<.001). BMD of femo ral neck and total hip showed a similar pattern 
but with generally smaller changes from baseline.   
18-OBE2109 -[ADDRESS_926450] been chosen for Phase 3 confirmatory registration studies: 75 mg alone and 200 mg in combination 
with hormone ABT  (E2 1  mg/NETA 0.5  mg).  
The two doses are chosen to provide two different long-term treatment options for women suffering 
from endometriosis: one dose providing a sig nificant pain control for the majority of patients whilst 
maintaining E2 at levels above 20 pg/mL, which will mitigate a major impact on bone mineral density 
and one high dose requiring administ ration  with hormone ABT  (E2 1 mg/NETA 0.5 mg) achieving a 
better  symptom control for some patients by [CONTACT_684088] E2 suppression but limiting the impact 
on bone mineral density due to the addition of ABT . 
The study is double -blind and placebo -controlled which is considered the gold standard to prove effica cy 
of new medicines, in particular if  potential advantages over alternative therapi[INVESTIGATOR_684042]  (15).  For this reason, a  placebo -controlled study is required by [CONTACT_684089] a product. In this study, the placebo control is restricted to 6 months after 
which all subjects  will be offered active treatment (while maintaining the double -blind) for a further [ADDRESS_926451] -treatment follow -
up, except for subjects who discontinued treatment prior to completing 3 months of treatment; those 
subjects will be directly discontinued from the study.   
5.[ADDRESS_926452] common gynecological 
diseases (1). It is characteri zed by [CONTACT_684090], dyspareunia, chronic pelvic pain, 
dysuria and dyschezia. Medical options are still limited and new treatment options are warranted . 
Linzagolix  is a new oral GnRH antagonist which has been shown significantly to reduce EAP  via dose 
dependent suppression of LH, FSH and E2. This has included clinically meaningful improvements in 
DYS , NMPP, dyschezia and dyspareunia. Efficacy compared to placebo was demonstrated at daily 
doses of 75–[ADDRESS_926453] been observed in the Phase 2 studies . No fetal or newborn abnormalities  were 
reported  in any of these pregnancies . 
There were no clinically relevant findings in laboratory measurements, vital signs or electrocardiogram 
(ECG ) recordings. The administration of linzagolix  results in infrequent, transient, moderate and not 
dose-related increases in transaminase levels which were not associated with any change in bilirubin 
levels.  A borderline increase in QTc interval was observed  in healthy volunteers which was not 
considered clinically significant. Nevertheless, all subjects in th e current  study will be monitored 
monthly with ECG.  
A modest degree of BMD loss has been seen in linzagolix -treated subjects with doses below 100 mg 
QD. Clinically significant BMD loss was observed with a dose of 200 mg QD at 6 months of treatment 
and requires combined use of ABT to mitigate BMD loss. The B MD loss will be monitored during the 
study and subjects who experience more than 8% confirmed BMD loss or a Z -score ≤ -2.5 will be 

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 40 of 156 
 OBSEVA  CONFIDENTIAL  discontinued from treatment  and will not be eligible to enter the extension study . In addition, subjects 
will be provided with vitamin D and calcium supplements which they will be recommended to take . 
In conclusion, linzagolix  has a favorable benefit/risk ratio and represents a potentially useful therapy for 
treating EAP . 
The overall benefit/risk of this study wa s re-evaluated by [CONTACT_684091] -19 pandemic 
and evolving regulatory guidance.  
The trial was not completely stopped; rather, ObsEva implemented a temporary hold on recruitment  in 
order to ensure patient safety.  Therefore, ObsEva believes the hold  had no potential effect on the 
benefit/risk balance  for subjects . 
Respecting national recommendations, as the COVID -[ADDRESS_926454]  were setup, whenever feasible, based on local restrictions related to the pandemic.  Sites 
scheduled telephone call s to subjects  as replacement for on -site visits, to en sure continuity in patient’s 
safety monitoring, treatment and study data collection.  
 
6 OBJECTIVES  
6.1 EFFICACY OBJECTIVES  
6.1.1 Primary  
The primary objective of this study is to demonstrate the efficacy and safety of linzagolix administered 
orally once daily for up to 3 months at a dose of 75 mg alone or of 200 mg in combination with ABT 
(E2 1 mg / NETA 0.5 mg) versus placebo, while under randomized treatment, in the management of 
moderate to severe EAP in women with surgically confirmed endometriosis. The two co -primary 
efficacy endpoints will be clinically meaningful reduction over the last 28 day s of randomized treatment 
up to the M onth 3 visit  along with a stable or decreased use of analgesics for EAP for 1) DYS and for 
2) NMPP.  
6.1.[ADDRESS_926455] 28 day s of random ized 
treatment up to the M onth 6 visit , evaluation of pain associated with sexual intercourse (dyspareunia) 
and defecation (dyschezia), difficulty of doing daily activities, analge sic use, assessment of subject 
perception of severity, change in uterine bleeding, Quality of Life (QoL) questionnaires, 
pharmacoeconomic burden of endometriosis by [CONTACT_684092], assessment 
18-OBE2109 -[ADDRESS_926456] 28 days preceding the Month 3 visit (the 4 -week period  preceding Month 3 visit) or, for subjects 
who discontinue randomized treatment prior to the Month [ADDRESS_926457] 28 days of randomized 
treatment, along with a stable or decreased use of analgesics for EAP,  in the mean daily assessment of 
1) DYS and of 2) NMPP measured on a Verbal Rating Scale (VRS) using an electronic diary (eDiary) . 
7.1.2 Secondary  
[IP_ADDRESS]  Ranked secondary efficacy endpoints  
Ranked  secondary efficacy endpoints  (in the order of the endpoints to be tested)  are: 
 Change from baseline to Month 6 in DYS (VRS)  
 Change from baseline to Month 6 in NMPP (VRS)  
 Change from baseline to Month 6 in dyschezia (Numeric Rating Scale - NRS)  
 Change from baseline to Month 6 in overall pelvic pain ( NRS ) 
 Change from baseline to Month 6 in the interference of pain with the ability to perform daily 
activities, measured using the pain dimension of the Endometriosis Health Profile -30 (EHP -
30)  
 Change from baseline to Month 6 in dyspareunia (VRS)  
 No analgesics use for EAP during the preceding 4 -week period at Month 6  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 42 of 156 
 OBSEVA  CONFIDENTIAL   No opia te use for EAP during the preceding 4 -week period at Month 6  
[IP_ADDRESS]  Additional secondary efficacy endpoints  
Additional secondar y efficacy endpoints include : 
 Clinically meaningful reduction at scheduled visits other than Month 3 for DYS and NMPP  
 Change from baseline to each scheduled assessment in the mean pelvic pain scores for DYS, 
NMPP and overall pelvic pain, during the previous 4 -week period assessed on the NRS and 
VRS  
 Change from baseline to each scheduled assessment in the number of days with moderate to 
severe pelvic pain during the previous 4 -week period assessed on the VRS  
 Change from baseline to each scheduled assessment in the mean worst pelvic pain score 
defined as the mean of the [ADDRESS_926458] daily pain scores reported during the previous 4 -week 
period assessed on the NRS  
 Change from baseline to each scheduled assessment in the mean of daily dyspareunia scores 
reported during the previous 4 -week period on the dyspareunia VRS  
 Change from baseline to each scheduled assessment in the mean of daily dysc hezia scores 
reported during the previous 4 -week period assessed on the dyschezia NRS  
 Change from baseline to each scheduled assessment in non -opi[INVESTIGATOR_2480], opi[INVESTIGATOR_684043] 4 -week period based on pi[INVESTIGATOR_684044]  
 Change from baseline to each scheduled assessment in opi[INVESTIGATOR_684045] 4-week period based on morphine milligram 
equivalent (MME)  
 Change from baseline to each scheduled assessment in the numbe r of days of analgesic use 
(including any class) for EAP during the previous 4 -week period as assessed in the eDiary  
 Change from baseline to each scheduled assessment in the number of days of opi[INVESTIGATOR_684046] 4 -week period a s assessed in the eDiary  
 Change from baseline to each scheduled assessment in the number of pelvic pain -free days 
(assessed on the VRS) during the previous 4 -week period  
 Change from baseline to each scheduled assessment in ability to perform daily activit ies 
during the previous 4-week period, as assessed in the eDiary (daily function NRS)  
 Change from baseline to each scheduled assessment in the number of days with no difficulty 
in doing daily activities due to EAP during the previous 4 -week period as assessed in the 
eDiary (daily function NRS)  
 Change from baseline to each scheduled assessment in the number of days when dyspareunia 
was a problem during the previous 4 -week period (including days when sexual intercourse was 
avoided because of anticipation  of pain) as assessed on the dyspareunia VRS  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 43 of 156 
 OBSEVA  CONFIDENTIAL   Change from baseline to each scheduled assessment in the number of days when sexual 
intercourse was avoided because of anticipation of pain during the previous 4 -week period as 
assessed on the dyspareunia VRS  
 Change from baseline to each scheduled assessment in the number of days with uterine 
bleeding (including spotting) during the previous 4 -week period  measured by [CONTACT_289427]  
 Change from baseline to each scheduled assessment in the number of days when school or 
work was missed due to EAP in the previous 4 -week period as reported in the eDiary  
 Change from baseline to each scheduled assessment in the number of days when the subject 
had to go to bed or lie down due to EAP in the previous 4 -week period as reported in th e eDiary  
 Change from baseline to each scheduled assessment in the Pain, Control and powerlessness, 
Emotional well -being, Social support, Self -image dimensions and the Modular sexual 
relationship questionnaire of EHP -30 scores  
 Change from baseline to each s cheduled assessment in the Health Related Productivity 
Questionnaire (HRPQ) scores  
 Number of non -study endometriosis related health visits, number of days in hospi[INVESTIGATOR_684047] (HRUQ ) at each 
scheduled assessment  
 Change from baseline to each scheduled assessment in the Physician/Subject Surgery Intention 
Question (PSIQ/SSIQ)  
 Change from baseline to each scheduled assessment in the PROMIS Fatigue – Short Form 6a  
 Change from baseline to  each scheduled assessment in the EuroQoL 5 -Dimension 5 -Level 
(EQ-5D-5L) questionnaire  
 Response at each scheduled assessment according to Patient Global Impression of Change 
(PGIC) (and Post -treatment Patient Global Impression of Change, PPGIC)  
 Change from  baseline to each scheduled assessment in the monthly PGIS (mPGIS) score  
7.2 SAFETY ENDPOINTS  
 Change from baseline to each scheduled assessment in BMD measured by [CONTACT_684093][INVESTIGATOR_050] 
(L1-L4), femoral neck, and total hip  
 Incidence and severity of treatment emergent adverse events (TEAEs)  
 Incidence and severity of hypoestrogenic TEAEs (hot flush)  
 Time to the first post -treatment menses  
 Changes in clinical laboratory assessments (hematology, biochemistry, coagulation parameters, 
hormones, lipi[INVESTIGATOR_303648] ) from baseline to each scheduled assessment  
 Any pathological changes from baseline in the endometrium as assessed by [CONTACT_684094]  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 44 of 156 
 OBSEVA  CONFIDENTIAL   Changes from baseline to each scheduled assessment in any other safety parameter including 
weight, vit al signs, ECG, gynecological assessments and endometrial thickness  
7.3 EXPLORATORY  ENDPOINTS  
 Change from baseline in bone turnover markers at each scheduled assessment  
 PK and PD of linzagolix  
8 STUDY DESIGN  
This is a prospective, randomized, double -blind, placebo -controlled study to demonstrate the efficacy 
and safety of linzagolix administered orally once daily at doses of 75 mg alone and 200 mg in 
combination with low dose ABT (E2 1 mg/NETA 0.5 mg) versus p lacebo in the management of 
moderate to severe EAP in women with surgically confirmed endometriosis.  
The study starts with an approximately 3 -month screening period during which subjects will receive 
no study drug. Eligibility will be confirmed based on da ta collected during the screening period. After 
randomization, a 6 -month Treatment Period will follow. Subjects will be randomized to one of the 
three treatment groups:  
1. Linzagolix 75 mg  
2. Linzagolix 200 mg combined with ABT  
3. Placebo  
Randomization will be conducted via an interactive web response system (IWRS) in a 1:1:[ADDRESS_926459] 
completed the 6 -month treatment period may enter a separate extension study for 6 additional months 
of active treatment (no placebo control). In this extension study, subjects who previously received 
placebo will be randomly switched to one of the two active treatments (75 mg alone or 200 mg + 
ABT). Subjects who re ceived active treatment will continue with the same treatment.  
Subjects who decline to participate to or do not qualify for the extension study and who were exposed 
to at least 3 months of treatment will enter a 6 -month drug -free follow -up. At the end of t he 6-month 
follow -up period, subjects with a BMD decrease from baseline of >1.5% for lumbar spi[INVESTIGATOR_20793] /or 
>2.5% for total hip will have an additional DXA scan 6 months later. Subjects who discontinue 
treatment prior to Month 3 will not enter the follow -up period.  
The main analysis will be performed after 6 months of treatment and will include all of the subj ects’ 
data up to Month 6.  
The study will last on average 15 months; 3 -month Screening Period, 6 -month Treatment Period and 
6-month Follow -up (with 1 month being defined as 28 days/4 weeks). The duration excludes any 
washout period.  
18-OBE2109 -[ADDRESS_926460] 
a DXA scan.  
A schematic of the study design is shown in  Figure 1. 
 
Figure 1 : Study design  
 
All subjects will receive once daily either linzagolix 75 mg alone (with ABT placebo) or linzagolix 
200 mg combined with low dose ABT , or placebo  (linzagolix placebo with ABT placebo)  for 6 months. 
ABT is a combination of estradiol (E2) 1 mg and norethisterone acetate (NETA) 0.5 mg. Linzagolix 
or its corresponding placebo will be supplied as tablets for oral administration. ABT or its 
corresponding placebo will be supplied as capsules for oral administration.   
Linzagolix/placebo treatments will be provided in monthly treatment kits, packaged, labelled and 
administered in the same manner to protect the blinded nature of the trial.  
ABT/pla cebo treatments will be supplied as [ADDRESS_926461]’s randomized treatment will be provided 
through an IWRS.  

18-OBE2109 -[ADDRESS_926462] agree to use double non -hormonal barrier 
contraception from screening until 3 months after the end of treatment. From 3 months after the end of 
treatment to the end of th e drug -free follow -up period, contraception is still mandatory but hormonal 
contraception is allowed.  
9.1.2 Number of subjects  
Four hundred and fifty (450) randomi zed subjects  are planned in total ( approximately 150 subjects per 
group ). It is expected that the screen failure rate will be around 60%. Therefore , approximately 1125 
subjects will be screened in order to randomize 450 subjects into the study.  
9.1.3 Study region/location  
The study will be conducted in approximately 1 00 investigational sites in the Unites States (US) and 
Europe . Additional sites will be identified, qualified and activated in case of recruitment issues. 
Recruitment will be competitive between countries and sites.  
9.[ADDRESS_926463] recent surgical and – if available – histological diagnosis 
of pelvic endometriosis (laparoscopy, laparotomy, vaginal fornix or other biopsy) up to [ADDRESS_926464] agree to the washout intervals for prohibited therapi[INVESTIGATOR_014] (if applicable).  
5. The subject must agree to switch from her usual analge sic rescue medication to only those 
permitted by [CONTACT_684078], Treatment and Follow -up Period.  
6. The subject has moderate to severe EAP during the screening period defined as:  
a. At the screening visit, a score of at least [ADDRESS_926465] 2 for NMPP for the 
previous month assessed with the modified Biberoglu & Behrman (mB&B) scale.  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 47 of 156 
 OBSEVA  CONFIDENTIAL  b. Over two full menstrual cycles (i.e. from day [ADDRESS_926466] menstruation) finishing just before the baseline visit:  
i. Mean overall pelvic pain scores of at least 4 on the 0 –[ADDRESS_926467] score for each cycle separately, i.e. required for both cycles;  
ii. At least two days with “moderate” or “severe” pain on the 0 –3 VRS for pelvic 
pain over the days with uterine bleeding for each cycle separately, i.e. required 
for both cycles;  
iii. At least two days with “moderate” or “severe” pain on the 0 –[ADDRESS_926468] 75% of days during 
the screening period.  
8. The subject has regular menstrual cycles and the total len gth of the two screening menstrual 
cycles should be between [ADDRESS_926469] has a Body Mass Index (BMI) ≥ 18 kg/m2 at the screening visit.  
10. If of childbearing potential, the subject agrees to use one of the following birth control meth ods 
during the Screening  Period , the entire Treatment Period of the study and until 3 months after 
the end of treatment:  
a. Sexual abstinence, if this is the subject's habitual practice and/or the subject is 
routinely abstinent from heterosexual intercourse,  
b. Partner with a vasectomy with confirmed azoospermia,  
c. Double non -hormonal barrier contraception such as condom or diaphragm each 
combined with spermicide.  
11. If of non -childbearing potential, the subject must have had tubal ligation sterilization at least 
two months before the screening visit.  
12. The subject is ≥ [ADDRESS_926470] not meet any of the following criteria:  
1. The subject is pregnant or breast feeding or is planning a pregnancy within the duration of the 
Treatment Period of the study.  
2. The subject is less than [ADDRESS_926471] -abortion/miscarriage at the time 
of entry into the screening period.  
3. The subject has a surgical history of:  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 48 of 156 
 OBSEVA  CONFIDENTIAL  a. Hysterectomy,  
b. Bilateral oophorectomy,  
c. Vagotomy, bowel resection or any surgical procedure (including gastric surgery) that 
might interfere with gastrointestinal motility, pH, or absorption,  
d. Any major abdominal surgery (including laparotomy for endometriosis) within [ADDRESS_926472] had a tubal sterilization which was performed with ESSURE™.  
5. The subject had endo metrial ablation resulting in amenorrhea.  
6. The subject has at least one ovarian endometrioma with a diameter of [ADDRESS_926473] is likely to require treatment during the study OR received treatment within a 
specified period prior to screening w ith any of the medications listed below:  
a. GnRH antagonists  [ADDRESS_926474] injections/3 -month depot injections  3/6 months  
c. Danazol  3 months  
d. Oral contraceptives and other sex hormones  1 month  
e. Depot contraceptives  10 months  
f. Selective Progesterone Receptor Modulators (SPRMs), 
Selective Estrogen Receptor Modulators (SERMs) and 
aromatase inhibitors  3 months  
g. Long acting narcotics (i.e. requiring less than once daily 
dosing)  1 day  
h. Systemic glucocorticoid treatments for acute diseases 
(not depot)  1 month  
i. Medical (prescribed) marijuana  1 week  
j. In situ copper intra -uterine device (IUD)  [ADDRESS_926475] received strong CYP3A4 inducers or inhibitors that (might potentially) interact 
with ABT within [ADDRESS_926476] has a contra -indication to ABT including:  
a. Active deep vein thrombosis, pulmonary embolism, or history of these conditions;  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 49 of 156 
 OBSEVA  CONFIDENTIAL  b. Active or recent (e.g. within the past year) arterial thromboembolic disease (e.g. stroke, 
myocardial infarcti on); 
c. Known, suspected, or history of breast cancer;  
d. Known or suspected estrogen -dependent neoplasia;  
e. Known protein C, protein S, or antithrombin deficiency, or other known thrombophilia 
disorders, including Factor V Leiden;  
f. Migraine with aura;  
g. History of porphyria;  
h. Known hypersensitivity to the ingredients.  
12. The subject has a history of or current systemic glucocorticoid therapy for treatment of chronic 
diseases (e.g. Systemic Lupus Erythematosus (SLE), rheumatic arthritis). Inhaled 
glucocorticoids for e.g.  asthma are not considered systemic glucocorticoids.  
13. The subject did not respond to prior treatment with GnRH agonists or GnRH antagonists for 
endometriosis.  
14. The subject has alanine aminotransferase (ALT), aspartate aminotransferase (AST), total 
bilirubin levels or gamma -glutamyl transpeptidase (GGT) level ≥ 2 times the upper limit of 
normal and indicative of potential liver damage at Screening or Day 1 (subjects with 
abnormalities at Day 1 will be withdrawn from study at reception of the results).  
15. The subj ect has clinically significant abnormal ECG, or ECG with QTc using Fridericia's 
correction formula (QTcF) > 450 msec at Screening or Day 1 (prior to dosing).  
16. The subject has a known positive human immunodeficiency virus  (HIV) or viral Hepatitis 
serology.  
17. The subject has abnormal uterine bleeding of undiagnosed cause.  
18. The subject had/has clinically significant findings from a Papanikolaou (PAP) smear test 
performed within the past 12 months or at the screening visit which will require surgical 
intervention (e.g. Loop electrosurgical excision procedure (LEEP) or cervical conization).  
19. The subject has chronic pelvic pain that, in the opi[INVESTIGATOR_125362], is not caused by 
[CONTACT_684079] (e.g., interstitial cystitis, presumptive adenomyosis, fibroids, non -
endometriosis -related pelvic adhesive disease, post-tubal ligation or irritable bowel 
syndrome).  
20. The subject has any other clinically significant gynecological condition identified during 
screening t ransvaginal ultrasound  (TVUS) or endometrial biopsy which might interfere with 
the study efficacy and s afety objectives  (e.g. endometritis, endometrial hyperplasia) . However, 
uterine fibroids (as long as uterus size ≤ 12 weeks, i.e. equivalent gestational weeks) and 
adenomyosis are allowed provided they do not interfere with the assessment of EAP (see 
previ ous criterion).  
21. The subject has any known condition, including findings in the medical history or in the 
screening assessments, which in the opi[INVESTIGATOR_684033] a risk or a 
18-OBE2109 -[ADDRESS_926477] has a history of, or known, osteoporosis , hyperparathyroidism  or other metabolic 
bone disease.  
a. Screening DXA results of the lumbar spi[INVESTIGATOR_050] (L1 –L4), femoral neck, or total hip BMD 
showing a Z -score ≤ –1.5  
b. Any condition that would interfere with obtaining adequate DXA measurements (e.g. 
weight [> 300 pounds or 136 kg], history of spi[INVESTIGATOR_61691], spi[INVESTIGATOR_684048], severe 
scoliosis)  
c. Intercurrent bone disease  
d. History of hip fracture  
e. History of pathologic or compression fractures  
f. History of bilateral hip replacement  
23. The subject has a mental condition rendering her unable to understand the nature, scope and 
possible consequences of the study, or evidence of an uncooperative attitude.  
24. The subject has current problem with alcohol or drug abuse (including painkiller abuse).  
25. The subject has been administered with any experimental drug in the [ADDRESS_926478] has a history of, or active malignancy (with or without systemic chemotherapy) 
(except treated basal carcinoma of the skin wh ich is not an exclusion criterion ). 
28. The subject  has a history of attempted suicide and/or a history of, or known major psychiatric 
disorders that are not well controlled.  
[ADDRESS_926479] (IMP), study  procedures and potential risks and they 
will also be informed verbally by [CONTACT_684095] . They will be instructed that they can obtain further information from the 
Investigator at any time and that they are free to withdraw their consent and to discontinue thei r 
participation in the project at any time without prejudice.  
If the subject is willing to participate in the study, she will be requested to give written informed consent 
prior to conducting any of the study screening procedures , after being given suffici ent time to consider 
her participation and the opportunity to ask for further details. One original cop y of the consent form 
will be signed and personally dated by [CONTACT_684096] 
18-OBE2109 -[ADDRESS_926480]  will be asked if she authorize s the Investigator to notify her general practitioner of her 
participation in the trial.  
Upon signature [CONTACT_42956]  (ICF), each subject will be assigned a Subject 
Identification Number  (SIN)  through a n IWRS . SINs  will be made of 6 digits, as follows:  
 1st, 2nd and 3rd digits:  site identifier ( 100 to 999) 
 4th, 5th and 6th digits: subject number ( 001 to 999) 
During the whole study, the subject will be identified using the SIN for all documentation and 
discussion. The SIN assigned to a subject in this way must only be used for that subject.  
Should a subject drop  out from the study , the SIN will not be re -allocated.  
Screen failures may be re -screened at a later date with the Sponsor’s approval if it is believed that the 
reason for excluding them initially is no longer applicable. Any re -screened subject will be assigned a 
new SIN through a n IWRS  and a ll the screening information will be collected again.  All screening 
procedures should be repeated except  endometri al biopsy collection (if done during the preceding 6 
months of re -screening) , PAP smear  (if done during the preceding 12 months of re -screening) , DXA (if 
done during the preceding 3 months of randomization ) and mammogram  (if done during the preceding 
12 months of randomization) . 
An electronic Case Report Form  (eCRF ) will be completed for all  subjects who signed the ICF.  
For screen failed subjects, the following information will be collected at a minimum: Informed Consent, 
Demographics, AEs and reason for screen failure.  
When a subject has been found to be eligible for the study, she will be ra ndomi zed to one of the three  
treatment groups  in a 1:1:1  ratio ( approximately 150 subjects per treatment group ) as shown in Figure 
1. 
Randomization will be done according to a computer -generated list. Treatment assignments will be 
obtained via IWRS according to the randomization list. The subject will be allocated  a randomization 
number and  treatment kit number s via IWRS.  The randomization number allocated to the subject will 
allow any unblinded study person nel to identify the treatment group to which the subject is randomized.  
Treatment kits will be dispensed to the subjects as follows:  
- on Day [ADDRESS_926481] will receive two kits , one for linzagolix /placebo  (monthly 
kit) and one for the ABT /placebo  (3-monthly kit) .  
- On Month 1, Month 2, Month [ADDRESS_926482] will receive one kit only , for 
linzagolix /placebo .  
The treatment kit numbers for linzagolix/placebo and ABT/placebo will refer to unique kits present at 
site and corresponding to the randomization allocation.  

18-OBE2109 -[ADDRESS_926483] at the end of the defined period (i.e. Month 1  visit should be 
scheduled at the end of Month 1 , Month 2  visit should be scheduled at the end of Month 2 , etc.).  One 
month is defined as 28 days /[ADDRESS_926484]-baselin e visit dates are calculated from Day 1 visit date  :  
- Month 1 ( Day 29), Month 2 ( Day 57), Month 3 ( Day 85), Month 4 ( Day 113), Month 5 
(Day 141) and Month 6 ( Day 169) for the Treatment Period,  
- Month 1 FU  (Day 197), Month  2 FU (Day 225), Month  3 FU  (Day 253), Month  4 FU  (Day 
281), Month  5 FU  (Day 309) and Month  6 FU  (Day 337) for the Follow -up Period.  
A window of ± 3 days is allowed for each visit schedule d during the treatment period . A window of ± 7 
days/ 1 week is allowed for each visit schedule d during the follow -up period. The visit schedule is 
illustrated in Figure 2 below:   
 
Figure 2 : Schedule of Visits  
 
The timing of events is shown in the Schedule of Asses sments  (Appendix A  and Appendix B ). 
10.2.1  Screening Period  – Screening visit  
The subject will be informed of the study objectives and overall requirements, and written informed 
consent will be obtained before performing any study -specific procedures  that are not standard of care . 
The subject will be considered as included  into the study after the ICF is signed and dated by [CONTACT_684097] . 
For subjects who require washout for oral contraceptives , or other sex hormones, or GnRH 
antagonists/agonists  (provided that the reason for discontinuing the previous GnRH -antagonist is not 
lack of efficacy ), a period of up to [ADDRESS_926485] screening visit 
(e.g. the endometri al biopsy must be performed after day 7 of the menstrual cycle) . 
During th e screening period  the following study screening assessments  will be completed  (see Schedule 
of Assessments  in Appendix A ): 
- Demographic  data, height  and weight  
- Medical and surgical  history including concomitant diseases  (and especially presence of 
rectovaginal endometriosis and adenomyosis) , previous medication, obstetric/gynecological 
history  and history of endometriosis including diagnosis and previous treatments  for 
endometriosis.  
- Assessment of DYS , dyspareunia and NMPP  with the m B&B scale (see Appendix C ). Answers 
will be captured in eCRF.  
- Completion of the paper C -SSRS questionnaire “Baseline” version specific for subjects under 
screening  (see Appendix R ) 
- ECG  
- Physical examination  
- Vital signs (blood pressure  (BP)  and heart rate)  
- Urine pregnancy test  
- TVUS  of uterus and ovaries to measure endometrial thickness, to rule out any clinically 
significant gynecologic al condition s which might interfere with the study efficacy and safety 
objectives and to confirm that the subject has no ovarian endometrioma  ≥ 7 cm in diameter  
- Gynecological examination , including the m B&B  scale  (see Appendix C ) clinical signs 
reporting  (pelvic tenderness and pelvic induration ) 
- Endometrial biopsy  (should be performed at least [ADDRESS_926486] day of menstruation and 
sent for central assessment).  If no tissue  is available, the biopsy should be repeated as soon as 
possible in the following days.  In case of multiple (at least two  including the initial one ) and 
unsuccessful attempts to get sufficient endometrial tissue, the subject is allowed to be 
randomized without any screening endometrial biopsy under the following conditions:  
a. the investigator confirms and documents in source that the subject  has no signs of 
suspected endometrium malignancy (e.g. abnormal bleeding profile) .  
b. The investigator and subject agree that at end of treatment all necessary actions will be 
taken to get a sufficient endometrium sample (e.g. short anaesthesia, if necessar y). 
c. The medical monitor of the study approves the inclusion of the subject . 
The endometri al biopsy is not required for subjects having performed an endometri al biopsy 
within the past 6 months of the screening visit, which shows no endometrium hyperplasia of 
any type or adenocarcinoma  and for which slides are available for current study assessment 
through retrospective central laboratory reading.  

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 54 of 156 
 OBSEVA  CONFIDENTIAL  - PAP smear  
A screening PAP smear is not required for subjects in whom  a PAP smear was performed within 
the 12 months prior to the screening visit and which results indicate no clinically significant 
abnormalities requiring surgical intervent ion (e.g. LEEP or cervical coniz ation) and are 
available for source document verification.  
- Manual breast examination by [CONTACT_304728]  (and mammography if applicable : subject ≥ [ADDRESS_926487] perform ed a mammogram within 12 months  before 
randomization ) 
- Blood samples for haematology, coagulation parameters, chemistry  and lipi[INVESTIGATOR_684049]  
- Urinary protein dipstick.  
- Contraception dispensing and counselling  
- BMD assessed by  [CONTACT_304726], hip and spi[INVESTIGATOR_050]. The DXA scans will be read centrally.  
To avoid unnecessary exposure to X -ray it is recommended to perform this procedure towards 
the end of the screening period  (when all other Incl usion /Excl usion  criteria are already met) , 
but at least [ADDRESS_926488] will receive double barrier contraception (condoms with spermicide) if requested . If the 
subject is at risk for acquiring HIV, she must be instructed to use double non -hormonal barrier 
contraception without spermicides ( eg: condoms and diaphragms).  
In addition, a limited quantity (as per Investigator’s judgement) of permitted analgesics  will be 
provided /prescribed  to the subject at the screening visit to cover the screening period.  
The subject will be given a n eDiary  with a user manual to take home and will be trained  by [CONTACT_684098] . Subject eDiary  completion should be 
started on the day of screening visit  (after completion of  washout period when applicable ). The eDiary  
should be completed dail y, in the evening at approximately the same time, for use of p rovided/prescribed  
analgesics, uterine bleeding (including start of menstruation), pelvic pain, dyspareunia, dyschezia  and 
daily function. The eDiary screening assessments should cover at least two full menstrual cycle s (from 
day [ADDRESS_926489] menstruation ).  
A daily alarm will be set up in the eDiary  to remind the patient to comple te her daily questions. In 
addition, appropriate email alerts will be sent to the site staff and to the operation al team in case of 
missed diar y entries . eDiary  compliance will be checked  remotely on an ongoing basis by [CONTACT_684099] . 
Any concomitant medications  taken after signature [CONTACT_304764]  
(excluding  any p rovided/prescribed  analgesics used for EAP which will be recorded daily in the eDiary ). 
Any AE occurring after signature [CONTACT_304765] . 
The s ubject will be asked to return to the site  and bring her eDiary  between the first and seventh day 
(inclusive) of her next menstrual period (the period after the 2 screening  full menstrual cycle s) for the 
Day [ADDRESS_926490]  is unable to come to the clinic for Day 1 within 
the acceptable time window (1st to 7th day inclusive of the cycle ) then the subject will be allowed to start 
Day 1 in the following cycle  (again on the 1st to 7th day of the cycle) . In this case, the eligibility 
assessments should be assessed  based on the first two cycles only. However, the eDiary  recording should 
be continued daily  during the third cycle . 
Note that in exceptional cases, the Day [ADDRESS_926491] should 
communicate (e.g., via phone) r esults of the test to the site for recording into the source medical file.  
10.2.[ADDRESS_926492]  daily  in her eDiary , at approximately the same time 
each evening, the following questionnaires: IMP intake, use of provided/prescribed analgesics, uterine 
bleeding, pelvic pain, dyspareunia, dyschezia  and daily function .  
During  the entire treatment period, t he subject will be asked  to bring her eDiary and her IMP kits  at each 
visit to the site .  
[IP_ADDRESS]  Baseline visit : Day [ADDRESS_926493] and seventh  
day (inclusive) of her menstruation , she will go to the investigational site for the following evaluations 
and tests before  drug administration : 
- eDiary eligibility data  review  
- ePRO and ClinRO completion, ideally before any other procedures or asses sments: EHP -
30, HRPQ, HRUQ, PSIQ, SSIQ, PROMIS, EQ -5D-5L, specific monthly severity questions,  
mPGIS (anchors  must be completed last)  
- Completion of the paper C -SSRS questionnaire “Baseline” version, if not already completed 
during screening period (see Appendix R)  
- Screening DXA results  review  
- Screening lab results  review  
- Screening endometri al biopsy results review (randomization will not be postponed if the 
results of the endometri al biopsy performed during the screening period  are not available 
on Day 1 ) 
- Previous and concomitant treatments  recording  
- AE recording  
- ECG  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 56 of 156 
 OBSEVA  CONFIDENTIAL  - Vital signs ( BP and heart rate)  
- Urine pregnancy test  
- Urinary protein dipstick  
- Fasting (overnight) blood samples for haematology, coagulation parameters, chemistry, 
lipi[INVESTIGATOR_805] , glucose, hormones  and bone biomarkers , prior to the first administration of study 
treatment , and after confirmation  of the subject’s eligibility (considering the invasive nature 
of this procedure ). 
Upon confirmation of inclusion/exclusion criteria, t he subject will be rand omized to one of the three  
treatment groups and will be provided with the study drug s (1 kit of linzagolix/placebo and 1 kit of 
ABT/placebo) and provided/prescribed with permitted analgesics  as well as v itami n D and c alcium 
supplements . The s ubject will be instructed on how to take the  study drugs and analgesics, and advised 
to take the provided vitamin D and calcium  daily . The subject will be provided /prescribed  as necessary 
with analgesics and vitamin D/c alcium supplements at each subsequent  visit to cover requirements until 
the end of the follow -up period . 
The s ubject will take her first dose of study medication  at the study site. The exact time of dosing 
(hour/minute) will be recorded in eCRF.  
After  drug administration, the following procedure s will be performed:  
- ECG at about the same time as but before  the post-dose PK sample  
- Post-dose PK sample taken at least 1.[ADDRESS_926494] time of 
dosing  and of PK sampling  (hour/minute)  will be recorded  in the eCRF . 
- Contraception dispensing  (if applicable)  and counselling  
The subject will receive double barrier contraception (condoms with spermicide) if requested . If the 
subject is at risk for acquiring HIV, she will be instructed  to use double non -hormonal barrier 
contraception without spermicides (condoms and diaphragms).  
Upon completion of the visit,  the subject will be provided with emergency contact [CONTACT_684100].  
For the whole duration of the treatment period, the subject will take her daily dose of study medication 
at home except on the day of study visits where she will take her daily dose at site.  
[IP_ADDRESS]  Study visits : Month 1  (Day 29 -3/+2 days) and Month  2 (Day 57 ± 3 days)  
The following tests  and evaluations will be performed  : 
- eDiary completion compliance check  
- ePRO and ClinRO completion, ideally before any other procedures or asses sments:  
 at Month 1 visit: EHP -30, HRPQ, HRUQ, PROMIS, EQ -5D-5L, mPGIS, PGIC  
 at Month 2 visit:  HRPQ, HRUQ, mPGIS, PGIC  
18-OBE2109 -[ADDRESS_926495].  
- Concomitant treatment s recording  
- AE recording  
- Completion of the paper C -SSRS questionnaire (version for “already enrolled subjects” (see 
Appendix S ) for patients responding to the C -SSRS for the first time during the study, or 
version “since last study visit” (see Appendix T ) for patients for whom the C -SSRS was 
completed at the previous study visit)  
- IMP accountability based on blisters  
- ECG (at about the same time as but before the PK sample)  
- Vital signs ( BP and h eart rate)  
- Urine pregnancy test  
- Urinary protein dipstick  
- Blood samples for haematology, coagulation parameters, chemistry, lipi[INVESTIGATOR_805], hormones  
(overnight fasting required at Month 1 visit only)  
- Pre-dose PK sample (the time of study medication administration on previous 4 days and time 
of PK sampling will be recorded)  
- Contraception dispensing (if applicable) and counselling  
- Dispensing via IWRS of one new kit of linzagolix/placebo  
The subject will take her daily dose of study medication at the study site from the newly dispensed  
linzagolix/placebo kit, and from  the ABT/placebo kit dispensed at the baseline  visit. 
[IP_ADDRESS]  Study visit : Month 3  (day 85 ± 3 days)  
The following tests and evaluations will be performed:  
- eDiary completion compliance check  
- ePRO and ClinRO completion, ideally before any other procedures or asses sments: EHP -30, 
HRPQ, HRUQ, PROMIS, EQ -5D-5L, specific monthly severity questions,  mPGIS, PGIC 
completion ( anchors  must be completed last)  
- Concomitant treatment s recording  
- AE recording  
- Completion of the paper C -SSRS questionnaire (version for “already enrolled subjects” (see 
Appendix S ) for patients responding to the C -SSRS for the  first time during the study, or version 
“since last study visit” (see Appendix T ) for patients for whom the C -SSRS was completed at 
the previous stud y visit)  
- IMP accountability based on blisters  

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 58 of 156 
 OBSEVA  CONFIDENTIAL  - ECG (at about the same time as but before the PK sample)  
- Physical examination  
- Vital signs ( BP and heart rate)  
- Urine pregnancy test  
- Gynecological examination  
- TVUS of the uterus  
- Urinary protein dipstick  
- Fasting (overnight) blood samples for haematology, coagulation parameters, chemistry, lipi[INVESTIGATOR_805], 
hormones and bone biomarkers  
- Pre-dose PK samples (the time of dose administration on previous 4 days and time of PK 
sampling will be recorded)  
- Contraception dispensing (i f applicable) and counselling  
- Dispensing via IWRS of one new kit of linzagolix/placebo and one new kit of ABT/placebo  
The subject will take her daily dose of study medication at the study site from the newly dispensed kits. 
[IP_ADDRESS]  Study visits : Month 4  (day 113 ± 3 days) and Month 5  (day 141 ± 3 days)  
The following tests and evaluations will be performed:  
- eDiary completion compliance check   
- ePRO and ClinRO completion, ideally before any other procedures or asses sments: HRPQ, 
HRUQ, mPGIS, PGIC completion (mPGIS and PGIC must be completed last)  
- Concomitant treatment s recording  
- AE recording  
- Completion of the paper C -SSRS questionnaire (version for “already enrolled subjects” (see 
Appendix S ) for patients responding to the C -SSRS for the first time during the study, or version 
“since last study visit” (see Appendix T ) for patients for whom the C -SSRS was completed at 
the previous study visit)  
- IMP accountability based on blisters  
- ECG (at about the same time as but before the PK sample)  
- Vital signs ( BP and h eart rate)  
- Urine pregnancy test  
- Urinary protein dipstick  
- Blood samples for haematology, coagulation parameters, chemistry, lipi[INVESTIGATOR_805], hormones  

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 59 of 156 
 OBSEVA  CONFIDENTIAL  - Pre-dose PK samples (the time of dose administration on previous 4 days and time of PK 
sampling will be recorded)  
- Contraception dispensing (if applicable) and counselling  
- Dispensing via IWRS of one new kit of linzagolix/placebo  
The subject will take her daily dose of study medication at the study site from the newly dispensed 
linzagolix/placebo kit , and from the ABT/p lacebo kit dispensed at the Month [ADDRESS_926496] will be informed of the possibility to enter the extension study at Month 6 
(if eligible) and will be provided with a copy of the subject information sheet to read prior to the Month 
6 visit.  
[IP_ADDRESS]  Study visit : Month 6  (day 169 ± 3 days)  
The following tests and evaluations will be performed  : 
- eDiary completion compliance check   
- ePRO and ClinRO completion, ideally before any other procedures or asses sments:  EHP -30, 
HRPQ, HRUQ, PSIQ, SSIQ, PROMIS, EQ -5D-5L, specific monthly severity questions, 
mPGIS, PGIC completion ( anchors  must be completed last)  
- Concomitant treatments recording  
- AE recording  
- Completion of the paper C -SSRS questionnaire (version for “already  enrolled subjects” (see 
Appendix S ) for patients responding to the C -SSRS for the first time during the study, or version 
“since last study visit” (see Appendix T ) for patients for whom the C -SSRS was completed at 
the previous study visit)  
- Final IMP accountability based on blisters  
- ECG (at about the same time as but before the PK sample)  
- Physical examination, including weigh t recording  
- Vital signs ( BP and heart rate)  
- Urine pregnancy test  
- Gynecological examination  
- Manual breast examination (by [CONTACT_23302])  
- TVUS of uterus  
- Urinary protein dipstick  
- Fasting (overnight) blood samples for haematology, coagulation parameters, chemistry, lipi[INVESTIGATOR_805], 
hormones and bone biomarkers  

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 60 of 156 
 OBSEVA  CONFIDENTIAL  - Pre-dose PK samples (the time of dose administration on previous [ADDRESS_926497] ing will be recorded)  
- Endometri al biopsy , unless the endometrium thickness in TVUS is ≤ 5 mm, in which case no 
endom etrial biopsy will be necessary (see section 10.4.5 ). Appropriate photo documentation of 
the endometrium thickness is mandatory.   
- BMD assessed by [CONTACT_304726], hi p and spi[INVESTIGATOR_050] . DXA can be performed up to [ADDRESS_926498] , knowing that  subjects who experience more than 8% BMD loss or a Z -
score ≤ -2.[ADDRESS_926499] will be verbally asked which treatment she believed she received during  the blinded 
Treatment Period . The answer will  be recorded in the eCRF . 
- Contraception dispensing (if applicable) and counselling  
An additional question will be asked to the subject about the burden of filling in the eDiary (0 = not at 
all a burden, 10 = very much a burden). The answer will be recorded in the eCRF.  
Study visit Month [ADDRESS_926500] – if eligible - will be proposed to enter the extension study . If she is willing to participate, 
she will have to provide written consent. If she does not wish to enter the extension study  or if she does 
not qualify for the extension , she will continue in the treatment -free follow -up period . 
10.2.[ADDRESS_926501] on her eDiary , daily at approximately the 
same time  each evening , her use of provided/prescribed analgesics, uterine bleeding, pelvic pain, 
dyspareunia, dyschezia  and daily function .  
The subject will be asked to bring her eDiary at each visit to the site during  the entire follow -up period.  
[IP_ADDRESS]  Study visit : Month 1 FU   
M1 FU visit should be scheduled on Day 197 ± 7 days after Day 1 (or 28 days ± [ADDRESS_926502] IMP 
intake for early discontinued subjects).  
The following tests and evaluations will be performed at Month 1 FU  visit: 
- eDiary completion compliance check   
- ePRO completion, ideally before any other procedures or asse ssments : mPGIS and PPGIC  
- Concomitant treatment s recording  
- AE recording  
- Completion of the paper C -SSRS questionnaire (version for “already enrolled subjects” (see 
Appendix S ) for patients responding to the C -SSRS for the first time during the study, or version 

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 61 of 156 
 OBSEVA  CONFIDENTIAL  “since last study visit” (see Appendix T ) for patients for whom the C -SSRS was completed at 
the previous study visit)  
- ECG  
- Vital signs ( BP and heart rate)  
- Urine pregnancy test and contraception counselling  
- Urinary protein dipstick  
- Blood samples for haematology, coagulation parameters, chemistry, lipi[INVESTIGATOR_805], hormones  
- Endometri al biopsy only if diagnosis at Month 6 was different than “benign endometrium” or if 
no endometrial biopsy was done  at Month 6 (see section 10.4.5 ).  
[IP_ADDRESS]  Study visits: Month 2 FU , Month 4 FU  and Month 5 FU  
Month 2 FU visit should be scheduled on Day 225 ± 7 days after Day 1 (or 56 days ± [ADDRESS_926503] 
IMP intake for early discontinued subjects).  
Month 4 FU visit should be scheduled on Day 281 ± 7 days after Day 1 (or 112 days ± [ADDRESS_926504] 
IMP intake for early discontinued subjects).  
Month 5 FU visit should be scheduled on Day 309 ± 7 days after Day 1 (or 140 days ± [ADDRESS_926505] 
IMP intake for early discontinued subjects).  
The following tests and evaluations will be performed at Month 2 FU , Month 4 FU  and Month 5 FU 
visits:  
- eDiary completion compliance check  
- ePRO completion, ideally before any other procedures or asse ssments : mPGIS and PPGIC  
- Concomitant treatment s recording  
- AE recording  
- Completion of the paper C -SSRS questionnaire (version for “already enrolled subjects” (see ) 
for patients responding to the C -SSRS for the first time during the study, or version “since last 
study visit” (see Appendix T ) for patients for whom the C -SSRS was completed at the previous 
study visit)  
- Urine pregnancy test and contraception counselling  (at Month 2 FU  visit only)  
- Endometri al biopsy only if diagnosis at preceding biopsy was different than “benign 
endometrium” or if no endometrial biopsy was done at Month 6 nor at any visit since Month 6 
(see section 10.4.5 ).  
[IP_ADDRESS]  Study  visit Month 3 FU  
Month 3 FU visit should be scheduled on Day 253 ± 7 days after Day 1 (or 84 days ± [ADDRESS_926506] 
IMP intake for early discontinued subjects).  

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 62 of 156 
 OBSEVA  CONFIDENTIAL  The following tests and evaluations will be performed at Month 3 FU  Visit:  
- eDiary completion compliance check  
- ePRO and ClinRO completion, ideally before any other procedures or asse ssments : EHP -30, 
HRPQ, HRUQ, PROMIS, EQ -5D-5L, mPGIS, PPGIC completion  (mPGIS and PPGIC must be 
completed last)  
- Concomitant treatments recording  
- AE recording  
- Completion of the paper C -SSRS questionnaire (version for “already enrolled subjects” (see 
Appendix S ) for patients responding  to the C -SSRS for the first time during the study, or version 
“since last study visit” (see Appendix T ) for patients for whom the C -SSRS was completed at 
the previous study visit)  
- ECG  
- Physical examination  
- Vital signs ( BP and heart rate)  
- Urine pregnancy test  and contraception counselling  
- Gynecological examination  
- Manual breast examination (by [CONTACT_23302])  
- TVUS of uterus  
- Urinary protein dipstick  
- Fasting (overnight) b lood samples for haematology, coagulation parameters, chemistry, lipi[INVESTIGATOR_805], 
hormones  and bone markers . For subjects that do not resume menses at Month [ADDRESS_926507] should be performed at local laboratory and the subjects should be advised to consult 
for a gynaecological evaluation.  
- Endometri al biopsy only if diagnosis at preceding biopsy  was different than “benign 
endometrium” or if no endometrial biopsy was done at Month 6 nor at any visit since Month 6 
(see section 10.4.5 ).  
[IP_ADDRESS]  Study visit : Month 6 FU  – End of Follow -up visit 
Month 6 FU visit should be scheduled on Day 337 ± 7 days after Day 1 (or 168 days ± [ADDRESS_926508] 
IMP intake for early discontinued subjects).  
The following evaluation s and tests will be performed at Month 6 FU  Visit:  
- ePRO and ClinRO completion, ideally before any other procedures or asses sments : EHP -30, 
HRPQ, HRUQ, PROMIS, EQ -5D-5L, mPGIS, PPGIC completion (mPGIS and PPGIC must be 
completed last)  
- Collection and deactivation of eDiary  

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 63 of 156 
 OBSEVA  CONFIDENTIAL  - Concomitant treatments recording  
- AE recording  
- Completion of the paper C -SSRS questionnaire version “since last study visit” (see Appendix 
T) for patients for whom the C -SSRS was completed at the p revious study visit . 
- ECG  
- Physical examination, including weight recording  
- Urine pregnancy test  
- TVUS  of uterus  
- Endometri alm biopsy if no endometrial biopsy was obtained at Month  6 nor at any visit since 
Month 6 (see section 10.4.5 ). If no tissue is available, the biopsy should be repeated as soon as 
possible in the following days . 
- BMD assessed by  [CONTACT_304726], hip and spi[INVESTIGATOR_050]. This DXA can be performed ±  10 days 
from the Month 6 FU study visit . 
This visit constitutes the end of study participation except for subjects with a BMD decrease from 
baseline > 1.5% for lumbar spi[INVESTIGATOR_20793]/or > 2.5% for total hip who should have a repeat DXA scan 6 
months later for a  BMD follow -up assessment .  
[IP_ADDRESS]  Study visit: BMD  Follow -up visit  
BMD Follow -up visit should be scheduled on Day 505 ± 10 days after Day 1 (or 168 days ± 10 days 
after M6 FU visit ). 
This visit is applicable only to subjects with a BMD decrease from baseline > 1 .5% for lumbar spi[INVESTIGATOR_321712]/or > 2.5% for total hip at M6 FU visit.  
BMD will be assessed by  [CONTACT_304726], hip and spi[INVESTIGATOR_050].  
Subjects who have ≥ 3% BMD decrease  at any site (femoral neck, hip or spi[INVESTIGATOR_050]) at this visit  should be 
referred to a bone specialist.  
10.3 EFFICACY OBSERVATION S AND MEASUREMENTS  
All the questionnaires described below except the mB&B scale will be completed in the eDiary  by [CONTACT_285927]/or the site staff.  If the subject forgets to bring her eDiary to one site visit, the completion of 
ePRO and ClinRO will be done on a site back -up device . 
10.3.[ADDRESS_926509] using the mB&B scale (see Appendix C ). 

18-OBE2109 -[ADDRESS_926510] eDiary c ompletion should be 
started on the day of screening visit (after completion of washout period when applicable).  
The eDiary should be completed daily, in the evening at approximately the same time. A daily alarm 
will be set up in the eDiary to remind the p atient to complete her daily questions. In addition, appropriate 
email alerts will be sent to the site staff and to the operational team in case of missed diary entries. 
eDiary compliance will be checked remotely on an ongoing basis by a dedicated data man agement team.  
[IP_ADDRESS]  Pelvic pain  
The s ubject’s assessment of  pelvic pain will be collected daily  via the eDiary  using a n NRS and a VRS . 
NRS : The subject will be asked to rate her worst endometriosis associated pelvic pain in the last 24 
hours on a 0 –[ADDRESS_926511] pelvic pain 
imaginable.  
VRS : The subject will be asked to ch oose the category that best describes her endometriosis associated 
pelvic pain in the last 24 hours : 
0  No pain. 
1  Mild pain but I was easily able to do the things I usually do . 
2  Moderate pain. I had some difficulty doing the things I usually do .  
3  Severe pain. I had great difficulty doing the things I usually do .  
[IP_ADDRESS]  Daily function (difficulty of doing daily activities)  
The subject will complete a daily questionnaire in the eDiary  if she  had any difficulty  doing her daily 
activities in the last 24 hours on a 0 –10 scale  (NRS)  with 0 representing no difficulty  doing daily 
activities and 10 representing inability  to do daily activities . 
[IP_ADDRESS]  Uterine bleeding  
The subject will complete a daily questionna ire in the eDiary assessing strength of uterine/vaginal 
bleeding in the last 24 hours. The strength of uterine bleeding will be assessed using the following scale:  
Please  choose the category that best describes your vaginal bleeding or spotting in the last 24 hours  
None  No bleeding nor spotting  
Spotting  Blood loss not requiring sanitary protection (except for panty liners)  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 65 of 156 
 OBSEVA  CONFIDENTIAL  Bleeding  Blood loss requiring sanitary protection (tampons or pads)  
Heavy 
Bleeding  Heavy blood loss requiring sanitary protection (tampons or pads) for example:  
• Need for double protection to manage menstrual bleeding  
• Menstrual bleeding accompanied by [CONTACT_684101] “gushing” or 
“flooding”  
• Soaking one pad and/or tampon or more per hour for three or more 
consecutive hours  
• Needing to change the tampon or pad at night or soiling bedclothes  
Subject will be asked additional questions to identify  the first day of her menstrual period s during  the 
Screening  Period . 
[IP_ADDRESS]  Analgesic use  
The subject will report daily in the eDiary  whether she has taken any p rovided/prescribed  analgesic 
(including the dose) for her EAP during the last [ADDRESS_926512] to the site staff and recorded in the 
eCRF.  
[IP_ADDRESS]  Dyspareunia  (pain associated with sexual intercourse)  
The subject will be asked daily about d yspareunia via the eDiary  using a VR S. 
She will be asked to rate how her EAP interfered with sexual intercourse in the last 24 hours, with the 
following response options:  
 
 
 
 
 
 
She will be given as well the option to answer that she was not sexually active for reasons other than 
her endometriosis, in which case no score would be allocated.  
[IP_ADDRESS]  Dyschezia  (pain associated with defecation)  
Dyschezia will be assessed daily via the eDiary  and will be scored by [CONTACT_48681] a 0–[ADDRESS_926513] pain imaginable . 0 No pain during sexual intercourse.  
1 I was able to tolerate the pain during sexual intercourse.  
2 Intercourse was interrupted due to pain.  
3 I avoided sexual intercourse because of anticipation of pain.  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 66 of 156 
 OBSEVA  CONFIDENTIAL  [IP_ADDRESS]  School or work missed  
The subject will be asked whether she missed school or work in the last 24 hours due to EAP.  
[IP_ADDRESS]  Event cancelled  
The subject will be asked if she had to cancel an event in the last [ADDRESS_926514] from the FDA, this question is removed in protocol version 4.0 to reduce respondent 
burden and maximize the quality and completeness of clinical outcome assessment data. This question 
has been asked o nly to subjects who were enrolled prior implementation of protocol version 4.0.  
[IP_ADDRESS]  Sleepi[INVESTIGATOR_684050] 24 hours due to EAP.  
[IP_ADDRESS]   Difficulty sleepi[INVESTIGATOR_684051] [ADDRESS_926515] from the FDA, this question is removed in protocol version 4.0 to reduce respondent 
burden and maximize the quality and completeness of clinical outcome assessment data. This question 
has been asked only to subjects who were enrolled pr ior implementation of protocol version 4.0 . 
[IP_ADDRESS]   Patient G lobal Impression of Severity  – daily recall  (dPGIS ) 
The s ubject will record on a daily basis in the eDiary  the severity of her endometriosis symptoms  
assessed on a 5 -point scale with the following possible answers: no symptoms, very mild, mild, 
moderate, severe (see Appendix J ). 
Following a reque st from the FDA, this assessment is removed in protocol version 4.[ADDRESS_926516] 
during the site visit  include:  specific monthly severity questions (i.e  monthly dysmenorrhea question , 
monthly  non-menstrual pelvic pain question , monthly overall pelvic pain question , monthly difficulty 
in doing daily activit ies question , monthly dyschezia question, monthly dyspareunia question) , EHP -30, 
HRPQ, SSIQ, PROMIS, E Q-5D-5L, mPGIS  and PGIC /PPGIC . 
ClinROs are questionnaires administered by [CONTACT_684102] . ClinROs include  monthly dyspareunia question , HRUQ and PSIQ.  
Specific monthly severity questions (monthly  dysmenorrhea  question, monthly non -menstrual pelvic 
pain question, mont hly overall pelvic pain  question, monthly difficulty in doing daily activities ques tion, 

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 67 of 156 
 OBSEVA  CONFIDENTIAL  monthly dyschezia  question , monthly dyspareunia  question ), mPGIS, and PGIC/PPGIC will be used a s 
anchors to estimate meaningf ul change  and deriving responder thresholds.  
During site visits, ePRO s and ClinRO s should be completed ideally prior to any other study procedures, 
with the  anchors being completed last. . Assessments will be performed at the visits as indicated in 
Appendix A  and Appendix B .  
Prior to the start of the study, site personnel will be trained on all rating scales  (ePRO s, ClinRO s and 
scales of daily diary)  used in this study. The training will be provided at the investigator meeting  and/or 
site initiation visit. The objective of this training is to establish uniformity across  subjects and sites in 
completion  of these rating instruments.  
[IP_ADDRESS]  Endometriosis Health Profile -30 (EHP -30) 
The EHP -30 is a disease -specific self -administered questionnaire used to measure health related quality 
of life in women with endometriosis. The EHP -30 is composed of two parts: a core questionnaire 
containing five scales that are applicable to all women w ith endometriosis and a modular part containing 
six scales which do not necessarily apply to all women with endometriosis. This study will employ the 
Core EHP -30 and modular section C (Part 2) as outlined in Appendix D . 
[IP_ADDRESS]  PROMIS Fatigue Short Form 6a14  
This questionnaire is composed of six questions to evaluate the severity of fatigue (see Appendix E ). 
[IP_ADDRESS]  Health Related Productivity Questionnaire (HRPQ)  
The HRPQ consists of nine questions measuring the impact of EAP and its treatment on work 
productivity and daily activities at home (see Appendix F ). 
[IP_ADDRESS]  Health Resource Utilization Questionnaire (HRUQ)  
The HRUQ records use of health resources (emergency room, physician visit, hospi[INVESTIGATOR_059], etc.) 
during the study. This includes the n umber of non -study health visits – the total, the reason, primary 
reason, and type of clinician for the visit ; Diagnostic/therapeutic procedures performed (Hysteroscopy, 
SIS, Colposcopy, Biopsy, Ultrasound or Other) and  Emergency Room/Outpatient Procedures (see 
Appendix G ). 
[IP_ADDRESS]  Patient Global Impression of Change (PGIC)  
The PGIC is used by [CONTACT_423] s to evaluate the  change in their endometriosis symptoms since initiation 
of study drug on a 7 -point scale with following possible answers: very much improved, much improved, 
minimally improved, no change, minimally worse, much worse, very much worse (see Appendix H ). 
[IP_ADDRESS]  Post-treatment Patient Global Impression of Change (PPGIC)  
Subjects will evaluate the change in their endometriosis symptoms after discontinuation of s tudy drug 
on a 7 -point scale with the following possible answers: very much improved, much improved, minimally 
improved, no change, minimally worse, much worse, very much worse (see Appendix I ).  

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 68 of 156 
 OBSEVA  CONFIDENTIAL  [IP_ADDRESS]  Patient G lobal Impression of Severity  - monthly recall  (mPGIS)  
At each study visit from Day [ADDRESS_926517] 28 days using a 5-point scale  with the 
following possible answers: no symptoms, very mild, mild, moderate, severe (see Appendix J ). 
[IP_ADDRESS]  Subject Surgery Intention Question (SSIQ)  
The SSIQ evaluates subject willingness to opt for endometriosis -related surgery if current symptoms 
continue (see Appendix K ). 
[IP_ADDRESS]  Physician Surgery Intention Question (PSIQ)  
The PSIQ evaluates physician likelihood of recommending endometriosis -related surger y(s) to the 
subject if current symptoms continue  (see Appendix L ). 
[IP_ADDRESS]  EQ-5D-5L 
Subjects’ health related quality of life will be measured using the EQ -5D-5L (see Appendix M ). The 
EQ-5D-5L essentially consists of two pages: the EQ -5D descriptive system and the EQ visual analogue 
scale (EQ VAS).  
The descriptive system comprises five dimensions: mobility, self -care, usual activities, pain/discomfort 
and anxiety/depression. Each dimension has five levels: no problems, slight problems, moderate 
problems, severe problems and extreme problems.  
The EQ VAS records the subject’s self -rated health on a vertical VAS, where the endpoints are labelled 
‘The best health you can imagine’ and ‘The worst health you can imagine’.   
[IP_ADDRESS]  Specific Monthly severity questions  
The monthly severity questions specific to DYS, NMPP, overall pelvic pain, difficulty in doing daily 
activities, dyschezia and dyspareunia  will be used as separate anchors  to determine what constitutes a 
meaningful within -patient score change in the respective assessment.  
[IP_ADDRESS].[ADDRESS_926518] 28 days using a 5 -point scale with the following possible answers: no pain, 
very mild, mild, moderate, severe . 
Subject’s answer to the question “How would you describe your menstrual pelvic pain  (on any days 
of vaginal bleeding or spotting) over the past 28 days?” will be collected via the eDiary.  
Not all subjects will have this assessment completed as it was added  during the study course as a protocol 
amendment.  

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 69 of 156 
 OBSEVA  CONFIDENTIAL  [IP_ADDRESS].[ADDRESS_926519] 28 days using a 5 -point scale with the following possible 
answers: no pain, very mild, mild, moderate, severe . 
Subject’s answer to the question “How would you describe your  non-menstrual pelvic pain  (on any 
days with no vaginal bleeding nor spotting)  over the past 28 days?” will be collected via the eDiary.  
Not all subjects will have this assessment completed as it was added during the study course as a protocol 
amendment.  
[IP_ADDRESS].[ADDRESS_926520] 28 days using a 5 -point scale with the following possible answers: no 
pain, very mild, mild, moderate, severe . 
Subject’s answer to the question “How would you describe your overall pelvic pain  (menstrual and 
non-menstrual) over the past 28 days?” will be collected via the eDiary.  
Not all subjects will have this assessment completed as it was added during the study course as a protocol 
amendment.  
[IP_ADDRESS].[ADDRESS_926521] 28 days 
using a 5 -point scale with the following possible answers: No difficulty, slight difficulty, mild difficulty, 
moderate difficulty, severe difficulty.  
Subject’s answer to the question “ How much has your endometriosis -related pain caused you difficulty 
in performing your daily activities over the past 28 days? ” will be collected via the eDiary.  
Not all subjects will have this assessment completed as it was added during the study course as a protocol 
amendment.  
[IP_ADDRESS].[ADDRESS_926522] 28 days using a 5 -point scale with the following possible answers: no pain, very 
mild, mild, moderate, severe . 
Subjec t’s answer to the question “ Overall, how would you describe any endometriosis -related pain 
during defecation (bowel movement) over the past 28 days ?” will be collected via the eDiary.  
Not all subjects will have this assessment completed as it was added dur ing the study course as a protocol 
amendment.  
[IP_ADDRESS].6  Monthly dyspareunia question  
The question will be administered and completed  in the eDiary  using the mB&B scale for Deep 
Dyspareunia, a t Day 1, Month [ADDRESS_926523] 28 
days.   
If she didn’t have any sexual intercourse over the past 28 days, she will report  whether she avoided 
sexual intercourse mainly because of anticipation of pain during intercourse , with the following possible 
answers: Yes, No . 
If she had any sexual intercourse over the past 28 days, her overall experience of pain with intercourse 
over the previous 28 days will be asked by [CONTACT_684103]&B scale for Deep 
Dyspareunia : 
None   0 = No symptoms  
Mild   1 = Tolerated discomfort during intercourse  
Moderate  2 = Interference of usual frequency of sexual intercourse due to pain  
Severe   3 = Avoids, or wishes to avoid, intercourse because of pain  
Not all subjec ts will have this assessment completed as it was added during the study course as a protocol 
amendment.  
10.4 SAFETY OBSERVATIONS AND MEASUREMENTS  
10.4.1  Adverse Events  
AE data will be collected continuously during the study as described in  Section  12.2. 
AE data will be obtained at scheduled study visits based on physical examin ation, vital signs , ECG  and 
biological laboratory assessments (see flowchart in Appendix A ). In addition, subjects will report AEs 
spontaneously and/or through questioning.  
Complete appropriate data on all AEs experienced for the du ration of the reporting period will be 
reported on an ongoing basis in the AE pages of the eCRF . 
10.4.2  Physical Examination  
A complete physical examination, i.e. examination of organ systems, including thyroid gland, lungs, 
heart, abdomen, liver, kidneys and per ipheral pulses (by [CONTACT_684104], auscultation or percussion), eyes, 
ears, nose, throat and skin (by [CONTACT_122317]) and neurological reflexes will be performed at scheduled 
visits . In addition, a manual breast examination (by [CONTACT_23302]) will  be performed at Scree ning, Month [ADDRESS_926524]  data file  and in 
the eCRF . Baseline m edical conditions (see section 12.1.3 ) that do worsen in severity and/or frequency 
during the study and that are  considered as clinically signif icant by [CONTACT_684105].  
The physical examination should be performed after the ECG.  

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 71 of 156 
 OBSEVA  CONFIDENTIAL  10.4.3  Vital signs  
BP and heart rate will be measured in sitting position . In case of abnormal vital signs (i.e. BP ≥ 150/100 
mmHg or ≤ 90/50 mmHg and/or heart rate ≥ 100 bpm or ≤ 40 bpm) and if abnormality was not pre -
existing, a repeat assessment after 5 min should be taken. In case of confirmed abnormality , which was 
not pre -existing  or worsened in severity and/or frequency during the study and is considered as clinically 
signi ficant by [CONTACT_74169] , an AE must systematically be reported by [CONTACT_684106]. The Investigator is to provide a diagnosis rather than reporting of individual vital signs 
parameters whenever possible.  
BP and heart rate should be measured after pe rforming the 12 -lead ECG.  
10.4.4  Trans vaginal ultrasound  
Endometrial thickness , uterus volume and abnormality (fibroids, adenomyosis, etc…)  and left/right 
ovary abnormality status will be assessed by [CONTACT_684107] . If TVUS is not possible, abdominal ultrasound can 
be used. The print -outs of the ultrasound will be inter preted and commented by [CONTACT_684108] . Results of the examination will be recorded on source data forms and in the eCRF.  
TVU S should be recommended (for cause) for subjects with heavy/suspi[INVESTIGATOR_684052].  
10.4.[ADDRESS_926525] : 
 One at screening (unless an endometri al biopsy was performed within the past 6 months of the 
screening visit, which shows no endometri al hyperplasia of any type or adenocarcinoma and for 
which slides are available for current study assessment through retrospective central laboratory 
reading . 
 One at Month 6 if endometrium thickness on TVUS is > 5 mm (see Figure 3) 
 One at Month 1 FU , 2 FU , 3 FU , 4 FU , 5 FU  or 6 FU  if not obtained at Month 6  or if the 
preceding biopsy diagnosis is different than “benign endometrium”  but is not “malignant” or 
not “hyperplasia” (see Figure 4)   
The endometrial biopsies will be analyzed by a central laboratory blinded to treatment group.  
Endometrial biopsies of hyperplasia of any type will be submitted for assessment by [CONTACT_684109]’s assessment.  
 
Figure 3 : Biopsy process  for Month 6 s tudy visit  

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 72 of 156 
 OBSEVA  CONFIDENTIAL   
 
Figure 4 : Biopsy process for the follow -up period visits  
 
Screening e ndometrial biopsy should be performed at least [ADDRESS_926526] day of menstruation and 
sent for central assessment. If no tissue is available, the biopsy should be repeated as soon as possible 
in the following days. In case of multiple (at least two  including the initial one) and unsuccessful 
attempts to get sufficient endometrial tissue, the subject is allowed to be randomized without any 
screening endometrial biopsy under the following conditions:  
a. The investigator confirms and documents in source that the subject has no signs of suspected 
endometrium malignancy (e.g. abnormal bleeding profile) . 
b. The investigator and subject agree that at end of treatment all necessary actions will be taken to 
get a sufficient endometrium sample (e.g. short anaesthes ia, if necessary). However, it should 
be noted that for subjects who discontinue the study and complete less than [ADDRESS_926527] will be withdrawn 
immediately  
At any time during the study, i n case of endometrial biopsy diagnosis being hyperplasia of any type 
(with or without  atypia ) or worse  (neoplasm)  for patients on treatment,  the laboratory will send an alert 
to the site and the Sponsor. The medical monitor will contact [CONTACT_684110] . The subject will be discontinued from the treatment, (and will not be eligible to enter 
the extension study) , will enter the follow -up period (unless she is discontinued prior to Month 3  visit)  
and will be advised  to consult for a gynecological evaluation and treatment.  
Biopsy should be recommended (for cause) for subjects w ith heavy/suspi[INVESTIGATOR_684052]. Results from 
these procedures should be documented in the eCRF . 
Endometrial biopsy samples will be performed with the Pi[INVESTIGATOR_304686]® (or equivalent), as 
described in the manual provided by [CONTACT_2237].  
10.4.[ADDRESS_926528] be used for all scan acquisitions.  
All DXA scans will be read by a central imaging laboratory  blind ed to treatment group.  There will also 
be centralized monitoring of DXA scan quality for each site including a pre -qualification phantom scan 
and a monthly review of daily QC data.  
In the event a sca n does not meet quality standards , the site will be asked to  repeat the scan.  A repeated 
scan will be required for each scan showing 5% or more BMD loss from baseline.  
Instructions to measure the BMD, detailed information on the centralized reading and QC and the 
stoppi[INVESTIGATOR_684053] a specific imaging manual.  
10.4.7  Bone markers  
Blood samples for exploratory bone biomarkers such as, but not limited to, collagen type 1 β -carboxy -
telopeptide (CTx), procollagen [ADDRESS_926529] N -Terminal  (P1NP) , bone -specific alkaline phosphatase (B -
ALP) and osteocalcin will be collected as part of clinical chemistry. These exploratory data will not b e 
communicated to keep the operational team and the sites blinded to treatment administration.  
10.4.8  Laboratory parameter s 
Haematology, coagulation parameters, chemistry, lipi[INVESTIGATOR_805] , glucose  and hormones will be assessed from 
blood samples. Haematology, coagulation parameters, chemistry  and lipi[INVESTIGATOR_684054], as well as at M1 FU and M3 FU visits. E2, progesterone 
(P4) and LH will be assessed at each visit during the treatment period (not at screening visit), as well as 
at M1 FU  and M3 FU visits. Serum levels of the anti -müllerian hormone (AMH)  and fasting glucose  
will be assessed on Day 1  only. S erum levels of the sex hormone -binding globulin (SHBG) will be 
assessed on Day 1 and Month 3 and M onth 6 visits .  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 74 of 156 
 OBSEVA  CONFIDENTIAL  Overnight fasting is required for Day 1, Months 1, 3 and 6, and Month 3 FU visits.  
Blood samples will be analy zed by [CONTACT_2237] . Details of blood sampling process, sample 
handling and shipment are described separately in a laboratory manual provided by [CONTACT_11378]. Central laboratory reference ranges will be filed in the investigator site file and in the trial 
master file. All laboratory results except E2 , SHBG , P4, LH and bone marker  levels  will be assessed by 
[CONTACT_737]/sub -investigator and clinically significant abnormalities compared to screening/baseline 
status will be reported as AEs in the eCRF . E2, SHBG , P4 and LH levels will not be communicated to 
keep the operational team and the sites blinded to treat ment administration.  
The laboratory parameters are listed in  Appendix N . 
There may be some additional  laboratory parameters to be analysed  as requested by [CONTACT_684111] -up on existing abnormalities . 
10.4.9  Electrocardiogram  
Local 12 -lead ECG readings of QTcF will be performed at the scheduled visits .  
ECG s shoul d be performed prior to blood sampling, physical examination and vital signs.  
10.4.10  Columbia -Suicide Severity Rating Scale (C -SSRS)  
The C -SSRS questionnaire prospectively assess the occurrence of treatment -emergent suicidal ideation 
and behavior. The questions will be administered by [CONTACT_684112], using  one of the following paper versions:  
- either the “Baseline ” C-SSRS version,  dedica ted to subjects  under screening, capturing lifetime history 
of suicidal ideation  and behavior  (see Appendix R ) 
- or the “already enrolled subjects” C -SSRS version, dedicated to randomized subjects who are 
providing answers to the C -SSRS for the first time during the study (see Appendix S ) 
- the “since last study visit” C -SSRS version (see Appendix T ), dedicated to subjects for whom the C -
SSRS was completed at the previous study visit, for use at all remaining study visits . 
10.[ADDRESS_926530] dose.  
During the treatment period, on days of site visits at Months 1, 2, 3, 4  and 5), the subject will be asked 
to take the dose of IMP at site , after a pre -dose PK sampling. The approximate time of dose 
administration on the four previous day s and time of PK sampl ing will be recorded  in the eCRF . 
In case of early discontinuation visit, PK sampling is not require d at the withdrawal visit if the subject 
had no IMP administration the day prior to the withdrawal visit .  

18-OBE2109 -[ADDRESS_926531] during the study , from the date of signature [CONTACT_684140].  
However, t he use of provid ed/prescribed  analgesics  for EAP will be recorded solely in the eDiary . 
10.6.1  Permitted Medicines  
Any medications other than those excluded by [CONTACT_760]  (see section 10.6.2 ), which are considered 
necessary for the subject’ s welfare and/or which will not interfere with the study medication, may be 
given at the discretion of the Investigator.  
Analgesics : 
Only the analgesics provided/prescribed  by [CONTACT_684113], Treatment 
and Follow -up Period . Other analgesics will be prohibited. Provided/prescribed  analgesics should be 
taken only when required for treatment of pain. Prophylactic use o f analgesics will be prohibited.  
Permitted opi[INVESTIGATOR_684055].  
Subject s will be required to restrict  the use of analgesic s to those permitted by [CONTACT_684114]  1.  
Table 1: Permitted rescue analgesics  
Analgesic class  Name  [CONTACT_13691] * 
NSAID  ibuprofen  200 mg  
Narcotic Analgesic  5 mg hydrocodone +  300 mg acetaminophen **  
* Use of these analgesic medications should be according to the product prescribing 
information.  
** Or local equivalent  
 
Local equivalent Narcotic Analgesics : 
Austria  tramadol 37.5mg + paracetamol 325mg  
Bulgaria  tramadol 37.5mg + paracetamol 325mg  
Czech Republic  codeine 30mg  

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 76 of 156 
 OBSEVA  CONFIDENTIAL  paracetamol 500 mg+ codeine 30 mg  
tramadol 37.5mg + paracetamol 325mg  
[LOCATION_009]  paracetamol 500 mg+ codeine 30 mg  
tramadol 37.5mg + paracetamol 325mg  
Hungary  paracetamol 500 mg+ codeine 30 mg  
codeine 30mg  
tramadol 37.5mg + paracetamol 325mg  
Poland  tramadol 37.5mg + paracetamol 325mg  
Romania  codeine 30mg  
paracetamol 500 mg+ codeine 30 mg  
Spain  paracetamol 500 mg+ codeine 30 mg  
tramadol 37.5mg + paracetamol 325mg  
Ukraine  N/A  
 
Other:  
In order to prevent or minimize possible impact on bone mineral density, subjects will receive calcium 
[ADDRESS_926532] 4 hours from the intake of the study  drug.  
If necessary, the dose of calcium or vitamin D supplementation may be reduced  or discontinued at the 
discretion of the investigator.  
10.6.2  Prohibited Medicines  
Medication listed in exclusion criteria (see section 9.2.2 ) will be prohibited up to Month 6.  
To consider a subject who is currently taking any prohibited therapi[INVESTIGATOR_304689], the Investigator must ensure  that the subject has sufficient washout time prior to  screening (see 
Section 10.2.1 ). 
Strong CYP3A 4 inhibitors or inducers are prohibited up to end  of treatment in view of the ABT  
(Appendix P ). 
Linzagolix is considered to be a weak inhibitor of CYP2C8. Substrates to CYP2C8 with a narrow 
therapeutic index should be administered with caution.  
Hormonal contraception including hormona l IUD must be stopped following ICF signature [INVESTIGATOR_107990] [ADDRESS_926533]’s well -being, the sponsor must 
be notified and possible alternatives are to be discussed before administration of the prohibited 
medication or treatment whenever possible.  
10.6.3  Non-Drug Therapi[INVESTIGATOR_684056]:  
For subjects of childbearing potential and requiring contraception, non -hormonal contraception is 
required from beginning of screening period until 3 months after the end of treatment. Two forms of 
non-hormonal contraception will be required e.g. condom wi th spermicide  (if in the opi[INVESTIGATOR_1070] a  wom an is at risk of acquiring HIV, spermicide should be avoid ed; condom with dia phragm 
may be used ). Suitable condoms with spermicide will be provided free of charge to subjects over the 
duration of th e study.  
After [ADDRESS_926534] will be considered as a “completer” when she has completed all study procedures /visits  she is 
supposed to follow according to the protocol . 
10.7.[ADDRESS_926535] the right to withdraw from the study at any ti me, without 
prejudice to their medical care, and that they are not obliged to state the reason(s). Any withdrawal must 
be fully documented in the eCRF  exit form.  
The Investigator may withdraw a subject at any time if this is considered to be in the subject’s best 
interest .  
In addition, the sponsor could make a decision to temporarily or permanently discontinue the study for 
safety, ethical, compliance or other reasons.  In this case, the subject’s  participation may be ended 
prematurely without asking  for her consent . 
In case of early discontinuation, the subject will be instructed to complete the relevant eDiary 
questionnaires as soon as possible upon treatment discontinuation.  
Subjects who did not receive the study drug will be withdrawn from the stu dy and no further study 
procedures will be performed.  
Withdrawal d uring treatment period : 
Subjects who discontinue between Day 1 and Month 3 should undergo the procedures required at Month 
6 (except the DXA scan  and the endometri al biopsy  if a biopsy was obtained at screening ) and will not 
enter the [ADDRESS_926536] had no IMP administration the day prior to the withdrawal 
visit.  
Withdrawal d uring follow -up period : 
Subjects discontinuing participation in the study during the  follow -up period should undergo the 
procedures required at Month  6 FU visit , which includes completion of all ClinRO and ePRO  
questionnaires,  except the DXA in case of discontinuation before Month 3 FU visit . 
[IP_ADDRESS]  Discontinuation criteria  
During the course of the study, the subject may be discontinued for the following reasons : 
- Adverse Event : Includes clinically significant new or worsening existing condition as judged 
by [CONTACT_737]. Document in the AE form.  
- Subject ’s Request:  Consent withdrawal, subject moved, schedule conflicts, etc. Specify the 
reason in the comment section of the eCRF  Exit Form.  
- Protocol Violation:  Major protocol violation which may affect the subject’s safety . Specify the 
protocol violation in the comment section of the eCRF  Exit Form.  
- Lost to Follow -up: Document with at least two phone calls and a certified letter requesting return 
receipt without response. Document in the comment section of the eCRF  Exit 
Form. 
- Pregnancy:  Subjects  that have been exposed to study treatment and  who become pregnant 
during the Treatment Period  will be immediately withdrawn from treatment. 
Pregnancies that have been exposed to study treatment  and occurred up to  
Month [ADDRESS_926537] be reported with the Pregnancy 
Surveillance Form (see section  12.6). 
- Other:  Specify in the Comments section in the eCRF  Exit Form. This reason should 
only be used if the reason for discontinuation is not better accounted for by 
[CONTACT_304731].  
Discontinuation Rules at Day 1 : Subjects presenting with ALT, AST, GGT  or total bilirubin ≥  [ADDRESS_926538] a serum calcium level at Day 1 above 2.9 mmol/L and who have completed Day 1, 
should  have calcium supplements interrupted. If serum calcium level at Day 1 is above 3.1 mmol/L 
calcium supplements and study treatment  are to be interrupted.  A repeat test of this parameter within 
2 weeks under fasting conditions is to be performed. If the results of the repeat remain above 2.9 
mmol/L, study treatment should definitively be discontinued and the subject should be advised  to consult 
an endocrinologist for further evaluation.  
Discontinuation Rules during the Treatment Period : 
Endometrial biopsies:  in case of endometrial biopsy diagnosis being an endometrial hyperplasia of any 
type or worse , the subject will have to discontinue the treatment  (and will not be eligible to enter the 
extension study)  and will be advised to consult for a gynecological evaluation and treatment . 
Serum calcium:  Subjects who have a serum calcium level on treatment abo ve 2.9 mmol/L should 
have  calcium  supplements interrupted. If serum calcium level on treatment is above 3.1 mmol/L calcium 
supplements and study treatment  are to be interrupted.   A repeat test of this parameter within 2 weeks 
under fasting conditions is to be performed. If the  results  of the repeat  remain  above 2.9 mmol/L, study 
treatment should definitively be discontinued and the subject should be advised to consult an  
endocrino logist for further evaluation . 
Bone mineral density loss: s ubjects who experience more than 8% BMD loss or a Z -score ≤ -2.5 at any 
site (femoral neck, hip or spi[INVESTIGATOR_050]) will be discontinued from study treatment  and will enter the follow -up 
period (they will not be eligible to enter the extension  study ). 
 
Liver function tests: following the Food and Drug Administration (FDA) guidance on drug -induced 
liver injury ( 17), subjects who have an elevation of hepatic enzymes are to be withdrawn immediately 
from treatment if:  
• ALT or AST >8xULN  
• ALT or AST >5xULN for more than 2 weeks  
• ALT or AST >3xULN and (TBL >2xULN or INR >1.5)  
• ALT or AST >3xULN with the appearance of fatigue, nausea, vomiting, right upper quadrant 
pain or tenderness, fever, rash, and/or eosinophilia (>5%)  
Withdrawn subjects will be followed up until hepatic parameters return to normal.  
ECG  : subjects who have a  QTcF > 500 ms or increase > [ADDRESS_926539] to be withdrawn from study treatment and followed up  until return to QTcF < 480 ms or – if 
not reached after [ADDRESS_926540], GGT 
or total bilirubin ≥ 2 times the upper limit of normal  at Day 1 , or due to a clinically significant biopsy 
finding at Day  1 (treatment start) , or due to high calcium level at Day [ADDRESS_926541] S 
The term “Investigational Medicina l Product” (IMP) will refer to the ObsEva investigational drug 
linzagolix , the ABT  (E2 1 mg/NETA 0.5 mg) or their matching placebo s.  
 Investigational 
product  Placebo  ABT  ABT  
Placebo  
International 
nonproprietary name  
(INN)  Linzagolix  NA E2 and NETA  NA 
Name [CONTACT_684141] E2 and NETA  NA 
Form  Film -coated 
tablet  Film -coated  
tablet  Capsules  Capsules  
Strength  75 mg and  
200 mg  placebo for 75 mg and 
placebo for 200 mg  1.0 mg/0.5 mg  Placebo  
Dose or 
concentration of 
active treatment  75 mg  
and 200 mg  0 mg  1.0 mg/0.5 mg  0 mg  
Frequency and 
duration of 
administration  Once daily for up to 6 months  
Route of 
administration  Oral 
Manufacturer 
(Name [CONTACT_3816])  Patheon, Canada  Sharp Clinical Services Inc.  
[ADDRESS_926542], Bethlehem, 
PA [ZIP_CODE], [LOCATION_002]  
Primary packaging  PVC -PVdC/Al blister containing  
15 tablets  PVC/Al blister containing  
7 capsules  
Secondary 
packaging (1 kit)  [ADDRESS_926543]*  14 blisters in a carton box  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 81 of 156 
 OBSEVA  CONFIDENTIAL  Storage 
Requirements  As indicated on the study drug kit label  
*The blisters being linked together  inside  the wallet card, the kit is considered as a single unit and 
therefore labelling on the wallet is sufficient (individual blisters are not labelled).  
11.2 DOSAGE AND ADMINISTRATION  
Linzagolix  and corre sponding placebo treatments will be supplied as film-coated tablets for oral 
administration  and given as monthly treatment kits  (Figure 5). 
ABT  and corre sponding placebo will be supplied as red capsules  and given as [ADDRESS_926544] to swallow  two tablets of linzagolix/placebo and one capsule of 
ABT/placebo , ideally at the same time each day . 
On the day of a study visit , the subject must take the study medication at site , after the PK blood sample 
collection , except on Day [ADDRESS_926545] be taken before the PK blood sample  
collection  (at least 1.5 h before) . The site staff will record  in the eCRF the time of study medication 
intake. The linzagolix/placebo tablets must be taken from the kits dispensed on that visit (and not from 
the previously dispensed kits). On Day 1 and Month 3 visits, ABT/placebo capsules must be taken from 
the kits dispensed during these  visits. On Month 1, 2, 4 an d 5 visits, ABT/placebo capsules must be 
taken from the previously dispensed kits.  
The treatment groups are described below : 
Treatment 
group  Daily dose Day 1 to Month 6  
 Linzagolix  
active tablet s Linzagolix  
placebo tablets  ABT  
active capsules  ABT  
placebo capsules  
75 mg  1 
 75 mg  1 
 placebo 200 
mg  None  1 capsule  
200 mg  1 
 200 mg  1 
 placebo 75 mg 1 capsule  None  
Placebo  None  1 
 placebo 75 mg  
AND  
1 
 placebo 200 
mg  None  1 capsule  

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 82 of 156 
 OBSEVA  CONFIDENTIAL  11.3 PACKAGING AND LABELL ING  
Study drug (linzagolix/placebo) will be provided by [CONTACT_456]  (or delegate)  as monthly  kits.  
On Day [ADDRESS_926546] containing four blisters in total:  
- Two blisters of 15 tablets each of 200 mg linzagolix  or matching placebo  (corresponding to the 
grey card on Figure 5), 
- Two blisters of 15 tablets each of 75 mg linzagolix  or matching placebo  (correspond ing to the 
pi[INVESTIGATOR_684057] 5). 
This kit cover s 30 days  of treatment .  
 
Figure 5 : Linzagolix/placebo kit design  
Each linzagolix kit will be labeled  with a unique kit number  starting from B [ZIP_CODE],  B00002, B [ZIP_CODE] , 
etc. (6 -characters) . The blisters being attached into the wallet card, linzagolix kit is considered as a single 
unit and therefore labelling on the wallet is sufficient (individual blisters are not labelled).  
ABT and matching placebo will be provided by [CONTACT_456] (or delegate) as [ADDRESS_926547] will be given a carton box containing 14 blisters of seven  
capsules each of ABT or matching placebo . This kit  cover s 98 days of treatment.  
Each ABT kit  will be labeled with a unique  kit number (different from the linzagolix  kit number), 
starting from  N00001, N0 0002, N00 003 etc . 
Each kit of linzagolix/placebo or ABT/placebo will have a label including a tear-off part. The tear-off 
part containing the study number and the kit number will be placed into a drug accountability form at 
site.  
Labels will be printed in the local language of the countries where the study will take place in accordance 
with applicable local regulations , the recommendations of GMP guideline (Annex 13) and FDA [ADDRESS_926548] the following items:  
 Protocol number  

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 83 of 156 
 OBSEVA  CONFIDENTIAL   Kit n umber  
 Batch number  
 Expi[INVESTIGATOR_5695] (for Europe only)  
 Storage conditions  
 Sponsor name [CONTACT_684142]’s site and in the trial master file.  
11.[ADDRESS_926549] be stored at 68 °F to 77°F  (20°C to 25°C ), excursions permitted between 59°F 
and 77°F (between 15°C and 25°C). The storage temperature at the clinical site must be recorded by 
[CONTACT_2329] a minimum/maximum thermometer or electronically [ADDRESS_926550] or by a membe r of staff specifically authori zed by 
[CONTACT_737].  
Any deviations from the recommended storage conditions at the site should be immediately reported to 
the sponsor  (or delegate), and the IMP should not be used until authori zation has been given by [CONTACT_103]  (or delegate).  
11.5 IMP  ACCOUNTABILITY  
The Investigator is responsible for ensuring IMP accountability, including reconciliation and 
maintenance of drug records.  
 Upon receipt of the IMP, the Investigator (or  delegate ) will c heck for accurate delivery and 
acknowledge receipt  in IWRS . A copy of acknowledgement of receipt will be retained in the 
investigator file. 
 The dispensing of the IMP will be carefully recorded on the appropriate drug account ability 
form  provided by [CONTACT_456]  (or delegate)  and in eCRF, and an accurate accounting will be 
availabl e for verification by [CONTACT_304732].  
 IMP accountability records will include:  
o Confirmation of IMP delivery to the trial site  
o The inventory at the  site of IMP delivered  
o The use of each dose by [CONTACT_6992]  (accountability to be done at each visit)  
18-OBE2109 -[ADDRESS_926551] . 
o The return to the sponsor  (or delegate) or alternative disposition of u sed and u nused 
IMP 
 The Investigator should maintain records that adequately document:  
o The subject s were provided with the doses specified by [CONTACT_760]/amendment(s) . 
o All IMP provided were fully reconciled . 
Unused IMP must not be discarded or used for any purpose other than the present study. IMP that has 
been partially dispensed to a subject  must not be re -dispensed to a different subject . 
The Study  monitor will check  on an ongoing basis the IMP accountability form  and verify all IMP 
dispensations and  returns (both unused and used treatments ) during the entire study period and prior to 
making arrange ments for their return to the sponsor  (or delegate)  or authori zing their destruction by [CONTACT_304733] . 
11.[ADDRESS_926552] s (one for linzagolix/placebo, 
one for ABT/placebo)  will be generated by a designated statistician from the sponsor or delegate  to be 
transmitted to the assigned  clinical packaging organization for labelling and to a fully integrated IWR S. 
The IWRS will provide the kit numbers, which will correspond to the linzagolix /placebo and  
ABT /placebo kit numbers.  
Subjects will be randomized to one of three  treatment groups  in a 1:1:[ADDRESS_926553] be instructed to bring with her to each visit  both opened and unopened IMP packages  
(linzagolix/placebo, ABT/placebo) , in order to allow the assessment of compliance with study treatment.  
The decision to withdraw a non -compliant subject from the study will be discussed between the 
Investigator and the sponsor . A bli nd review meeting will take place prior to unblinding. Subjects with 
poor compliance and other significant protocol violations may be exclud ed from the Per Protocol 
Analysi s Set. 
During the entire study period, t he study monitor will perform  drug accountab ility and the assessment 
of compliance with study treatment  by [CONTACT_684115], as well as 
empty blisters .  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 85 of 156 
 OBSEVA  CONFIDENTIAL  11.8 METHOD OF BLINDING  
The study design is double blind. Linzagolix/placebo treatments will be provided in monthly treatment 
kits, packaged, labelled and administered in the same manner to protect the blinded nature of the trial. 
ABT/placebo treatments will be supplied as [ADDRESS_926554] inform the sponsor  immediately wi thout revealing the 
code to the sponsor  study personnel nor the complete Study Team.  
11.10  TREATMENT OF OVERDOS E AND MISUSE  
An overdose is defined as any dose (i.e. quantity of drug given per administration or per day) above the 
maximum  dosage defin ed in the protocol  (200 mg per day) .  
Misuse is  the term used if more precise information is not available and additional information is needed 
to determine if there was a “medication error”, “dr ug abuse” or “overdose”.  
Any details of overdose  or misuse must be recorded in the eCRF .  
Any case of overdose or misuse associated with an AE or a SAE must be reported  as per the instructions 
detailed in Section s 12.2.3  for AEs or 12.3.2  for SAEs . 
The effects of an overdose of linzagolix  are unknown , but single and repeated doses of up to 400  mg 
were shown to be safe in a Phase 1 single and multiple ascending dose study , and doses up to 200 mg 
daily for 3 months were safe in endometriosis subjects  (see Section 5.5.3 ). 

18-OBE2109 -[ADDRESS_926555] UDY  
A limited quantity (as per Investigator’s judgement) of standard doses of permitted analges ics will be 
provided /prescribed  to the subject as rescue medication for EAP . These  will be provided  by [CONTACT_684116] .  
Electronic diaries will be provided for subjects use . These remain the property of the sponsor.  
Condoms with spermicide as well as calcium and vitamin D supplements will also be provided by [CONTACT_684117].  If required, spermicide -free condoms  and diaphragms  may be 
reimbursed to the subject.  
[ADDRESS_926556]’s signature [CONTACT_43998]. Study site 
personnel will report any AE, whether observed by [CONTACT_19007] (see 
section 12.2.1 ). 
The safety profile of linzagolix  will be assessed through the recording, reporting and analys is of baseline 
medical conditions, AEs, physical examination findings , ECGs, vital signs , laborator y tests , BMD  
assessments . 
The reporting  period for AEs is described in section 12.5. 
12.1 ADVERSE EVENTS  
12.1.1  Definitions  
Adverse Event : 
An adverse event (AE) is defined as any  untoward medical occurrence in a clinical trial subject 
administered a n investigational  medicinal product (IMP) and which does not necessarily have a causal 
relationship with this treatment. It can therefore be any unfavourable sign (including an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of an IMP, whether or not 
considered related to the IMP. 
Events occurring prior to first IMP administration in the study are not considered AEs per se, but an 
event that could be due to the disease or specific circumstances. For monitoring purposes, any event  
occurring after signature [CONTACT_56534] , as assessed by [CONTACT_737], should be 
reported on an AE form or an SAE form, as appropriate.  In case of AE reporting prior to IMP intake, an 
assessment should be performed whether an event constitutes rather a baseline medical condition ( e.g. 
Gilbert’s disease - to be reported on the “medical history page of the eCRF ”) or an AE. 
Severity : 
The severity of AEs must be assessed by [CONTACT_304735]. The 
term “severity” is used to descri be the intensity of a specific event. This has to be distinguished from 
the term “serious”.  

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 87 of 156 
 OBSEVA  CONFIDENTIAL  Mild:  The subject is aware of the event or symptom, but the event or symptom is 
easily tolerated (e.g. no reduction in daily activities is required).  
Moderate:  The subject experiences sufficient discomfort to interfere with or reduce her 
usual level of activity.  
Severe:  Significant impairment of functioning: the subject is unable to carry out usual 
activities and/or the subject’s life is at risk from the event.  
Causality assessment : 
The causality assessment of an AE to the linzagolix and/or ABT will be rated as follows by [CONTACT_3786]:  
Not related:  There is no reasonable possibility of causal relationship between an AE and 
IMP.  
Related:  There is at least a r easonable possibility of a causal relationship between an 
AE and an IMP. This means that there are facts (evidence) or arguments to 
suggest a causal relationship.  
Unexpected Adverse Event : 
Any AE which is not consistent in specificity or severity with the  current Investigator’s Brochure  
(section 6.7.1) , including all amendments, is considered unexpected.  
Outcome : 
Outcome describes the status of the AE. The Investigator will provide information regarding the subject 
outcome of each AE, and the options include:  
Fatal  Termination of life as a result of an AE . 
Not recovered/not resolved  Subject has not recuperated or the AE has not improved . 
Recovering/resolving  Subject is recuperating or the AE is improving . 
Recovered/resolved  Subject has recuperated or the AE has resolved . 
Recovered with sequelae/resolved 
with sequelae  AE has resolved, but the subject has symptoms or pathology . 
Unknown  Unknown, not observed, not recorded, or refused . 
Action taken regarding study drug : 
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 88 of 156 
 OBSEVA  CONFIDENTIAL  The Investigator will provide the action taken regarding study drug in response to each AE, and the 
options include:  
Dose not changed  No change in the administration of study drug . 
Drug (study drug) interrupted  Study drug is being temporarily interrupted due to AE . 
Drug (study drug) withdrawn  Decision was made to withdraw the study drug due to AE . 
Unknown  Unknown, not observed  or not recorded . 
Not applicable  AE started before dosing or after dosing finalized.  
12.1.2  Abnormal laboratory findings and other objective measurements  
Abnormal laboratory findings and other objective measurements (e.g. vital signs ) must be reported as 
an AE only if assessed by [CONTACT_5256] “clinically significant ” e.g. meet ing at least one of the 
following conditions:  
1. The abnormality suggests a disease and/or organ toxicity AND this abnormality was not present 
at the screening visit or is assessed as having evolved since the screening visit.  
2. The abnormality is a Serious Adverse Event . 
3. The abnormality results in discontinuation of the IMP. 
4. The abn ormality requires medical intervention or concomitant therapy . 
The Investigator  must initial and date each laboratory report /eCRF  page and note directly on the 
report /eCRF  page  whether or not each out -of-range laboratory result is clinically significant.  The 
outcome of this assessment will be reported using an AE or SAE form, as appropriate.  
When reporting an abnormal finding for laboratory parameters or other objective measurements  on the 
AE page of the eCRF , a clinical diagnosis should be recorded rather than the abnormal value itself, if 
available (for example, “anaemia” rather than “decreased red blood cell count”) . 
For all of these AEs, whether or not related to the treatment, the laboratory test(s) will be followed -up 
as appropriate.  
12.1.3  Baseline Medical Conditions  
Medical conditions present at the Screening  visit(s), including results of the study screening 
assessments,  are defined as Baseline Medical Conditions. These medical conditions should be 
adequately  documented on the “medical history page of the eCRF ”. Baseline Medical Conditions that 
worsen in severity or frequency during the study should be recorded and reported as AEs. 
18-OBE2109 -[ADDRESS_926557] and/or through questioning o f the subject.  
To elicit AEs, questioning at each study visit should begin with simple non -leading questions. For 
example:  
 How have you felt since your last visit?  
 Have you had any health problems since you were here last?  
If a subject is seen by a physician not involved w ith the study in relation to an AE, the Investigator  
should make every effort to contact [CONTACT_684118] a timely manner in order to obtain all 
information necessary for the appropriate reporting of the event.  
12.2.2  Recording of Adverse Events in the eCRF  
As the quality and precision of acquired AE data are critical, Investigator s should use the AE definitions 
provided in the above sections and should follow  this guideline when completing the AE pages of the 
eCRF : 
 Whenever possible, recogni zed medical terms should be used to describe AEs rather than 
colloquialisms (for example, ‘influenza’ rather than ‘flu’), and abbreviations should be avoided  
in provided AE term . 
 AEs should be described using a specific clinical diagnosis, if this is available, rather  than a list 
of component signs or symptoms (for example, ‘congestive heart failure’ rather tha n ‘dyspnoea, 
rales and cyanosis ’).  
 However, signs and symptoms that are not linked (as "co -manifestations”) to an identified 
disease or syndrome, or for which a n overall diagnosis is not available, should be reported as 
individual AEs  in separate eCRF  AE page(s) .  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 90 of 156 
 OBSEVA  CONFIDENTIAL   Provisional diagnosis (e.g. “suspected Myocardial Infarction”) are acceptable but should be 
followed up to a definite diagnosis , if finally available.  
 AEs occurring secondary to other events (e.g. sequelae or complications) should be identified 
by [CONTACT_86187]. A primary AE, if clearly identifiable, generally represents the most 
accurate clinical term to record in the eCRF . The Investigator  should b e invited to provide 
his/her opi[INVESTIGATOR_263904].  
12.2.3  Reporting of Adverse Events  
Complete and accurate data on all AEs experienced for the duration of the reporting period, as defined 
in section 12.5, will be reported on an ongoing basis in the AE pages of the eCRF . 
It is important that each AE report includes a description of the event, whether it is considered serious 
(and if so the criterion satisfied), its duration (onset and resolution dates), its severity, its relationship to 
the IMP(s) , any other p otential caus ality factors, any  treatment given or other action taken (including 
dose modification or discontinuation of the IMP) and its outcome.  
12.3 SERIOUS ADVERSE EVENTS  
12.3.1  Definitions  
A Serious Adverse Event (SAE) is defined as a ny untoward medical occurrence or effect that at any 
dose:  
 results in death , 
i.e. the AE causes or contributes to the death.  
 is life -threatening , 
i.e. the AE places the subject at immediate risk of death; it does not refer to AE which 
hypothetically might have caused death if it were more severe.  
 requires inpatient hospi[INVESTIGATOR_1081] , 
i.e. the AE requires at least an overnight admission or prolongs a hospi[INVESTIGATOR_304691]. Hospi[INVESTIGATOR_304692], for social 
reasons, for any elective surgery (i.e. plastic surgery) or for normal disease management 
(including treatment adjustment) are NOT to be considered as SAE according to this criterion .. 
 results in persistent or significant disability / inc apacity , 
i.e. the AE resulted in a substantial disruption of the subject’s ability to conduct normal 
activities.  
 is a congenital anomaly / birth defect , 
i.e. an adverse outcome in a child or fetus  of a subject exposed to the IMP before conception or 
during  pregnancy.  

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 91 of 156 
 OBSEVA  CONFIDENTIAL   is an important medical event , i.e. is medically significant  ; 
Medical and scien tific judgment should be exerciz ed in deciding whether an AE is serious in 
other situation. Important medical events that may not be immediately life -threatening or result 
in death or hospi[INVESTIGATOR_684058]. 
Examples of such events are intensive treatment in an emergency room, or at home for allergic 
broncho spasm, blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_18543], or 
development of drug dependen cy or drug abuse.  
12.3.[ADDRESS_926558] notify  VOISIN CONSULTING  (acting on behalf of ObsEva  
Pharmacovigilance ) WITHIN 24 HOURS  of awareness of a new SAE or of new information on a 
previously reported SAE (=  follow -up). 
To do so, the Investigator  must complete a SAE report and any specific eCRF  pages if justified by [CONTACT_12695] e.g. AE, medical history, concomitant medication eCRF  pages and blinded and anonymized 
copi[INVESTIGATOR_304694], hospi[INVESTIGATOR_304695]/report, 
etc. ) , sign it and send it direct ly to Voisin Consulting  by e-mail using the dedicated e -mail address 
specified below : 
 Name/Title :  Voisin Consulting  Life Sciences  / ObsEva  Pharmacovigilance  
 E-mail:    [EMAIL_5974]  
VOISIN CONSULTING  will notify ObsEva Pharmacovigilance within 1 working day  after the receipt 
of the SAE form report or follow -up information, using the same reporting forms.  
The SAE follow -up observation period , for the concerned subjects , will be jointly decided by [CONTACT_304736] -investigator s (in case of Investigator ’s absence) and the sponsor .  
In addition, the Investigator  must respond to any request for follow -up information or questions 
regarding the SAE the sponsor  may have , within  1 working day for urgent queries or 5 working days 
for normal queries . SAE will be followed until the Investigator  and ObsEva agree that the event is 
satisfactor ily documented and resolved /stabilized . 
For any new SAE, the following minimum information is required as initial notification:  
 Clear identification of the Investigator /Reporter with full contact [CONTACT_304737] , 
 Subject identification details (study number, site number, subject’s unique study identif ication 
number and date of birth ), 
 IMP(s) administration details (dose and dates) , 
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 92 of 156 
 OBSEVA  CONFIDENTIAL   Diagnosis of the event (or a brief description of signs/symptoms/clinical course if the diagnosis 
is not available) and the date of onset,  
 Seriousness criteria, see 12.3.1 , 
 Causal r elationship (Investigator ’s opi[INVESTIGATOR_1649]) of the event with the IMP(s) or with the trial 
procedure (e.g. the causality according to the Investigator  during screening ). 
12.[ADDRESS_926559] comply with any applicable requirements related to the reporting of SAEs 
involving the study  subjects to the IRB/ IEC that approved the study.  
ObsEva will comply with the applicable regulatory requirements related to the expedited reporting  of 
suspected unexpected  serious adverse reactions  (S[LOCATION_003]Rs) to the regulatory authorities  (e.g. Health 
Authority, Central IRB/ IEC). The sponsor will be responsible, through their US Agent, for notifying the 
FDA of any S[LOCATION_003]R , and the sponsor or designee is responsible for notifying the Central IRB/ IEC. In 
regions/countries other than the US, reporting of events to local authorities will be  performed by [CONTACT_3786] /sponsor or designee and in accordance with local procedures/regulations.  
In accordance with ICH GCP guidelines, the sponsor  will inform the Investigator  of “findings that could 
affect adversely the safety of subjects, impact the conduct of the trial or alter the IRB/ IEC’s 
approval/favourable opi[INVESTIGATOR_150831]” . In particular and in line with respect ive regulations , 
the sponsor  will inform the Investigator  of AEs that are both serious and unexpected (i.e. as per the  
linzagolix  Investigator Brochure  and SmPC for the ABT ) and are considered by [CONTACT_684119], to have a reasonably possibility of causal relationship between  the administered IMP and the 
AE (i.e. S[LOCATION_003]R) . The Investigator  will keep copi[INVESTIGATOR_304696] ’s file. 
National regulations with regards to safety reports notifications to Investigator s will be taken into 
account.  
Unless clearly defined otherwise by [CONTACT_108103] -specific regulations, and duly documented, the 
responsible Investigator  will promptly notify the concerned IRB/ IEC of any safety reports provided by 
[CONTACT_304738][INVESTIGATOR_684059] . Only when specifically 
required by [CONTACT_19124], the sponsor  (or delegate) will provide appropriate safety reports directly to the 
concerned IRB/ IEC and maintain records of these notifications.  
12.[ADDRESS_926560] be recorded  up to the M6 FU visit . 
Events occurring during the screening period (i.e between ICF signature [CONTACT_304767] 1 visit)  must be 
recorded in the eCRFs using the AE form (and  SAE form if appropriate) until the date the subject is 
determined to be a screening failure. Beyond that date, only serious or medically relevant protocol -
related  events will be followed -up. 
A last batch of queries will be sent after last study visit if remaining ongoing/unknown outcomes of 
reported AEs are pending. After the last batch of queries with all collected data ha s been fully processed, 

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 93 of 156 
 OBSEVA  CONFIDENTIAL  eCRF  and database will no longe r be updated. Only SAEs and medically relevant ongoing/unknown 
outcome AEs  will be followed -up until resolution or sta bilization , under Voisin Consulting  
responsibility.  
12.[ADDRESS_926561] be recorded using the Pregnancy 
Surveillance Form  (PSF)  – Part I  (History and Start of Pregnancy; PSF -part I), provided by [CONTACT_103]  (or delegate) at the beginning of the study.  
Initial reporting of pregnancies : 
Subjects who become pregnant during the study Treatment Period  will be immediately withdrawn from 
the IMP treatment.  
The Investigator  must notify the sponsor  in an expedited manner (same as SAE reporting) of any 
pregnancy occurring during the above -mentioned period, by [CONTACT_304739]-part I . 
This form should be sent to ObsEva’s Representative for Pharmacovigilance as per the same procedures 
and timelines d escribed for SAE Urgent Reporting  in section 12.3.2 . This form should be accompanied, 
as needed, by [CONTACT_304740][INVESTIGATOR_304698], Previous and Concomitant Therapy and the Exit 
Form.  
Follow -up of pregnancies:  
The Investigator  must actively follow -up, document and report to ObsEva’s Representative for 
Pharmacovigilance the progress by [CONTACT_248879]-monthly updates up to the final outcome of the pregnancy  
using the Pregnancy Surveillance Form – Part II : (Course of Pregnancy; PSF -part II). If the subject 
can no longer be reached (lost to follow -up), documentation of the non -response/contact [CONTACT_304741] a letter (certified with return receipt) a re required.  
Pregnancy outcomes are not recorded in the eCRF unless considered AEs.  
Pregnancy outcomes  must be reported to ObsEva ’s Representative for Pharmacovigilance by 
[CONTACT_304742] – Part III : (Course and Outcome of Pregna ncy; PSF -
part III). Timelines vary according to the nature of the pregnancy outcome:  
- For normal outcomes, ObsEva’s Representative for Pharmacovigilance should be notified within 
45 days of birth/delivery.  
- For abnormal outcomes, the fully completed form must be sent to ObsEva’s Representative for 
Pharmacovigilance according to the same procedures and timelines described for expedited AE 
reporting in section 12.3.2  (within 24 hours of awareness of this outcome).  An SAE Report form 
should  be completed  in addition to the PSF -part III if  the subject sustains an event meeting 
seriousness criteria (e.g. abno rmality for the pregnancy (spontaneous abortion, stillbirth) or 
abnormality for the birth itself (e.g. prolongation of hospi[INVESTIGATOR_684060]). In case of congenital malformation or  birth defect  of the child , a SAE form for 
the child should be complete d in addition to the PSF -part III (Subject identifier = Subject ID – 1 
for a singleton neonate) . 

18-OBE2109 -[ADDRESS_926562] OF HYPOTHESES  
All statistical hypothesis tests and confidence intervals will be tw o sided. To maintain an overall t ype I 
error rate of 0.05 , as there are two linzagolix versus placebo comparisons, Bonferoni corrected p -values 
will be produced (raw p -values will be multiplied by [CONTACT_684120] 0.05 ), along with 
corresponding 97.5% confidence intervals.  
The two co -primary efficacy endpoints will be clinically meaningful reduction  (see section 13.5.2 ) over 
the last 28 day s of randomized treatment up to the M onth 3 visit  (the 4 -week period preceding Month 3  
visit) from baseline in the mean daily assessment of DYS and of NMPP measured on a VRS, along with 
a stable or decreased use of analgesics for EAP . 
The primary objective will be assessed by [CONTACT_684121]-sided hypotheses for each  co-
primary endpoint, for each  linzagolix  group versus plac ebo separately:  
Null hypothesis (H0): There is no difference in the odds of subjects meeting the primary endpoint for 
the active treatment group compared to placebo , that is, the odds ratio (OR) equals 1 . 
H0: OR =1  
Alternative hypothesis (H1): There is a difference in the odds of subjects meeting the primary endpoint 
for the active treatment group compared to placebo , that is, the OR is not equal to 1 . 
H1: OR ≠ [ADDRESS_926563] the ranked 
secondary endpoints as ordered  in Section [IP_ADDRESS] , so as to maintain the family -wise type I error rate . 
That is, the comparison for each linzagolix group versus placebo for each ranked endpoint will only be 
declared statistically significant different if the raw p -value multiplied by [CONTACT_684122] 
0.05 for that endpoint and for all preceding endpoints for that dose versus placebo .  
Response rates for DYS and NMPP pain at each visit will be analyzed to evaluate the changes in pain  
over time , with nominal bonferroni corrected p -values used in the comparisons of treatment groups at 
each visit.  These are suppo rtive analyses and will primarily be considered as descriptive. The analyses 
do not form part of the fixed -sequence strategy being used for the ranked secondary  endpoints and will 
not be fully controlled for an overall type I error rate. However, to mainta in consistency with the primary 
and sec ondary analyses, Bonferroni corrections will be used due to there being two linzagolix versus 
placebo comparisons for each endpoint / time point.  

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 95 of 156 
 OBSEVA  CONFIDENTIAL  13.2 SAMPLE SIZE  
The planned sample size for this study is 150 subjects per treatment group (450 subjects in total).  
An overall two -sided type I error of 0.05 will be used. As there are two linzagolix versus placebo 
comparisons, Bonferoni corrected p -values will be produc ed (raw p -values will be multiplied by [CONTACT_684123] 0.05). The planned sample size takes into account the hierarchical, fixed sequence 
testing of the ranked secondary endpoints as well as the co -primary endpoints. The assumptions used 
for the sample size calculations are based on analyses of clinically meaningful reduction in pain with a 
stable or decreased use of analgesics from the Phase 2b Edelweiss  study. Calculations were performed 
using E ast® 6.5 software . 
One hundred and fifty (150) subj ects per treatment group will provide a power greater than 95% to reject 
the null hypothesis for both co -primary endpoints for either treatment group, assuming a placebo 
response rate of 14.6% and an active treatment response rate of 48.6% (75 mg, Edelweis s result) or 
64.7% (200 mg, Edelweiss  result) for DYS , and a placebo response rate of 18.8% and an active treatment 
response rate of 42.1% (75 mg, Edelweiss  result ; the response rate for 200 mg in Edelweiss was lower 
but was inconsistent with the other doses and also the other timepoints for the same dose and so has not 
been used ) for NMPP. In addition, 150 subjects per treatment group provides 85% power to reject all 
the ranked secondary endpoints based on the observed results from the placebo and 200 m g treatment 
group in the Edelweiss  study.  
The values used for the sample size calculations assume that this is what would be seen on average when 
under treatment including taking into account any subjects who might withdraw from treatment early 
and theref ore the calculations do not need to be further adjusted for dropouts.   
13.3 RANDOMI ZATION  
Randomization will be performed via a centralized IWR S. Subjects will be randomized on Day 1 to one 
of three  treatment groups in a 1:1:1  ratio for linzagolix  75 mg, linzagolix  200 mg with ABT  and placebo . 
Subjects will be randomized into permutated  blocks of a pre -determined length.  
Subjects participating in the extension phase and who are in the placebo treatment group  will be 
randomized at Month 6 visit to either linzagolix 75 mg or linzagolix 200 mg with ABT  in a 1:1 ratio. 
Subjects participating in the extension phase and who are in the linzagolix treatment group s will remain 
on the same dose that they were taking at  the end of Month 6 and will undergo a du mmy randomization 
in order to maintain the blind.  
13.4 ANALYSIS SETS  
The following data sets will be used for the statistical analysis : 
1. Safety Set: All randomized subjects who received at least one dose of double -blind study drug 
irrespective of the treatment received. Subjects will be analyzed according to treatment 
received.  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 96 of 156 
 OBSEVA  CONFIDENTIAL  2. Full Analysis Set (FAS):  All randomized subjects who received at least one  dose of double -
blind study drug irrespective of the treatment received . This is the same as the Safety Set, but 
for the FAS subjects  will be analyzed according to randomized treatment.  
3. Per Protocol (PP) Set: All randomized subjects who completed the six m onths of treatment 
excluding those identified as having major protocol  deviations that could potentially affect the 
efficacy assessments  up to Month 6 . Subjects will be analyzed according to randomized 
treatment.  
4. Follow -up (FU) Set : All randomized subjects  who completed the six months of treatment and 
enter ed the drug free follow -up period . Subjects will be analyzed according to randomized 
treatment.  
5. Pharmacokinetic  (PK)  Set: all subjects who received active study medication , had no major 
protocol deviation s impacting PK and with available PK data . 
Individual data points may also be excluded from the analysis sets. Rules for such exclusions will be 
described in the statistical analysis plan (SAP) , including, where appropriate, time windows for various 
safety  and efficacy analyses . In general, analyses of efficacy will be conducted using the FAS and PP 
sets, analyses of safety will be conducted using the Safety Set and analyses of PK will be conducted 
using the PK Set.  
A sub -group analysis will be performed f or the secondary endpoint of dyspareunia as described in 
Section [IP_ADDRESS] . Additional  pre-planned s ub-group analyses will be described in the SAP.  
13.[ADDRESS_926564] quartiles, minimum and maximum will 
be calculated , including for change from baseline when applicable . The baseline mean will be calculated 
for all subjects based on the FAS . A baseline mean will also be calculated for each visit  using  the 
baseline data for the subset of patients who attend that visit, such that the same subjects contribute to 
the mean for the visit and the mean for the corresponding baseline values. Summary sta tistics will be 
based primarily on non -missing values . For ordered categorical data and nominal data, absolute counts 
and relative frequencies (in %) will be calculated.  As appropriate, time windows for various safety and 
efficacy analyses will be defined in the SAP.  
This study will be conducted at approximately [ADDRESS_926565] one dose of study drug, who completed the 
study and who prematurely discontinued will be calculated overall and for each site by [CONTACT_1570], 
as well as for all subjects combined. Premature disconti nuation of study drug will be summarized for 

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 97 of 156 
 OBSEVA  CONFIDENTIAL  each treatment group, as well as for all subjects combined, with frequencies and percentages overall and 
by [CONTACT_684124] . 
Raw and derived  data will be listed.  
13.5.1  Baseline Assessment  
Descriptive statistics will be performed on relevant screening and baseline data (i.e. data collected prior 
to the treatment administration) and on demographic characteristics for each treatment group and 
overall. There will be no formal compari son of baseline data, that is, no statistical hypothesis testing.  
13.5.[ADDRESS_926566] 28 days of randomi zed treatment . Use of 
analgesic medication for EAP  will be included in the responder definition s. A responder for each of the 
co-primary endpoints needs to demonstrate both a reduction in pain (DYS or NMPP, depending on the 
endpoint) and a stable or decreased use of analgesics for EAP. Anyone who does not meet both of these 
criteria will be defined as a non -responder.  
The pri mary efficacy analysis will be conducted using the FAS.  
For each of the co -primary endpoints, the criterion for defining a subject as a responder  over the last [ADDRESS_926567] eDiary; NMPP will use days with no uterine bleeding . If a subject's mean score for DYS  
is undefined numerically because her daily eDiary  reports indicate that she did not experience uterine 
bleeding o n any days during the 28 calendar day time period, then th e mean score for DYS will be set 
equal to zero (which reflects the absence of any DYS  during that reporting time period). For subjects 
who discontinue treatment prior to Month 3, the last available observations prior to discontinu ation will 
be used, in order to estimate the treatment eff ect of while under  treatment , that is the [ADDRESS_926568] dose date  (or fewer if treatment is stopped less than 4 weeks 
after randomiz ation) . The baseline mean overall pelvic p ain score s for DYS and NMPP will be 
calculated by [CONTACT_684125], which may not be 
exactly 28 days each.  For both DYS and NMPP, responses of "None," "Mild," "Moderate," and "Severe" 
will be assigned a scor e of 0, 1, 2, and 3, respectively.  
For the assessment of a stable or decreased use of analgesics for EAP, the analgesic use for any defined 
period will be based on the mean  of the total pi[INVESTIGATOR_684034] (endometriosis -
associated). The total pi[INVESTIGATOR_684061], as reported in the eDiary  during the time period of interest. The 
baseline analg esic use will be calculated as the mean of daily pi[INVESTIGATOR_684062]. For purposes of determining a stable or decreased use of 
18-OBE2109 -[ADDRESS_926569]  (three values)  and including the baseline pain score as a covariate.  
Individual linzagolix versus placebo treatment group  comparisons will be made using the same logistic 
regression model.  
Responder threshold  analysis : 
For each of the co -primary endpoints, the criterion for defining a subject as a responder over the last 28 
days of randomized treatment up to the M onth 3 visit  will be a reduction of X or greater from baseline 
in pain. The threshold for response in the responder analysis (i.e., the value of X) will be chosen to 
represent a clinically meaningful reduction in pai n and may not be the same for each endpoint . The 
threshold will be determined based on separate analyses of overall mean change using the mPGIS at 
Month 3 as an anchor. A 2 -point improvement in the mPGIS will be used to define responders for the 
primary analysis. Response categories of “very mild” and “mild” will be collapsed into one category 
prior to the analyses. Monthly question s specific to DYS, NMPP, overall pelvic pain, dyschezia, 
dyspareunia a nd daily function  will be  used as separate anchors . PGIC as an anchor, Cumulative 
Distribution Function  (CDF) and Probability Density Function  (PDF) curves, and Receiver Operating 
Characteristic  (ROC) analyses will be used as supportive analyses. The thresholds have been estimated 
in an analysis of DYS and NMPP data from the Phase 2b Edelweiss  study and will be re -estimated in 
this study , calculated based on the blinded Month [ADDRESS_926570] time matched PGIS and PGIC.  The final 
response thresholds taking into account the previous estimates from  phase 2b will be included in the 
final SAP prior to breaking the blind after Month 6. Based on the results from the Phase 2b Edelweiss  
study, it is expected that the responder threshold will be in the range of a 0.7 to 1.25 point  (40% to 50%) 
reduction in pain in the 4 -point VRS f or a 2 -point improvement and a 0.25 to 0.75 point  (20% to 30%) 
reduction in pain in the [ADDRESS_926571] ics for each treatment group , 
for each time point, including summaries of change from baseline when applicable. As with the primary 
analysis, individual linzagolix  versus placebo treatment groups  comparisons  will be made.  
[IP_ADDRESS]  Change from baseline to Month 6 in DYS (VRS)  / NMPP (VRS)  
Mean pelvic pain scores for DYS and for NMPP for each subject will be calculated in the same way as 
for the primary endpoint s. The change f rom baseline to Month 6 (the last [ADDRESS_926572] 
dose date for subjects who discontinue treatment prior to Month 6 ) in DYS using the VRS, and the 
change from baseline to Month 6 (the last [ADDRESS_926573] dose date for subjects who discontinue 

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 99 of 156 
 OBSEVA  CONFIDENTIAL  treatment prior to M onth 6 ) in NMPP (VRS), will be analyzed via analysis of co -variance with treatment 
group  as the main effect (three values ) and including the baseline pain score as a covariate .  
[IP_ADDRESS]  Change from baseline to Month 6 in dyschezia (NRS)  
Mean dyschezia scores for each subject will be calculated by [CONTACT_684126] 28 
calendar days immediately prior to and including the day of the Month 6 visit (or the [ADDRESS_926574] dose date fo r subjects who discontinue treatment prior to 
Month 6). The baseline mean dyschezia score will be calculated by [CONTACT_684127]. The change from baseline to Month [ADDRESS_926575] (three values) and 
including the baseline pain score as a covariate.  
[IP_ADDRESS]  Change from baseline to Month 6 in overall pelvic pain  (NRS ) 
The change from baseline to Month 6  (the last [ADDRESS_926576] dose date for subjects who 
discontinue treatment prior to Month 6 ) in overall pelvic pain using the NRS will be analyzed the 
same way as for  dyschezia.  
[IP_ADDRESS]  Change from baseline to Month [ADDRESS_926577] of pain on various activities 
and each assessed on a 5-point  scale (0=Never through to 4=Always) . The EHP -[ADDRESS_926578] Domain 
comprises  the following items :  
During the last [ADDRESS_926579] you ... 
1. Been unable to go to social events because of the pain?  
2. Been unable to do jobs around the house because of the pain?  
3. Found it difficult to stand because of the pain?  
4. Found it difficult to sit because of the pain?  
5. Found it difficult to walk because of  the pain?  
6. Found it difficult to exercise or do the leisure activities you would like to do because of the 
pain?  
7. Lost your appetite and/or been unable to eat because of the pain?  
8. Been unable to sleep properly because of the pain?  
9. Had to go to bed/lie down because of the pain?  
10. Been unable to do the things you want because of the pain?  
11. Felt unable to cope with the pain?  
It shall be scored as per the user manual, resulting in a score on a scale from 0 (best possible health 
status) to 100 (worst possible health  status). The change from baseline to Month 6  (the last 28 day s of 
randomized treatment up to the Month 6 visit)  in ability to perform daily activities, measured using the 
pain dimension of the EHP -[ADDRESS_926580] (three values) and including the baseline pain score as a covariate.   
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 100 of 156 
 OBSEVA  CONFIDENTIAL  [IP_ADDRESS]  Change from baseline to Month 6 in dyspareunia (VRS)  
The responses to the daily dyspareunia question s will be scored as follows.  Responses where the subject 
was not sexually active for reasons other than their endometriosis  will not be included in the analysis.  
 
Response  Score  
No pain during sexual intercourse.  [ADDRESS_926581] will be calculated by [CONTACT_684126] 28 
calendar days immediately prior to and including the day of the Month 6 visit (or the [ADDRESS_926582] dose date for subjects who discontinue treatment prior to 
Month 6). The baseline mean dyspareunia score will be calculated by [CONTACT_684127].  
Dyspareunia scores will be summari zed using the FAS and for the sub -group of subjects who have a 
mean dyspareunia score > [ADDRESS_926583] of treatment on such subjects. It is anticipated that this 
will be around 60% to 70% of the randomi zed subjects. This is a baseline assessment and does not 
influence the blinded, randomi zed treatment group. As per section 13.1, the type I error is maintained 
due to using fixed -sequence testing strategy . The change from baseline to Month [ADDRESS_926584] (three values) and 
including the baseline  pain score as a covariate.  
[IP_ADDRESS]  No analgesics use / no opi[INVESTIGATOR_684063] [ADDRESS_926585] (three values).  
In addition to analy zing the absence of analgesic use for EAP, the amount used for each 4-week  period 
will be summari zed, including the change from baseline. As it is likely that more than one opi[INVESTIGATOR_684064] (opi[INVESTIGATOR_684065]), the amount of opi[INVESTIGATOR_684066]  (MME) in order to better quantify the actual amount of 
opi[INVESTIGATOR_684067].   

18-OBE2109 -[ADDRESS_926586] dose date for subjects who discontinue treatment prior to the visit in question  (or 
fewer if treatment is stopped less than 4 weeks after randomi zation) , in order to estim ate the treatment 
effect of while under treatment. Corresponding baseline values will be calculated based on the two 
complete menstrual cycles during screening, which may not be exactly [ADDRESS_926587] of 
treatment policy rather than that of while on treatment. A reference based multiple imputation approach 
will be use d for subjects who discontinue the study prior to Month 3. Further details will be provided in 
the SAP.  
All exploratory  efficacy endpoints will be summarized by [CONTACT_95838], 
for each time point, including summaries of change from baseline when applicable.  Individual linzagolix 
versus placebo treatment group comparisons will be made.  
In general, between group comparisons for continuous endpoints will be analyzed via ana lysis of (co) -
variance. Between -group comparisons for binary endpoints will be analyzed via logistic regression. 
Between -group comparisons for ordinal categorical data will be analy zed using a Mantel -Haenszel test, 
or using Koch’s method when there is also a baseline covariate. Full details describing the der ivation 
and analyses of each exploratory endpoint will be provided in the SAP.  
Sub-group analyses based on demographic and baseline characteristics will be performed for each co -
primary endpoint  and select secondary endpoints,  and will be specified in the SAP.  
13.5.5  Safety Analysis  
The safety and tolerability profile will be assessed versus baseline conditions and differences between 
treatment groups and descriptive statistics will be produced  for both values and change from baseline, 
where applicable .  
Extent of  exposure and compliance to treatment will be evaluated.  
Concomitant medications  will be summarized using the World Health Organization (WHO) Drug 
Dictionary with frequencies and percentages for each treatment group. All medications administered 
between the  date of the first dose of study drug and the date of the last dose of study dr ug, inclusive, 
(i.e., all medications starting or ongoing during the time interval) will be included. Thus, all medications 
with an end date prior to the first study drug dose will be excluded from the summary table.  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 102 of 156 
 OBSEVA  CONFIDENTIAL  An analysis of the TEAEs will be done. AEs will be summariz ed using the Medical Dictionary for 
Regulatory Activities tabulated by (MedDRA ) dictionary  preferred term and system organ class. TEAEs  
will be summarized with frequencies and percentages for each treatment group. TEAEs  are defined as 
AEs with a start date on or after the first dose of study drug. Adverse events starting more than [ADDRESS_926588] -treatment AEs. Tabulations  by [CONTACT_304750] -relatedness will also be 
made.  
Laboratory parameters values will be summarized for each visit for each treatment group  including 
within -group changes from baseline. Evaluation of shifts for changes from baseline according to the 
normal range will be provided.  
BMD value s and corresponding Z-scores  will be summarized at baseline and at Month 6 for each 
treatment group , using the observed data . The within -group percent changes from baseline for BMD 
values will also be summarized , including 2-sided 95% confidence interval s. Categorical summaries of 
percent change from baseline will also be produced. The percent changes from baseline to Month [ADDRESS_926589] (three values) and including the baseline as a covariate . Sub-
group analyses based on demographic and baseline characteristics will be performed  for BMD, and will 
be specified in the SAP .The Safety Analysis Set shall be used when summarizing safety data.  
13.5.[ADDRESS_926590] number, sampling time 
and dose group .  
For descriptive statistics of plasma concentrations mean (arithmetic and geometric), standard deviation, 
median, 1st and 3rd quartiles, minimum, maximum, coefficient of variation (CV%) and number  of 
observations  will be provided . Concentrations below the limit of quantification (LOQ) will be assigned 
a value of zero.  Explorative analyses of correlations between plasma concentrations and intrinsic PK 
factors such as e.g. body  weight/BMI, race, age wil l be performed, as appropriate , and will be reported 
separately .  
PK analyses will be based on the PK Set.   
13.5.[ADDRESS_926591] under treatment , for example, missed 
days of completing the eDiary . The primary analyses will use observed data only in such cases  provided 
that a mini mum number of completed daily edairy entries are available . This effectively assumes that 
the individual values  such as daily eDiary  assessments  (observed or not) are independent of being 
missing .  
Further details on the handling of missing values and the methods and planned sensitivity analyses to 
check  the robustness of the analysis  results under alternative assumptions with regards to missing d ata 
will be provided in the SAP . 
13.[ADDRESS_926592] completed the Treatment Period ( Month 6 ), a complete analysis will be 
performed. This analysis will include all data up to the Month 6 visit. A database lock will be performed 
prior to unblinding of treatment, and any discrepant data will be clarified before the lock. Since this end -
of-treatment -period analysis is the only and final analysis of the primary  and ranked secondary 
endpoints, no additional adjustment of alpha -level is necessary  beyond that described in section 13.1. 
The results for the Treatment Period  will be summarized and described in an integrated Clinical Study 
Report.  
13.6.3  Treatment Free Follow -Up Period Analysis  
A 6 months  follow -up period without treatment is planned after the 6 months  Treatment Period , or after 
the optional extension study . 

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 104 of 156 
 OBSEVA  CONFIDENTIAL  Analyses of the follow -up period data  for subjects not entering the extension study  will be reported  in 
an addend um to the integrated Clinical Study Report.  
After the T reatment period  (Month 6) , the Sponsor will be unblinded to the subject’s treatment allocation 
but treatment allocation will remain blinded up to the end of the follow -up period  for the Investigator , 
the subject  and the CR As. 
[ADDRESS_926593] their 
origin in the Declaration of Helsinki  (18), the ICH Harmoni zed Tripartite Guideline for GCP and all 
applicable local regulatory requirements.  
14.1.[ADDRESS_926594] give written informed consent. The informed 
consent process will be in accordance with ICH GCP and local regulatory requirements.  
14.1.2  Regulatory Authority Approval  
Before the study is initiated at a site, the sponsor  (or it s delegate) will obtain approval to conduct the 
study from the appropriate regulatory authority in accordance with any applicable country -specific 
regulatory requirements.  
14.1.[ADDRESS_926595]  Requirements  / Independent Ethics Committee   
Before initiation of the study at a given site, written approval of the protocol, ICF and any information 
presented to potential subjects must be obtained from the appropriate Institutional Review Board (IRB) / 
Independent Ethics Committee  (IEC). If any ame ndments to any of these documents occur during the 
study, notification or written approval  as appropriate  must be obtained prior to their implementation. 
The Investigator  is responsible for ensuring that these actions occur.  
Where required by [CONTACT_276882], the sponsor  (or its delegate) is responsible for ensuring IRB/ IEC 
approval of the study.  
14.1.[ADDRESS_926596] the study according to ICH GCP guidelines , the 
FDA Code of Regulation  or the EU Clinical Trial Directive  and applicable local laws and regulations . 
Where required by [CONTACT_427], national level coordinating Investig ators may be appointed. Their 
responsibilities are outlined in a separate agreement with the sponsor . 
14.3 DATA MANAGEMENT  
The Investigator  or designee will be responsible for  recording study data in the eCRF  provided by [CONTACT_103] . It is the Investigator ’s responsibility to ensure the accuracy of the data entered in the eCRF s. 
The data will be entered into a validated database.  The sponsor  or delegate will be responsible for data 
processing, in accordance with  the sponsor  (or delegate) data management pro cedures. Database lock 
will occur once quality assurance procedures have been completed. The database wi ll not be locked 
before all data clarifications have been resolved and monitored and the decision on subject evaluation 
has been completed.  PDF files of  the e CRF s will be sent to the Investigator  at the completion of the 
study.  
14.[ADDRESS_926597] allow a sponsor  
representative ( e.g. CRA or study monitor) periodical access to subject records and all study -related 
materials. The frequency of monitoring visits will be determined by [CONTACT_684128], the frequency of subject visits and the site enrolment rate. In or der to verify that the study is 
conducted in accordance with ICH GCP, regulatory requirements, and the study protocol and that the 
data are authentic, accurate and complete, the study monitor will review eCRF s and other study 
documents and will conduct sou rce data verification.  
Upon study completion, the sponsor  representative ( e.g. CRA or study monitor ) will visit the site to 
conduct a Study termination visit. This will involve collection of any outstanding documentation  and 
study material if applicable . 
14.5 DATA MONITORING  COMMITTEE  
The Data Monitoring Committee (DMC) is a group of independent experts external to the study that, 
collectively, has experience in the management of subjects with endometriosis and in the conduct and 
oversight of randomized clinical  trials.  
Composition, responsibilities, rules for decision and procedures of the DMC will be described in more 
details in the DMC charter.  
The DMC will be responsible for:  
- safeguarding the interests of trial participants,  
- assessing the safety of the IM P during the trial (reviewing unblinded safety data and AEs and 
SAEs, on a regular basis, as per charter prepared for the study).  
18-OBE2109 -[ADDRESS_926598] CONFIDENTIAL ITY 
The Investigator  and the CRA  (or study monitor) representing the sponsor  must ensure that the subject’ s 
anonymity is maintained. In the eCRF s or other documents submitted to the sponsor , the subject should 
not be identified by [CONTACT_684129], but by [CONTACT_684130]. If a subject ’s name  [CONTACT_304768][INVESTIGATOR_304701] , the name (except for initials) must be obliterated and the 
assigned SIN added to the documents.  
The Investigator  should keep a separate log of SINs , names, addresses, telephone numbers and hospi[INVESTIGATOR_281223] (if applicable). Documents not for submission to the sponsor , such as signed ICFs, should be 
maintained in strict confiden tiality  by [CONTACT_737] . 
14.[ADDRESS_926599] party acting on behalf 
of the sponsor , regulatory agencies or IRB/ IEC may conduct quality assurance audits at any time during 
or following a study. The Investigator  must agree to allow auditors direct access to all study -related 
documents including source documents, and must agree to allocate his or her time and the time of his or 
her study staff to the auditors in order to discuss findings and issues.  
14.8 PROTOCOL DEVIA TIONS  
A protocol deviation is any noncompliance with the clinical trial protocol or Inte rnational Conference 
on Harmoniz ation Good Clinical Practice (ICH GCP ) requirements. It is the responsibility of the site 
investigator to use continuous vigilance to id entify and report deviations. All deviations must be 
addressed in study source documents and reported to the reviewing IRB/ IEC per their policies. The site 
investigator is responsible for knowing and adhering to the reviewing IRB/ IEC requirements.  
All Prot ocol Deviations will be reported to the Sponsor  and documented in the monitoring report. These 
will be classified as minor or major based on their effect on the right, safety or well -being of the subjects 
and/or the quality and integrity of the data, and t he final rating of all deviations will be confirmed prior 
to database lock.  
14.9 STUDY OR SITE DISCON TINUATION  
The sponsor  may temporarily or permanently discontinue the study for safety, ethical, compliance or 
other reasons. If this is necessary, the sponsor  will endeavour to provide advance notification to the site. 
If the site or study is suspended or discontinued, the Investigator  will be responsible for promptly 
informing the IRB/IEC.  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 107 of 156 
 OBSEVA  CONFIDENTIAL  Where required by [CONTACT_427], the sponsor  (or delegate) will be responsible for informing the 
IRB/ IEC of study or site discontinuation. In such cases, all study data and unused IMP must be returned 
to the sponsor . 
14.10  RETENTION OF ESSENTI AL STUDY DOCUMENTS  
Essential documents as defined by [CONTACT_304756](s), copi[INVESTIGATOR_684068] s, signed ICFs from all subjects who consented, hospi[INVESTIGATOR_1097], diary cards and 
other source documents,  IRB/ IEC approvals and all rela ted correspondence including approved 
documents, drug accountability records, study correspondence and a list of the subjects’ names and 
addresses.  
The Investigator  must retain copi[INVESTIGATOR_684069].  
The Investigator  will inform the sponsor  of the storage location of the essential documents, and must 
contact [CONTACT_304757]. The Investigator  should take measures to 
prevent accidental or premature destruction of these documents.  
14.11  PUBLICATION POLICY  
ObsEva registers clinical trials (Phase I – IV) wherever and whenever mandatory on publicly accessible 
websites (e.g.: www.clinicaltrials.gov  ; www.clinicaltrialsregister.eu ), including posting the trial design, 
population, and study details as required.  
ObsEva posts the outcome of clinical trials on the  required medium(a), within required timelines, 
regardless of the nature of the outcome.  
ObsEva shares information on the outcome of clinical trials with the Principal/Coordinating 
Investigators of trials in the form of a final report synopsis, regardless of the trial outcome.  
ObsEva duly communicates to stakeholders all relevant information arising from research activities 
related to products developed by [CONTACT_7904], at any point and during any phase of the development of 
a product and the entire life -cycle of an ObsEva product.  
Registration, reporting and communication of clinical trial results, results and/or outcome of non -clinical 
research are subject to mandatory preliminary review and authorization by [CONTACT_684131], prior to disclosur e. 
  

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020 Page 108 of 156 
 OBSEVA  CONFIDENTIAL  15 APPENDICES  
APPENDIX A.  SCHEDULE OF STUDY AS SESSMENTS – SCREENIN G AND TREATMENT PERI ODS  ............  109 
APPENDIX B.  SCHEDULE OF STUDY AS SESSMENTS – FOLLOW -UP PERIOD  ................................ .........  114 
APPENDIX C.  MODIFIED BIBEROGLU &  BEHRMAN SYMPTOM SEV ERITY SCALE*  ...............................  117 
APPENDIX D.  ENDOMETRIOSIS HEALTH  PRO FILE QUESTIONNAIRE ( EHP-30) ................................ ..... 119 
APPENDIX E.  PROMIS FATIGUE – SHO RT FORM 6A  ................................ ................................ ...........  124 
APPENDIX F.  HEALTH -RELATED PRODU CTIVITY QUESTIONNAIR E (HRPQ)  ................................ .........  125 
APPENDIX G.  HEALTH RESOURCE UTIL IZATION QUESTIONNAIR E (HRUQ)  ................................ ..........  128 
APPENDIX H.  PATIENT GLOBAL IMPRE SSION OF  CHANGE (PGIC)  ................................ .......................  [ADDRESS_926600] -TREATMENT PATIE NT GLOBAL IMPRESSION  OF CHANGE (PPGIC)  .......................  134 
APPENDIX J.  PATIENT GLOBAL IMPRE SSION OF SEVERITY (P GIS)  ................................ ......................  [ADDRESS_926601] SURGERY INTE NTION QUESTIONNAIRE (SSIQ)  ................................ ................  136 
APPENDIX L.  PHYSICIAN SURGERY IN TENTION QUESTI ONNAIRE (PSIQ)  ................................ ............  [ADDRESS_926602] VI SIT ................................ ................................ ...............................  154 
 

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020     Page 109 of 156 
 OBSEVA  CONFIDENTIAL  Appendix A.  Schedule of study assessments – Screening and Treatment Periods  
 
Schedule of study assessments – Screening and Treatment Periods  
Timing1 Screening Period 
(up to 3 months2) Treatment Period  
Day 1  M1 M2 M3 M4 M5 M6 
Informed Consent  x        
Inclusion -Exclusion criteria  x x       
Demography, height, weight, medical history  x        x3 
mB&B  x        
Columbia -Suicide Severity Rating Scale  x x x x x x x x 
 
 
 
[ADDRESS_926603] at the end of the defined period (i.e. M1 visit should be scheduled at the end of Month 1, M2 visit should be scheduled at the end of Month 
2, etc.). Post -baseline visits dates are calculated from Day 1 visit dat e. A month is defined as 28 days/4 weeks. Visits should be scheduled ± 3 days from the calculated date.  
2 If required for washout of oral contraceptives, other sex hormones, or GnRH antagonists/agonists (provided that the reason for discontinuing the previ ous GnRH -antagonist is not 
lack of efficacy),  a period  of up to 3 months is allowed between signing the informed consent and the screening visit.  
3 Only weight will be recorded.  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020     Page 110 of 156 
 OBSEVA  CONFIDENTIAL  Schedule of study assessments – Screening and Treatment Periods  
Timing1 Screening Period 
(up to 3 months2) Treatment Period  
Day [ADDRESS_926604] examination (mammogram if required)  x       x 
 
 
 
4 ECG on Day 1 should be performed twice: once before treatment and once after treatment (just before PK sampling).  
5 If endometrium thickness in TVUS is ≤ 5 mm, no endometrial biopsy will be necessary.  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020     Page 111 of 156 
 OBSEVA  CONFIDENTIAL  Schedule of study assessments – Screening and Treatment Periods  
Timing1 Screening Period 
(up to 3 months2) Treatment Period  
Day 1  M1 M2 M3 M4 M5 M6 
Clinical laboratory & urinary protein dipstick  x x6 x6 x x6 x x x6 
Blood sample for PK7  x x x x x x x 
BMD by [CONTACT_11324]  x       x 
Adverse events  x x x x x x x x 
Previous/concomitant medication  x x x x x x x x 
Contraceptive dispensing and counselling  x x x x x x x x 
Permitted analgesic prescribing/dispensing  x x x x x x x x 
Vitamin D and calcium dispensing   x x x x x x x 
Subject eDiary completion training/check  x x x x x x x x 
 
 
 
[ADDRESS_926605] 1.5 h aft er the IMP administration.  

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020     Page 112 of 156 
 OBSEVA  CONFIDENTIAL  Schedule of study assessments – Screening and Treatment Periods  
Timing1 Screening Period 
(up to 3 months2) Treatment Period  
Day 1  M1 M2 M3 M4 M5 M6 
IMP accountability    x x x x x x 
Dispense study drug   x x x x x x  
Dispense ABT   x   x    
EHP -30, EQ -5D-5L and PROMIS8  x x  x   x 
mPGIS, PGIC, HRUQ and HRPQ    x9 x x x x x x 
Specific m onthly severity question s8  x   x   x 
SSIQ and PSIQ8  x      x 
AMH   x       
E2, LH, P4   x x x x x x x 
SHBG   x   x   x 
Bone biomarkers   x   x   x 
 
 
 
8 ClinROs (Monthly dyspareunia question, PSIQ and HRUQ) will be administered to the subject by [CONTACT_684132]. ePROs (EHP -30, EQ -5D-
5L, PROMIS, PGIS, PGIC, HRPQ and SSIQ , and specific monthly severity questions ) will be filled in by [CONTACT_111412].  
9 PGIC not done at Day 1.  

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020     Page 113 of 156 
 OBSEVA  CONFIDENTIAL  Schedule of study assessments – Screening and Treatment Periods  
Timing1 Screening Period 
(up to 3 months2) Treatment Period  
Day 1  M1 M2 M3 M4 M5 M6 
Question regarding treatment received         x 
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020     Page 114 of 156 
 OBSEVA  CONFIDENTIAL  Appendix B.  Schedule of study assessments – Follow -up Period  
 
Schedule of study assessments – Follow -up Period  
Timing1 M1 FU  M2 FU  M3 FU  M4 FU  M5 FU  M6 FU  
Previous/concomitant medication  x x x x x x 
Adverse events  x x x x x x 
Columbia -Suicide Severity Rating Scale  x x x x x x 
ECG  x  x   x 
Physical examination    x   x 
Weight       x 
Vital signs  x  x    
Gynecological examination    x    
 
 
 
[ADDRESS_926606] at the end of the defined period (i.e. M1 FU visit should be scheduled at the end of the fi rst month of follow -up, M2 FU visit should be 
scheduled at the end of the second follow -up visit, etc.). A month is def ined as 28 days/4 weeks. Visits should be scheduled ± 7 days from the calculated date.  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020     Page 115 of 156 
 OBSEVA  CONFIDENTIAL  Schedule of study assessments – Follow -up Period  
Timing1 M1 FU  M2 FU  M3 FU  M4 FU  M5 FU  M6 FU  
Breast manual examination    x    
Endometrium TVUS    x   x 
Endometrial biopsy  x2 x2 x2 x2 x2 x3 
Clinical laboratory & urinary protein dipstick  x  x4    
Subject eDiary completion check  x x x x x x 
Subject eDiary collection and deactivation       x 
EHP -30, HRUQ, HRPQ, EQ -5D-5L and PROMIS    x   x 
mPGIS and PPGIC  x x x x x x 
BMD by [CONTACT_11324]       
x5 
E2, LH, P4  x  x    
 
 
 
2 Endometrial biopsy will be taken only if diagnosis at preceding month was different than “benign endometrium” or if no endome trial biopsy was done at Month 6 nor at an y visit 
since Month 6.  
3 An end -of-study biopsy is mandatory if no endometrial biopsy was obtained at M6 nor at any of the subsequent monthly visits.  
4 Overnight fasting is required.  
5 Subjects with a BMD decrease from baseline of > 1.5% for lumbar spi[INVESTIGATOR_050] a nd/or > 2.5% for total hip at Month [ADDRESS_926607] an additional DXA scan 6 months later.  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020     Page 116 of 156 
 OBSEVA  CONFIDENTIAL  Schedule of study assessments – Follow -up Period  
Timing1 M1 FU  M2 FU  M3 FU  M4 FU  M5 FU  M6 FU  
FSH at local laboratory for subjects that do not resume 
menses at M3 FU visit    x    
Bone biomarkers    
x   
 
Permitted analgesic prescribing/dispensing  x x x x x  
Vitamin D and calcium  dispensing  x x x x x  
Urine pregnancy test and contraceptive dispensing and 
counselling  x x x   x 
 
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020  Page 117 of 156 
 
 OBSEVA  CONFIDENTIAL  Appendix C.  Modified Biberoglu & Behrman symptom  severity scale*  
 
A. Dysmenorrhea  
None  0 = No symptoms  
Mild  1 = Some loss of ability to work or carry out normal activities  
Moderate  2 = Unable to work or carry out normal daily activities for part of 1 or more days 
and/or moderately decreased work efficiency  
Severe  3 = Unable to work or carry out normal daily activities for 1 or more full days and/or 
significantly decreased work efficiency  
 
B. Deep Dyspareunia  
None  0 = No symptoms  
Mild  1 = Tolerated discomfort during intercourse  
Moderate  2 = Interfere nce of usual frequency of sexual intercourse due to pain  
Severe  3 = Avoids, or wishes to avoid, intercourse because of pain  
 
C. Non Menstrual Pelvic Pain  
None  0 = No symptoms  
Mild  1 = Occasional pelvic discomfort  
Moderate  2 = Noticeable discomfort for most of cycle  
Severe  3 = Pain persistent during cycle other than during menstruation  
 
 
D. Pelvic Tenderness  (assessed by [CONTACT_31126] ) 
None  0 = No findings  
Mild  1 = Minimal tenderness on palpation  
Moderate  2 = Moderate tenderness on palpation  
Severe  3 = Exam limited due to tenderness  
 
E. Induration  (assessed by [CONTACT_099])  
None  0 = No findings  
Mild  1 = Uterus freely mobile, minimal induration in the cul -de-sac 
Moderate  2 = Significant induration in the cul -de-sac, restricted uterine mobility  
Severe  3 = Nodular adnexa and cul -de-sac, uterus fixed  
 
Composite Pelvic Pain and Physical Sign  Score (A + B + C + D + E)  
None   0 Total Pelvic Pain Score (A + B + C)  
None   0 
Mild   1 - 3 
Moderate  4 - 6 
Severe   7 - 9 
 
Total Physical Sign Score (D + E)  
None   0 
Mild   1 - 2 
Moderate  3 - 4 
Severe   5 - 6 
 
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020  Page 118 of 156 
 
 OBSEVA  CONFIDENTIAL  Mild   1 - 2 
Moderate   3 - 5  
Severe   6 - 10 
Very Severe  11 – 15 
 
* based on Biberoglu KO, Behrman SJ. Dosage aspects of danazol therapy in endometriosis: 
short term and long term effectiveness. Am J Obstet Gynecol. 1981;1 39:645.    
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020  Page 119 of 156 
 
 OBSEVA  CONFIDENTIAL  Appendix D.  Endometriosis Health Profile questionnaire (EHP -30) 
 
Final English (US) EHP -30 + Section C  
© Copyright, Oxford University Innovation Limited 2001. All Rights Reserved.  
The authors, being [CONTACT_454095], [CONTACT_684143] and [CONTACT_684144], 
have asserted their moral rights.  
 
PART  1: CORE  QUESTIONNAIRE  
 
DURING THE LAST [ADDRESS_926608] YOU... 
 Never  Rarely  Sometimes  Often  Always  
1. Been unable to go to social events 
because of the pain?        
2. Been unable to do jobs around the 
house because of the pain?        
3. Found it difficult to stand because of 
the pain?        
4. Found it difficult to sit because  
of the pain?        
5. Found it difficult to walk because  
of the pain?        
6. Found it difficult to exercise or do the 
leisure activities you would like to do 
because of the pain?        
18-OBE2109 -[ADDRESS_926609] your appetite and/or been unable 
to eat because of the pain?        
8. Been unable to sleep properly because 
of the pain?        
9. Had to go to bed/lie down because of  
the pain?        
10. Been unable to do the things you want 
because of the pain?        
11. Felt unable to cope with the pain?        
12. Generally felt unwell?        
13. Felt frustrated because your sympto ms 
are not getting better?        
14. Felt frustrated because you are not 
able to control your symptoms?        
18-OBE2109 -[ADDRESS_926610] YOU... 
 Never  Rarely  Sometimes  Often  Always  
15. Felt unable to forget your symptoms?        
16. Felt as though your symptoms  
are ruling your life?        
17. Felt your symptoms are taking away 
your life?        
18. Felt depressed?        
19. Felt weepy/tearful?        
20. Felt miserable?        
21. Had mood swings?        
22. Felt bad -tempered or short -tempered?        
18-OBE2109 -[ADDRESS_926611] YOU... 
 Never  Rarely  Sometimes  Often  Always  
23. Felt violent or aggressive?        
24. Felt unable to tell others how  
you feel?        
25. Felt others do not understand  
what  you are going through?        
26. Felt as though others think  
you are whining?        
27. Felt alone?        
28. Felt frustrated that you cannot always 
wear the clothes you  
would choose?        
29. Felt your appearance has been 
affec ted?       
30. Lacked confidence?        
 
 
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020  Page 123 of 156 
 
 OBSEVA  CONFIDENTIAL  PART  2: MODULAR QUESTIONNAIRE CORRE SPONDING TO SEXUAL RELATIONSHIPS  
 
DURING THE LAST [ADDRESS_926612] YOU... 
 Never  Rarely  Sometimes  Often  Always  
1. Experienced pain during  
or after intercourse?  
If not applicable,  
please check here        
2. Felt worried about having intercourse 
because of the pain?  
If not applicable,  
please check here         
3. Avoided intercourse  
because of the pain?  
If not applicable,  
please check here        
4. Felt guilty about not wanting  
to have intercourse?  
If not applicable,  
please check here        
5. Felt frustrated because you  
cannot enjoy intercourse?  
If not applicable,  
please check here         
 
  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020  Page 124 of 156 
 
 OBSEVA  CONFIDENTIAL   
Appendix E.  PROMIS Fatigue – Short Form 6a  
 
This scale is formally known as PROMIS Item Bank v1.0 – Fatigue – Short Form 6a. The questions 
and the response categories included in this scale are presented below.  
 
 
Please respond to each question or statement by [CONTACT_3730].  
 
 During the past 7 
days…  Not at all  A little bit  Somewhat  Quite a 
bit Very 
much  
1 I feel fatigued  □ □ □ □ □ 
[ADDRESS_926613] trouble starting 
things because I am tired  □ □ □ □ □ 
 In the past 7 days…       
3 How run -down did you 
feel on average?  □ □ □ □ □ 
4 How fatigued were you 
on average?  □ □ □ □ □ 
5 How much were you 
bothered by [CONTACT_684133]?  □ □ □ □ □ 
6 To what degree did your 
fatigue interfere with 
your physical 
functioning?  □ □ □ □ □ 
 
Scoring Rules:  
The mappi[INVESTIGATOR_684070]:  
1 = Not at all; 2 = A little bit; 3 = Somewhat; 4 = Quite a bit; 5 = Very much  
Assessment will be based on the sum of the individual scores across the six questions (possible scores 6 to 30, 6 = not at al l, 
30 = very much). Missing data will not be imputed.  
  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020  Page 125 of 156 
 
 OBSEVA  CONFIDENTIAL  Appendix F.  Health -Related Pro ductivity Questionnaire  (HRPQ)  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020  Page 126 of 156 
 
 OBSEVA  CONFIDENTIAL   

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020  Page 127 of 156 
 
 OBSEVA  CONFIDENTIAL    

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020  Page 128 of 156 
 
 OBSEVA  CONFIDENTIAL  Appendix G.  Health Resource Utilization Questionnaire (HRUQ)  
 (To be completed by [CONTACT_112806])  
Subject number: ___________________________  
Study Visit  (please ensure to tick 1 visit only) :  
Treatment period  ☐ Day 1  ☐ Month 1  ☐ Month 2 ☐ Month 3  
     ☐ Month 4  ☐ Month 5  ☐ Month 6  
Follow -up period  ☐ Month 3 FU   ☐ Month 6 FU   
Date of Assessment:  __________________________________________  
 
Instructions to complete:  
At each scheduled on -site visit in the Treatment Period (Day 1 through Month 6) and at Month [ADDRESS_926614] scheduled on -site visit for a routine/general  health care visit that is not 
associated with an adverse event . 
Only record below the health care visits with non -study health care practitioners.  Any visits associated 
with Adverse Events should be recorded on the AE eCRF form only  (do not record below).  
 
***********  
  
18-OBE2109 -[ADDRESS_926615]'s last scheduled study on -site visit, has she seen a non-study  health care practitioner 
(e.g., physician, nurse practitioner, physician assistant, dentist, physical therapi[INVESTIGATOR_541]) for a 
routine/general health care visit that is not associated with an adverse event?  
☐ No  ☐ Yes   If Yes, please complete the questions [ADDRESS_926616].  
b. Indicate if it was at an office or a clinic (includes a hospi[INVESTIGATOR_684071])  
c. Indicate the number of times the subject was seen by [CONTACT_684134].  
Types of non-study  health care 
practitioner who saw the subject  
(check all that apply)  Type of facility  Number of times 
subject was seen by [CONTACT_684135]-study  health care 
practitioner  
 Office  Clinic  Office  Clinic  
☐ AUDIOLOGIST  ☐ ☐   
☐ ALLERGIST  ☐ ☐   
☐ CARDIOLOGIST  ☐ ☐   
☐ DENTIST  ☐ ☐   
☐ DERMATOLOGIST  ☐ ☐   
☐ ENDOCRINOLOGIST  ☐ ☐   
☐ ENT  ☐ ☐   
☐ FAMILY PHYSICIAN  ☐ ☐   
☐ GASTROENTEROLOGIST  ☐ ☐   
☐ GYNECOLOGIST  ☐ ☐   
☐ HEMATOLOGIST  ☐ ☐   
☐ HEPATOLOGIST  ☐ ☐   
☐ IMMUNOLOGIST  ☐ ☐   
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020  Page 130 of 156 
 
 OBSEVA  CONFIDENTIAL  ☐ INFECTIOUS DISEASE 
SPECIALIST  ☐ ☐   
☐ INTERNAL MEDICINE 
SPECIALIST  ☐ ☐   
☐ INTERNIST  ☐ ☐   
☐ MEDICAL GENETICIST  ☐ ☐   
☐ NEPHROLOGIST  ☐ ☐   
☐ NEUROSURGEON  ☐ ☐   
☐ NURSE  ☐ ☐   
☐ NURSE PRACTITIONER  ☐ ☐   
☐ OCCUPATIONAL THERAPI[CONTACT_177020]  ☐ ☐   
☐ OPHTHALMOLOGIST  ☐ ☐   
☐ ORTHOPEDIC SURGEON  ☐ ☐   
☐ OPTOMETRIST  ☐ ☐   
☐ PHYSIATRIST  ☐ ☐   
☐ PHYSICAL THERAPI[CONTACT_177020]  ☐ ☐   
☐ PLASTIC SURGEON  ☐ ☐   
☐ PODIATRIST  ☐ ☐   
☐ PSYCHOLOGIST  ☐ ☐   
☐ PULMONOLOGIST  ☐ ☐   
☐ RADIOLOGIST  ☐ ☐   
☐ REPRODUCTIVE 
ENDOCRINOLOGIST  ☐ ☐   
☐ RHEUMATOLOGIST  ☐ ☐   
☐ SURGEON  ☐ ☐   
☐ UROLOGIST  ☐ ☐   
☐ UNKNOWN  ☐ ☐   
☐ OTHER HEALTH CARE 
PRACTITIONER (specify type):  ☐ ☐   
  
18-OBE2109 -[ADDRESS_926617] scheduled study on -site visit?  
☐ No   ☐ Yes   If Yes, complete question [ADDRESS_926618] the type of diagnosis/therapeutic procedures performed by [CONTACT_105] -study health care 
practitioner who saw the subject.  
b. Indicate the number of times the diagnosis/therapeutic procedures were performed.  
Diagnostic/Therapeutic Procedure  
(check all that ap ply) Number of times the procedure was performed  
Ultrasound Scan  ☐  
Physical Examination  ☐  
Vital Signs  ☐  
MRI  ☐  
CT Scan  ☐  
X-Ray ☐  
Biopsy and Histologic Examination  ☐  
Pelvic Exam  ☐  
Urine Test  ☐  
Blood Test  ☐  
Hysteroscopy  ☐  
SIS ( Saline infusion Sonohysterography)  ☐  
Colposcopy  ☐  
Other (specify):  
 ☐  
  
18-OBE2109 -[ADDRESS_926619] visit?  
☐ No   ☐ Yes  
If Yes, how many nights did they spend in hospi[INVESTIGATOR_307]?  
  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020  Page 133 of 156 
 
 OBSEVA  CONFIDENTIAL   
Appendix H.  Patient Global Impression of Change  (PGIC)  
 
  

18-OBE2109 -[ADDRESS_926620]-treatment Patient Global Impression of Change 
(PPGIC)  
 
 
“Overall, how have your endometriosis symptoms  
changed since you stopped taking the study drug?”  
 
 
  

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020  Page 135 of 156 
 
 OBSEVA  CONFIDENTIAL  Appendix J.  Patient Global Impression of Severity (PGIS)  
 
Daily recall (dPGIS)   Monthly recall (mPGIS)  
Overall, h ow would you describe your 
endometriosis symptoms  in the last 24 
hours ?  Overall, h ow would you describe your 
endometriosis symptoms  over the past 28 
days ? 
  
 
 
  

18-OBE2109 -[ADDRESS_926621] Surgery Intention Questionnaire (SSIQ)  
 
1. How likely are you to consider having laparoscopic surgery to treat your endometriosis if your 
symptoms continue as they are now?  
The SSIQ evaluates subject likelihood of  considering  endometriosis -related surgeries if current 
symptoms continue, with possible scores from 0 to 10,  
0 = not at all, 10 = very likely.  
  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020  Page 137 of 156 
 
 OBSEVA  CONFIDENTIAL  Appendix L.  Physician Surgery Intention Questionnaire (PSIQ ) 
 
1. How likely are you to recommend laparoscopic surgery to treat this patient's  endometriosis if her 
symptoms continue as they are now?  
The PSIQ evaluates physician likelihood of recommending endometriosis -related  surgeries to the 
subject if current symptoms continue, with possible scores from 0 to 10,  
0 = not at all, 10 = v ery likely.  
  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020  Page 138 of 156 
 
 OBSEVA  CONFIDENTIAL  Appendix M.  EQ-5D-5L 
 
EQ-5D-5L English US version  
© EuroQol Research Foundation. EQ -5D™ is a trade mark of the EuroQol Research Foundation  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18-OBE2109 -[ADDRESS_926622]  
MCV      ALT  
MCH      γGT 
MCHC      Alkaline phosphatase  
APTT      Creatine Kinase  
INR     LDH  
PT     HDL, LDL , total cholesterol, and LDL/HDL ratio,  
     triglyceride s 
     Glucose  
     Urea  and uric acid  
Urinary protein dipstick  
Hormones  
E2, LH, P4, SHBG, AMH  
All the above listed tests are to be performed at the frequencies indicated in Appendix A  and Appendix 
B. All above listed blood tests will be performed by a central laboratory. Please consult the central 
laboratory instructions manual for the preparation and handling of the blood samples to be drawn to 
perform these tests.  
Bone markers  
Blood samples for exploratory bone biomarkers such as, but not limited to, collagen type 1 β-carboxy -
telopeptide (CTx), procollagen [ADDRESS_926623] N -Terminal (P1NP), bone -specific alkaline phosphatase (B -
ALP) and osteocalcin will be collected as part of clinical chemistry.   

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020  Page 142 of 156 
 
 OBSEVA  CONFIDENTIAL  Appendix O.  Analgesic change during treatment period  
Use of No Analgesics at Baseline  
Analgesic used during 
Screening  Analgesic dose status at end 
of study  Assessment of Change   
None  None  Stable/Decrease   
Narcotic analgesic and/or 
ibuprofen  is started  Increase  
Use of Only Ibuprofen  at Baseline  
Analgesic uses at Baseline  Analgesic dose status at end 
of study  Assessment of Change  
ibuprofen  Dose stopped, decreases, or is 
stable  Stable/Decrease  
Dose increases by 15% or more  Increase  
Narcotic analgesic is 
substituted or added  Increase  
Use of Only Narcotic Analgesic at Baseline  
Analgesic uses at Baseline  Analgesic dose status at end 
of study  Assessment of Change   
Narcotic analgesic  Dose s topped, decreases, or is 
stable  Stable/Decrease   
Dose stopped and ibuprofen  
substituted (any dose)  Stable/Decrease  
Dose decreases and ibuprofen  
added (any dose)  Stable/Decrease  
 
Dose stable and ibuprofen  
added (any dose)  Increase  
Dose increases by 15% or more  Increase  
Use of Ibuprofen  and Narcotic Analgesic at Baseline  
Analgesic uses at Baseline  Analgesic dose status at end 
of study  Assessment of Change   
ibuprofen  + narcotic analgesic  Ibuprofen  dose stops + narcotic 
analgesic use stops, decreases, 
or is stable* * Stable/Decrease  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020  Page 143 of 156 
 
 OBSEVA  CONFIDENTIAL  Ibuprofen  use stops + narcotic 
analgesic dose increases by 
[CONTACT_726] 15%  Increase  
Ibuprofen  dose decreases + 
narcotic analgesic use stops, 
decreases, or is stable* * Stable/Decrease  
Ibuprofen  dose decreases + 
narcotic analgesic dose 
increases by [CONTACT_726] 15%  Increase  
Ibuprofen  dose stable + narcotic 
analgesic use  
stops, decreases, or is stab le** Stable/Decrease  
Ibuprofen  dose stable  + narcotic 
analgesic dose  
increases by [CONTACT_726] 15%  Increase  
 
Ibuprofen  dose increases by 
[CONTACT_726] 15% + narcotic 
analgesic use stops  Stable/Decrease  
 
Ibuprofen  dose increases by 
[CONTACT_726] 15% + narcotic 
analgesic dose decreases  Stable/Decrease  
Ibuprofen  dose increases by 
[CONTACT_726] 15% + narcotic 
analgesic dose is stable* * Increase  
Ibuprofen  dose increases by 
[CONTACT_726] 15% + narcotic 
analgesic dose increases by 
15% or more  Increase  
 
**Stable =Dose is the same as the screening dose or increases by [CONTACT_21316] 15% of the screening dose. 
In addition, a subject can increase the monthly total dose of analgesics by [CONTACT_596550][INVESTIGATOR_684072] (either 
ibuprofen  or narcotic) and still be considered stable.  
 
  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020  Page 144 of 156 
 
 OBSEVA  CONFIDENTIAL  Appendix P.  Strong  CYP3A 4 Inducers and Inhibitors  
 
The presented lists are indicative and should not be considered exhaustive.  
 
Strong CYP3A 4 inducers  prohibited up to end of treatment in view of the add -back treatment:  
 
Carbamazepi[INVESTIGATOR_684073]. John’s Wort  
 
Strong CYP3A 4 inhibitors prohibited  up to  end of treatment in view of the add -back treatment:  
 
Boceprevir  
clarithromycin  
Cobicistat  
Conivaptan  
danoprevir and ritonavir  
diltiazem  
elvitegravir and ritonavir  
grapefruit juice  
idelalisib  
indinavir and ritonavir  
itraconazole  
ketoconazole  
lopi[INVESTIGATOR_14475]  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020  Page 145 of 156 
 
 OBSEVA  CONFIDENTIAL  nefazodone  
nelfinavir  
paritaprevir and ritonavir and (ombitasvir and/o r dasabuvir)  
posaconazole  
ritonavir  
saquinavir and ritonavir  
telaprevir  
tipranavir and ritonavir  
troleandomycin  
voriconazole  
  
18-OBE2109 -[ADDRESS_926624]   
1. Eskenazi B, Warner ML. Epi[INVESTIGATOR_304704]. Obstet Gynecol Clin North Am. 
1997;24(2):235 -58. 
2. Fauconnier A, Chapron C. Endometriosis and pelvic pain: epi[INVESTIGATOR_304705]. Hum Reprod Update. 2005;11(6):595 -606. 
3. Dunselman GA, Vermeulen N, Becker C, Calhaz -Jorge C, D'Hooghe T, De Bie B, et al. 
ESHRE guideline:  management of women with endometriosis. Hum Reprod. 2014;29(3):400 -
12. 
4. Vercellini P, Somigliana E, Vigano P, Abbiati A, Daguati R, Crosignani PG. Endometriosis: 
current and future medical therapi[INVESTIGATOR_014]. Best Pract Res Clin Obstet Gynaecol. 2008;22(2):275 -
306. 
5. Vercellini P, Somigliana E, Vigano P, Abbiati A, Barbara G, Crosignani PG. Endometriosis: 
current therapi[INVESTIGATOR_684074]. Drugs. 2009;69(6):649 -75. 
6. Meresman GF, Auge L, Baranao RI, Lombardi E, Tesone M, Sueldo C. Oral contraceptive s 
suppress cell proliferation and enhance apoptosis of eutopic endometrial tissue from patients 
with endometriosis. Fertil Steril. 2002;77(6):1141 -7. 
7. Practice Committee of the American Society for Reproductive M. Treatment of pelvic pain 
associated with en dometriosis: a committee opi[INVESTIGATOR_1649]. Fertil Steril. 2014;101(4):[ADDRESS_926625] of progestins in the treatment of endometriosis -related 
complaints. Gynecol Endocrinol. 2001;[ADDRESS_926626] 6:22 -8. 
9. Vercellini P, Fedele L, Pi[INVESTIGATOR_304707] G, Frontino G,  Somigliana E, Crosignani PG. Progestogens 
for endometriosis: forward to the past. Hum Reprod Update. 2003;9(4):387 -96. 
10. Olive DL. Gonadotropin -releasing hormone agonists for endometriosis. N Engl J Med. 
2008;359(11):1136 -42. 
11. Farmer JE, Prentice A, Breeze A . Gonadotrophin -releasing hormone analogues for 
endometriosis: bone mineral density. Cochrane Database Syst Rev. 2003(4):CD001297.  
12. Lee DY, Park HG, Yoon BK, Choi D. Effects of different add -back regimens on  
hypoestrogenic problems by [CONTACT_684136]-releasing hormone agonist  treatment 
in endometriosis. Obstet Gynecol Sci. 2016;59(1):[ADDRESS_926627] under investigation 
for the treatment of endometriosis -related pain. Womens Health (Lo nd Engl ). 2015;11(1):[ADDRESS_926628]. N Engl J Med. 2017.  
18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020  Page 147 of 156 
 
 OBSEVA  CONFIDENTIAL  15. Lewis JA, Jonsson B, Kreutz G, Sampaio C, van Zwie ten-Boot B. Placebo -controlled trials 
and the Declaration of Helsinki. Lancet. 2002 Apr 13;359(9314):1337 -40. 
16. [COMPANY_013]. Orilissa: Prescribing information. 2018.  
17. FDA. Guidance for Industry - Drug -Induced Liver Injury: Premarketing Clinical Evaluation. 
2009.  
18. World Medical A. World Medical Association Declaration of Helsinki: ethical principles for 
medical research involving human subjects. JAMA. 2013;310(20):[ADDRESS_926629] Visit 
 
 

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020  Page 155 of 156 
 
 OBSEVA  CONFIDENTIAL   
 

18-OBE2109 -003 PROTO COL V4.0  DATED 27 JULY  2020  Page 156 of 156 
 
 OBSEVA  CONFIDENTIAL   
 
